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One approach to understand the underlying mechanisms for transcriptional repression 
by DNA methylation is through the study of mammalian methyl-CpG binding 
proteins. MeCP1 and MeCP2 are two methyl-CpG binding activities previously 
characterised in this laboratory. The molecular nature of MeCP1 is unknown, but the 
protein responsible for MeCP2 has been identified. Both in vitro and in vivo data 
strongly suggest that MeCP1 is a methyl-CpG dependent transcriptional repressor. 
MeCP2 is also a transcriptional repressor and contains a transcriptional repression 
domain. Recent efforts to identify other novel methyl-CpG binding proteins by 
searching the EST databases for proteins with methyl-CpG DNA binding domain of 
MeCP2 were successful. MBD1, MBD2 and MBD4 have been shown to bind 
specifically to methylated DNA in vitro. MBD4 is a DNA repair protein and therefore 
unlikely to be involved in transcriptional repression. 
The thesis describes collective studies of these methyl-CpG binding proteins (MeCP2, 
MBD1, and MBD2). MeCP2 is associated with the mSin3 corepressor complex which 
contains histone deacetylase subunits. Repression by the transcriptional repression 
domain of MeCP2 is sensitive to the histone deacetylase inhibitor, Trichostatin A 
(TSA), indicating that deacetylation is a critical component of the repression 
mechanism of MeCP2. Interestingly, MBD2 was found to be the DNA binding 
component of the long sought MeCP1 complex by several experimental criteria. 
MBD2 is also associated with histone deacetylases, and can repress transcription when 
tethered to the DNA. Repression of certain promoters by MBD2 can be relieved by 
treatment with TSA. MBD1 can also repress transcription and contains a potent 
repression domain. The repression by this novel domain was found to be sensitive to 
TSA, suggesting that deacetylation may again be involved. Altogether, these studies 
provide a molecular link to account for the long known relationship between DNA 
methylation, transcriptional repression and chromatin modification. 
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Chapter 1: Introduction 
1.1 Covalent modification of DNA 
5-methylcytosine (5-meC) is a modified base with a methyl group attached to the carbon 5 
position of cytosine and can be found in both plants and animals (Hotchkiss, 1948; 
Wyatt, 1951). There are however, several eukaryotes such as the yeast Saccharomyces 
cerevisiae, Drosophila melanogaster and Caenorhabditis elegans with no detectable of 5-
meC in the genome (Proffitt et a!, 1984; Urieli-Shoval et al, 1982; Simpson et a!, 1986). 
Other minor bases such as N6-methyladenine or N4-methylcytosine are also found in the 
DNA of some prokaryotes (Dunn and Smith, 1955). The identification of a DNA 
methyltransferase in Escherichia coli and the detection of DNA methyltransferase activity 
in mammalian extracts established that this covalent modification is mediated by enzymes, 
termed DNA methyltransferases (Figure 1.1, Gold and Hurwitz, 1964; Sheid, 1968). 
DNA methylation at cytosine and adenine does not affect the base pairing of cytosine to 
guanine or adenine to thymine, therefore the genetic coding system based on the four 
major bases (guanine, adenine, thymine and cytosine) is not altered. However, methyl 
modification may serve to increase the coding potential of the genetic material by 
providing additional information. 
1.2 DNA methylation in the prokaryotes 
The inception of the recombinant DNA era is partly the result of intensive research on 
bacteria and phage molecular biology. It is therefore not surprising that the biological 
functions of DNA methylation are well studied in prokaryotes. Both 5-methylcytosine and 
N6-methyladenine have been detected in the DNA of E.coli (Dunn and Smith, 1955). 
These modified bases are the products of Hsd (host specificity), Dcm (DNA cytosine 
methylation) and Dam (DNA adenine methylation) methyltransferases (reviewed in 
Noyer-Weidner and Trautner, 1993). Two well-documented functions of DNA 
methylation in E. coli are: the host defence restriction/modification system involving N6-
methyladenine methylation by Hsd methyltransferase and the methyl-directed mismatch 
repair system involving Dam methyltransferase. The biological function of Dcm 
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Figure 1.1 Enzymatic methylation of cytosine by DNA cytosine methyltransferase. 
S-adenosyl methionine (SAM) is the methyl group donor for the reaction. Carbon 5 
position of the cytosine is indicated. 
The restriction/modification (RAil) system serves as a mechanism to protect the genetic 
information from foreign phage DNA invasion (reviewed in Noyer-Weidner and 
Trautner, 1993). The RIM system consists of two components: 1) a methylation-sensitive 
restriction endonuclease that cleaves DNA at specific recognition site and 2) a 
modification methyltransferase that recognises the cognate restriction site and methylates a 
specific base (either adenine or cytosine depending on the bacteria). Methylation of target 
sites in the chromosomal DNA of the bacterium protects against "self' restriction. On the 
other hand, the unmodified DNA of invading phage will be degraded by the host 
restriction endonuclease. Therefore, the bacterial RIM system is clearly involved in host 
defence. 
The Dam methylation (methylation at GATC sites) is involved in directing strand specific 
DNA mismatch repair (Figure 1.2, reviewed in Modrich, 1986). Replication errors that 
arise during DNA replication can escape the proof-reading activity of DNA polymerase, 
and faithful correction of the mismatch relies on the recognition of parental DNA strand. 
The Dam methyltransferase methylates the N6 position of adenine at all the GATC sites. 
During a transient period after replication and before methylation by Dam 
methyltransferase, the hemi-methylated GATC sites serve as signals for the mismatch 
repair system to direct correction of mistakes on newly synthesised strand. The proteins 
involved in this postreplicative mismatch repair are MutS, MutL and MutH. Recognition 
of mismatch is mediated by MutS. Upon binding to a mispair, MutS recruits other 
components to the DNA. MutH binds to the hemimethylated GATC site and generates a 
nick immediately 5' to the GATC site on the unmethylated strand. MutL is an ATPase, 
but the role of ATP hydrolysis in mismatch repair is unclear (Worth et al, 1998). In 
addition, MutL has been shown to stimulate the binding of MutS to mispair and can 
activate the endonuclease activity of MutH (Drotschmann et al, 1998; Hall and Matson, 
1999). Cleavage at the hemi-methylated DNA initiates exonucleolytic removal of the 
unmethylated strand. De novo DNA synthesis, followed by ligation and remethylation 
complete the DNA repair process and correct the replication associated mistake. 
1.3 DNA methylation in the eukaryotes 
Cytosine methylation in animals occurs predominantly at the CpG dinucleotides. The 
plants are unique in that cytosine methylation can be found at both CpG and CpNpG sites 
where N is any nucleotide. Although the target for cytosine methylation is reduced to two 
(CpG) or three (CpNpG) basepairs, the eukaryotes differ from prokaryotes in that not all 
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Figure 1.2. Methyl-directed repair system in E.coli. 
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methylatable sites are methylated. However, non-symmetrical methylation also exists in 
plants and certain fungi. 
1.3.1 Inheritance of DNA methylation 
Two methyltransferase activities can be distinguished biochemically. The de novo 
methyltransferase activity adds a methyl group to previously unmodified DNA, whereas 
the maintenance methyltransferase activity transfers the methyl group to the non-
methylated cytosine at a hen -ii-methylated site (Figure 1.3.1). During semiconservative 
DNA replication, the symmetrically methylated CpG or CpNpG will become hemi-
methylated due to the incorporation of unmodified nucleotides at the newly synthesised 
strand. Thus, post-replicative restoration of hemi-methylated sites by the maintenance 
methyltransferase activity is proposed to ensure faithful duplication of the methylation 
pattern in the daughter cells (Riggs, 1975; Holliday and Pugh, 1975). 
The mammalian DNA cytosine methyltransferase 1 (DNMT1) has both activities, but 
maintenance methyltransferase activity is the predominant catalytic activity as hemi-
methylated CpG sites are the preferred substrates in vitro (Bestor and Ingram, 1983). 
Localisation studies showed that DNMT1 is associated with replication foci during S 
phase (Leonhardt et al, 1992; Chuang et al, 1997). Therefore, targeting of a maintenance 
methyltransferase to the sites of replication can potentially explain the rapid remethylation 
of newly synthesised DNA (Gruenbaum et al, 1983). 
1.3.2 Distribution of cytosine methylation in eukaryotes: 
Fungi. 
Lower eukaryotes such as fungi Neurospora crassa and Ascobolus immersus have non-
CpG (asymmetrical) methylation (Selker and Stevens, 1985; Selker et al, 1993). Such 
non-CpG methylation is associated with de novo methylation of duplicated or repeated 
DNA sequences. In Neurospora, the phenomenon is known as repeat-induced point 
mutation (RIP), and is characterised by repeated DNA sequences trigger G:C to A:T 
mutations. The mutated sequences become methylated at cytosine residues through de 
novo methylation. A very similar process in which duplicated DNA segments are de novo 
methylated is also observed in Ascobolus, and is termed MIP (methylation induced 
premeiotically). Unlike RIP, the methylation and inactivation of duplicated genes in 
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Figure 1.3.1 Different states of DNA methylation. 
De novo methylation by de novo methyltransferase results in the addition of 
methyl groups at non-modified CpG sites. Previously methylated DNA can 
lose methylation through DNA demethylation. After DNA replication, the 
newly synthesied strands (dotted lines) contain un-modified cytosines residues 
(shaded in gray). Maintenance methylation by maintenance methyltransferase 
restores a fully methylated site by methylating the un-modified cytosine 
residues at hemi-methylated site. 
Invertebrates and Vertebrates 
The genomes of invertebrates, apart from those without detectable 5-meC, contain a 
majority of non-methylated DNA and a minor fraction of methylated DNA (Bird et a!, 
1979; Bird and Taggart, 1980; Tweedie et al, 1997). However, the genomes of 
vertebrates are globally methylated, i.e. DNA methylation is distributed almost 
everywhere. Digestion of DNA from vertebrates with methylation sensitive restriction 
enzyme Hpall (CCGG) results in the release of methylation free, CG-rich tiny fragments, 
termed HpaJI tiny fragments (HTF) (Cooper et al, 1983). These HTFs are derived from 
CpG islands, which are 500 bp to 1 kb in length and commonly associated with 
promoters or 5' regions of housekeeping genes. Essentially, the vertebrate genomes 
exhibit a characteristic bimodal distribution of DNA methylation, with methylation-free 
CpG islands and methylation of bulk genomic DNA. 
Plants 
In contrast to the vertebrate genomes with 3-8 % of the cytosine residues methylated, the 
level of methylated cytosine residues in plants is highly variable and can be as high as 30 
% (Shapiro, 1975). The genomes of some higher plants also contain CG rich clusters 
resembling CpG islands of vertebrates, as revealed by HpaII restriction digestion 
(Antequera and Bird, 1988). 
Based on the diverse patterns of DNA methylation in eukaryotes, it is likely that DNA 
modification plays different, but perhaps not mutually exclusive, roles in different 
organisms. 
1.4 	Functions of DNA methylation in vertebrates 
1.4.1 Profile of genomic methylation during mouse development 
The level and pattern of DNA methylation during mammalian development are not static 
(Monk et al., 1987). During early embryonic development at the blastula stage, most of 
the genome undergoes global demethylation. The erasure is then followed by genome 
wide de novo methylation by the time of implantation. The restoration of methylation 
pattern is presumably catalysed by a de novo methyltransferase. The role of dynamic 
demethylation and remethylation of genomic DNA during mouse development remains 
unclear. Interestingly, dynamic fluctuation in methylation level appears to be absent in 
certain vertebrates such as the zebrafish (Macleod et al, 1999). CpG islands which are 
FJ 
enriched in CpGs and commonly associated with 5' end of genes, are however immune to 
the remethylation process. It is found that for both mouse and rat Aprt genes, Spi sites 
within the Aprt CpG island are necessary for keeping the island methylation-free 
(Macleod et a!, 1994; Brandeis et al, 1994). Deletion or mutagenesis of the Spi sites 
results in de novo methylation of the island. It is proposed that transcriptional activity of 
the promoter is required to maintain methylation-free CpG islands. 
1.4.2 Mammalian DNA cytosine methyltransferases 
Several DNA cytosine-5 methyltransferases (DNMT1 to 3) exist in mammals (Figure 
1.4.2). DNMT1 is a 190 kDa protein with a C-terminal catalytic domain related to 
bacterial cytosine methyltransferases and a novel N-terminal regulatory domain not found 
in the bacterial enzymes (Bestor et al, 1988). As hemimethylated substrates are highly 
preferred over non-methylated substrates, DNMT1 is an attractive maintenance 
methyltransferase candidate for restoring the DNA methylation pattern after DNA 
synthesis. Most importantly, DNMT1 is found associated with sites of DNA replication, 
and replication foci targeting is mediated through two distinct regions at the N-terminal 
domain (Leonhard et al, 1992; Chuang et al, 1997; Liu et al, 1998). DNMT2 was 
discovered by searching the EST databases for proteins with homology to the bacterial 
cytosine methyltransferases (Okano et al, 1998a; Yoder and Bestor, 1998; Van den 
Wyngaert et al, 1998). Unlike DNMT1, DNMT2 does not have a N-terminal domain, and 
is more related to the putative yeast cytosine methyltransferase, PMT 1 (Wilkinson et al, 
1995). Several lines of evidence indicate that DNMT2 is not an active cytosine 
methyltransferase: 1) purified recombinant protein 'from E.coli does not transfer methyl 
group to different DNA substrates (Van den Wyngaert et a!, 1998), 2) DNIv1T2 expressed 
in insect cells or mammalian cells is not active (Van den Wyngaert et al, 1998; Okano et 
al, 1998a), 3) inactivation of the DNMT2 gene in mouse cells by gene targeting does not 
lead to demethylation of endogenous viral DNA (Okano et a!, 1998a). The most recently 
discovered methyltransferases in mammals are the DNMT3 family, comprising DNMT3cx 
and DNMT3. These proteins were also identified by EST database screening (Okano et 
al, 1998b). Both DNMT3x and DNMT33 have a novel N-terminal extension before the 
C-terminal catalytic domain. Northern analysis reveals that they are highly expressed in 
embryonic stem (ES) cells, and not abundant in differentiated embryoid bodies or somatic 
tissues. Intriguingly, DNMT3a and DNMT3P expressed in insect cells have comparable 
de novo and maintenance methyltransferase activities in vitro, i.e. there is no preference 
for hemi-methylated DNA over non-methylated DNA as the methyl group acceptor. It 
should however be noted that the reported methyltransferase activity of DNMT3cL/13 is 
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Figure 1.4.2. Mammalian DNA cytosine methyltransferases (DNMTs). 
DNMT1 is the largest member of the cytosine methyltransferase family. Two 
regions in DNMT1 can target the protein to replication foci during S-phase. 
The catalytic domains are shaded in hatch. DNMT2 has not been shown to 
catalyse the transfer of methyl group to cytosine. DNMT3x and DNMT30 are 
related proteins based on sequence homology but are encoded by two 
different genes. Both DNMT3a and DNMT3P have comparable de novo and 
maintenance methyltransferase activities. 
very low in vitro (Okano et a!, 1998b). Thus, there are two major differences between 
DNMT1 and DNMT3a/. Firstly, DNMT1 is ubiquitously expressed in a wide variety of 
cell-types and tissues (Bestor et a!, 1988). Secondly, hemi-methylated DNA is the 
preferred substrate for DNMT1. It is well established that extracts from cell-lines and 
tissues contain predominantly maintenance methyltransferase activity, and this 
observation correlates with the expression profile of DNMT1 and DNMT3a/1. As certain 
cell-types such as ES cells have relatively high level of de novo methylation activity 
(Stewart et a!, 1982; Lei et al, 1996), it is tempting to speculate that DNMT3a and 
DNMT3I3 which are abundant in these cell-types, are responsible for the observed 
activity. 
1.4.3 Role of DNA methylation in development 
The role of DNA methylation in mammals can be critically assessed by studying mutants 
with reduced levels of genomic methylation. The gene encoding a major player of the 
mammalian DNA methylation system, DNMT1 has been disrupted by gene targeting (Li 
et al., 1992). Homozygous mutant embryos suffer from marked reduction in both 
genomic methylation and DNA methyltransferase activity, and do not survive beyond 
mid-gestation. This result indicates that DNA methylation is essential for mouse 
development. How and why reduced genomic methylation leads to embryonic lethality is 
largely unknown. Transgenic plants with reduced genomic DNA methylation have been 
generated by using antisense strategy to target the Arabidopsis methyltransferase MET1 
(Finnegan et al, 1996; Ronemus et al, 1996). Interestingly, these plants also exhibit 
developmental and phenotypic abnormalities, which include changes in developmental 
timing with prolonged vegetative and reproductive phases, smaller plant size, and reduced 
fertility. 
1.5 Dynamics of DNA methylation 
As mentioned in above section, the DNA methylation pattern during mouse development 
is not static. Although DNA methylation is somatically heritable (Shmookler Reis and 
Goldstein, 1982; Stein et al, 1982), it is also known that inheritance of methylation can be 
stochastic and does not occur with 100 % fidelity (Wigler et al, 1981; reviewed in Riggs 
et al, 1998). This is likely to give rise to interclonal methylation heterogeneity observed 
by some investigators (Fitzpatrick et a!, 1998; Zhu et al, 1999). Fluctuation of 
methylation could be accounted for by a demethylation process that results in the removal 
of methyl groups from methylated DNA (Figure 1.5). 
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Several models can be proposed for DNA demethylation: 
1) 	Dilution model (Passive demethylation) 
Anti-5-meC staining profiles of mouse metaphase chromosomes from the one-cell stage to 
blastocyst stage have been analysed (illustrated in Figure 1.5 A, Rougier et al, 1998). At 
the one cell stage, sister chromatids are symmetrically labeled, indicating a similar 
distribution of 5-meC on both chromatids. Curiously, only one of the two chromatids of 
each chromosomes is labeled by the antibody at the 2-cell stage. The asymmetrical 
labeling indicates that the overall distribution of genomic methylation between sister 
chromatids is not reproduced after chromosome duplication. This is opposite to that 
which would be expected if maintenance methylation restores methylation after each 
round of DNA replication (Riggs, 1975; Holliday and Pugh, 1975). More importantly, 
the number of asymmetrically stained chromosomes is halved after each chromosomal 
division and the intensity of labeling decreases progressively, indicating that methylation 
is lost through cell divisions. One plausible mechanism to explain this finding is that as 
DNMT 1 is not localised in the nuclei before the 8-cell stage, maintenance methylation 
does not occur at this time (Carlson et al, 1992). The result supports the model that DNA 
methylation is lost through passive demethylation during early development due to failure 
of maintenance methylation. 
Two recent studies also lend support to a passive mode of DNA demethylation, which is 
dependent on DNA replication (Figure 1.5 B, Matsuo et al, 1998; Hsieh, 1999). Binding 
of nuclear factors (either transcription factors or EBNA-1) to the DNA was shown to be 
necessary for the loss of DNA methylation after DNA replication. It is hypothesized that 
the nuclear factors may block the access of maintenance DNA methyltransferase to the 
hemi-methylated sites that are formed during DNA replication. Consequently, fully-
methylated sites cannot be restored, and the remaining hemi-methylated sites are either 
lost by dilution through further rounds of DNA replication, or may be substrate for active 
DNA demethylation (see below). 
An alternative way to prevent re-methylation of hemi-methylated sites is by preventing the 
maintenance methyltransferase from localising to replication foci. For example, the mitotic 
inhibitor, p21 (WAF1/Cipi) is shown to compete for binding of DNMT1 to replication 
auxiliary factor, PCNA in vitro (Chuang et al, 1997). If such displacement of DNMT1 
from PCNA can occur in vivo, hen-ti-methylated sites can escape re-methylation by 
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Figure 1.5 Mechanisms of DNA demethylation 
Passive demethylation during mammalian preimplantation development. 
Si to S4: S phases. (adapted from Rougier et al, 1998. Genes Dev. 12, 2108-2113.) 
Passive demethylation through binding of nuclear factors (NFs) at 
methylated sites. TF, transcription factor. 
Active demethylation catalysed by demethylase. 
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2) 	Active demethylation 
A wide variety of biological processes utilise reversible modification to achieve 
regulation. Examples include the phosphorylation and dephosphorylation of proteins by 
kinases and phosphatases in many signal transduction pathways. Therefore, it is 
conceivable that methylated DNA can be demethylated through a process of active 
enzymatic removal of methyl groups by a demethylase. Indeed, demethylase activities 
have been reported from extracts of vertebrate in origin. 
A methylated cx-actin gene becomes demethylated and transcriptionally active upon 
transfection into rat L8 myoblasts (Paroush et al, 1990). As demethylation can occur in 
the absence of DNA replication, loss of 5-meC (passive demethylation) through rounds of 
replication is unlikely. The demethylase activity in this experimental system has been 
characterised (Weiss et al, 1996). Demethylation appears to be carried out by a nucleotide 
exchange reaction which may involve RNA molecules as revealed by the sensitivity of the 
reaction towards RNase treatment. Unfortunately, it was later realised that the RNase 
sensitivity is an artifact due to usage of large amount of RNase (100 jtg/ml), which is 
likely to "coat" the methylated DNA substrates and inhibit the demethylase activity 
(Swisher et al, 1998). The demethylation reaction under study is no longer thought to 
involve RNA cofactors or ribozyme components. 
Jost (1993) discovered an activity in the nuclear extracts of chicken embryos that mediate 
the removal of 5-meC through a nucleotide excision repair pathway. The reaction is 
initiated by 5' nicking from 5-methyldeoxycytidine, and is followed by excision repair to 
replace the 5-meC with cytosine. Subsequent work showed that a 5-methylcytosine-DNA 
glycosylase is responsible for this activity. Intriguingly, this enzyme also contains a 
mismatch-specific thymine DNA glycosylase activity. A recurring theme in the 
demethylation studies is the involvement of RNA. RNA was found to copurify with the 
5-meC-DNA glycosylase activity through all chromatographic steps (Fremont et al, 
1997). The copurified RNA can be recovered at exactly the same position of the enzyme 
on a polyacrylamide-SDS gel. Reconstitution experiments demonstrate that both the RNA 
and protein components are required for the 5-meC-DNA glycosylase activity (Jost et al, 
1999). 
Recently, a demethylase activity has also been studied in human cell extracts 
(Ramchandani et al, 1999; Cervoni et al, 1999). The demethylase can hydrolyse 5-methyl 
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cytosine to cytosine and methanol (Ramchandani et al, 1999). This reaction would 
involve the breaking of a carbon-carbon bond between the methyl group and cytosine, 
and grafting of free methyl group to a water molecule. This novel demethylase activity 
from human cells has exceptional biochemical and unprecedented catalytic properties. 
Intriguingly, a truncated version of a methyl-CpG binding protein, MBD2 (MBD2b) has 
been reported to contain a novel 5-methyl cytosine demethylase activity (Bhattacharya et 
al., 1999). MIBD2b is shown to catalyse the conversion of methyl-CpG to CpG by the 
direct removal of methyl-group from methylated DNA. It is however not determined if 
MBD2b is responsible for the demethylase activity reported in Ramchandani et al (1999) 
and Cervoni et al (1999). The identification of a mCpG demethylase marks a new chapter 
in the field of DNA methylation. Antagonizing action between the DNA cytosine 
methyltransferases and demethylase may potentially be involved in intricate regulation of 
gene expression during development and tumorigenesis. It is also tempting to speculate if 
the MBD2 demethylase is involved in demethylation of mouse genome before 
implantation. Characterisation of MBD2 as part of the thesis work however does not 
support the finding that MBD2b is a demethylase (see Chapter 4 and Ng et al, 1999). 
1.6 5-meC is a mutagenic hotspot 
Both cytosine and 5-meC are inherently unstable and can deaminate spontaneously in 
vitro and in vivo to give rise to uracil and thymine, respectively (Duncan and Miller, 
1980; Wang et a!, 1982; Frederico et al, 1990; Shen et al, 1994). The mutation rate of 5-
meC is however 10- to 40- fold higher than cytosine (Rideout III et al, 1990). With the 
assumption that the half-life of 5-meC is 30 000 years, it is estimated that eight 5-meC 
deamination events occur per day per diploid human genome (Jones et al, 1992). Rideout 
ifi et al (1990) showed that mutational hotspots for CpG transitions at codon 175, 273, 
and 282 of the p53 tumour suppressor gene are methylated in white blood cells, sperm 
and urothelial cell DNA, suggesting that 5-meC may be responsible for causing elevated 
mutations at these sites. It is also evident that conversion of 5-meCpG to TpG is a 
relatively frequent event, as CpG deficiency of various animal genomes is matched with a 
proportional TpG/CpA excess (Bird, 1980). Therefore, spontaneous loss of 5-meC is 
likely to contribute to CpG suppression in organisms with heavily methylated genomes. 
Methylation-free CpG islands are however less prone to mutagenic replacement from 5-
meC to T and retain their characteristic CpG richness. 
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The question is: how does the cell cope with the endogenous mutagen 5-meC? 
Mammalian cells have two known proteins that can directly repair the G/T mismatch 
which arises when 5-meCpG/GpmeC is deaminated to TpGIGpmeC. The first identified 
protein is the thymine DNA glycosylase (TDG) which can excise the mispaired thymine 
(Wiebauer and Jiricny, 1989; 1990). The apyrimidinic (AP) site will subsequently be 
replaced with cytosine through a repair pathway that involves AP endonuclease, DNA 
polymerase 0 and DNA ligase. The second mammalian protein with similar activity is the 
ethyl-CpG binding domain protein 4, MBD4 (Hendrich and Bird, 1998; Hendrich et al, 
1999). MBD4 contains a glycosylase domain which is distinct from TDG. The 
glycosylase domain is shown to specifically remove thymine residue from a G/T 
mismatch, but has no activity towards C/C or GIG mismatches. Interestingly, MBD4 also 
contains a functional methyl-CpG binding domain, and ectopically expressed protein is 
localised to methylated DNA in vivo. The exact role of the DNA binding domain in 
relation to the thymine glycosylase activity is not clear. It is also shown that the methyl-
CpG binding domain of MBD4 can bind to a T/G mismatch in addition to a mCpG pair. 
The involvement of MBD4 in DNA repair is also strengthened by the finding that MIBD4 
can interact with hMILH1, a component of the mammalian MutSL mismatch repair system 
(Bellacosa et al, 1999). Based on a weak endonuclease activity detected in MBD4, it is 
speculated that IVIBD4 may be the long-sought' MutH homolog of the bacterial methyl-
directed mismatch repair system (see Figure 1.2, Bellacosa et al, 1999). Both TDG and 
MI13D4 can also cleave uracil from a GIU mismatch in vitro. Based on the specificity of 
these two proteins towards excision of thymine/uracil from mismatches that can arise 
through deamination of CpG or 5-meCpG, it is likely that they are involved in 
counteracting the mutagenic potential of 5-meC. Beside TDG and MBD4, the mammalian 
cells contain a novel G/T binding protein (GTBP, also known as hMSH6 and p160) 
which is implicated in mediating G/T mismatch repair (Palombo et al, 1996; 
Papadopoulos et al, 1995; Drummond et al, 1995). GTBP interacts with hMSH2 to form 
a heterodimer hMutScx that can recognise various abnormal structures such as base-base 
mismatches and small insertion/ deletion loops. Unlike TDG or MBD4, GTBP is not a 
glycosylase and is likely to play a role in detection of G/T mismatches. Recognition of 
G/T mismatch by GTBP presumably leads to recruitment of downstream DNA repair 
proteins and correction of the defect. Therefore, the mammalian cells may have at least 
three distinct pathways to target G/T mismatches. 
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1.7 DNA methylation and gene regulation 
1.7.1 Evidence that DNA methylation is associated with transcriptional 
repression 
One known fact about DNA methylation in vertebrates is its incompatibility with 
transcriptional activity. Work carried out over the last 20 years has established an inverse 
correlation between DNA methylation and gene expression (Razin and Riggs, 1980). For 
example, CpG island-containing genes on the X chromosomes become methylated 
following X chromosome inactivation in eutherian mammals (Grant and Chapman, 
1988). In addition, several lines of evidence indicate that DNA methylation is involved in 
gene silencing. Firstly, DNA demethylation, induced by an inhibitor of DNA cytosine 
methyltransferase, 5-azacytidine, causes reactivation of previously methylated, silenced 
autosomal or X-linked genes (Jones and Taylor, 1980; Mohandas et al, 1981) and 
retroviruses (Groudine et al, 1981). Similarly, removal of methylation through 
propagation of provirus in bacteria restores infectivity (Harbers et al, 1981). More direct 
evidence that DNA methylation prevents gene expression has been obtained by 
methylating specific genes in vitro and testing them either in in vitro transcription systems 
(Shen, 1984) or transfecting them into mammalian cells (Busslinger et al, 1983). 
The availability of a DNMT1 null mouse model with reduced genomic methylation allows 
one to study the effect of demethylation on endogenous gene expression (Li et al, 1992). 
Imprinted genes are differentially methylated and silenced depending on their parental 
origin, and in the mutant embryos these genes are mis-expressed (Li et al., 1993). This is 
the first demonstration that DNA methylation is essential for regulating differential 
expression of the paternal and maternal copies of imprinted genes. 
In the mammalian female, one of the two X-chromosomes is selectively inactivated to 
achieve dosage compensation for having two X chromosomes (Lyon, 1999). Xist 
encodes a untranslated nuclear RNA which is transcribed from and colocalised to the 
inactive X chromosome. In female somatic cells, inactive Xist on the active X 
chromosome is highly methylated, while active Xist on the inactive X chromosome is 
hypomethylated, suggesting that DNA methylation may be involved in allele-specific 
expression of Xist (Norris et al, 1994; Beard et al, 1995). Indeed, in male DNMT1 null 
mouse embryos, Xist becomes demethylated and expressed. Xist is also aberrantly 
expressed in female DNMT1 null mouse embryos, and Xist RNA coats both X 
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chromosomes (Beard et al, 1995; Panning and Jaenisch, 1996). Therefore, loss of 
methylation can lead to reactivation of Xist in somatic cells. 
Intracisternal A particle (lAP) retroviruses are normally methylated at the LTR regions and 
transcriptionally silent. In DNMT1- mutants, it is found that transcription of TAP 
retroviruses is elevated and mRNA transcripts are detected in most tissues of the embryos 
(Walsh et al., 1998). In the wildtype embryos, these elements are silenced, presumably 
by DNA methylation. Curiously, northern analysis of 3 tissue-specific genes (lcd 
collagen, skeletal muscle (c-actin, and -globin) did not reveal an up-regulation of 
transcripts in DNMT1- embryos even when these genes are undermethylated (Walsh and 
Bestor, 1999). Hence, it is suggested that DNA methylation does not play an important 
role in the regulation of tissue-specific genes. With the advent of DNA microarray 
technology, it is now possible to analyse changes in gene expression with greater 
precision (for example: see Iyer et al., 1999). This technology should help to clarify any 
mis-expression of tissue specific genes in DNMT -I- embryonic stem cells or embryos. 
Recently, an elegant animal model system was used to study the consequence of inducible 
methylation of regulatory elements on transcription in vivo (Siegfried et al., 1999). Spi 
sites contained within the promoter region of both the hamster and mouse Aprt genes have 
been shown to protect the Aprt CpG island from de novo methylation during development 
(Brandeis et al., 1994; Macleod et al., 1994). By flanking Spl sites-containing island 
elements (EE) with loxP sites and using Cre-mediated excision, it has been possible to 
conditionally remove the IF and bring about de novo methylation of a promoter. 
Transgenic mice harboring a loxP-flanked EE reporter construct have been generated. 
Introduction of Cre recombinase before implantation by genetic crossing induces the 
removal of IE. The promoter region downstream of the loxP site becomes methylated by 
the wave of de novo methylation during implantation and transcription from the reporter is 
diminished. Removal of the EE after implantation does not lead to methylation of the 
reporter construct and transcription activity is not significantly altered as compared to the 
founder animal with an intact IF. These results indicate that DNA methylation represses 
transcription in animal. However, questions arise as to whether the result can be 
extrapolated to endogenous genes and what mechanism of repression is conferred by 
methylation using this artificial system. 
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1.7.2 DNA methylation: a cause or consequence of gene silencing? 
"Is methylation dancing to the piper or calling the tune?". This question still awaits more 
experimental investigation (Bird, 1992). Several studies support DNA methylation as a 
secondary event that follows transcriptional silencing: a) the X-linked mouse Hprt genes 
remain unmethylated for several days after X-inactivation (Lock et al, 1987), b) proviral 
transcriptional inactivation in embryonal carcinoma cells occurs before de novo 
methylation (Gautsch and Wilson, 1983; Niwa et al, 1983), c) inactivation of y-globin 
gene takes place before methylation (Enver et al, 1988). Why are transcriptionally inactive 
genes susceptible to de novo methylation? What are the hallmarks of inactive genes that 
attract de novo methylation? It is likely that investigation along this line will uncover the 
relationship between transcriptional inactivation and de novo methylation. It should also 
be emphasised that DNA methylation is not necessarily an overriding factor over gene 
expression. For example, it was found that developmental activation of the H-2K gene 
correlates with an increase in methylation (Tanaka et al, 1983). 
1.8 DNA methylation and chromatin modification 
In eukaryotic cells, DNA is packaged along with other chromosomal proteins into 
chromatin (van Holde, 1989). This allows for the efficient compaction of genomic DNA 
within a nucleus. The repeating units of chromatin are nucleosomes. Each nucleosome 
consists of 147 bp of DNA wrapped round a histone octamer. Since the in vivo substrate 
for transcription is chromatin, it is not surprising that many transcriptional regulators 
impact directly on chromatin infrastructure to exert an influence on transcription. 
1.8.1 Methylated and non-methylated DNA adopt fundamentally 
different chromatin structures 
The mammalian genome is characterised by methylation-free CpG islands interspersed 
within the methylated bulk chromatin. Early studies indicated that chromatin containing 
high levels of 5-meC is resistant to micrococcal nuclease digestion in chicken nuclei 
(Razin and Cedar, 1977). On the other hand, actively transcribed sequences are found to 
be undermethylated compared with bulk DNA (Naveh-Many and Cedar, 1981). Upon 
transfection and integration of methylated DNA into the mouse L cell genome, the DNA 
becomes resistant to DNase I and restriction endonuclease digestion (Keshet et al, 1986). 
Upon integration, the non-methylated version remains sensitive to nuclease digestion. 
These studies provide direct evidence that chromatin containing methylated DNA has a 
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distinctive structure which is resistant to nuclease digestion. Using restriction enzymes 
that recognise CpG sites but are not sensitive to cytosine methylation, it is found that 
accessibility towards methylated sites in the nuclei is blocked (Antequera et al, 1989). 
Under similar conditions, bulk chromatin can be extensively cleaved by restriction 
enzymes that do not contain CpG in their recognition sites. The CpG restriction enzymes 
do however release oligonucleosomes that are exclusively derived from CpG islands. 
Biochemical analysis of CpG oligonucleosomes reveals that the chromatin is enriched in 
highly acetylated histones H3 and H4, but is deficient in histone Hi (Tazi and Bird, 
1990). 
Is the inactive chromatin structure associated with DNA methylation important for the loss 
of transcriptional activity? This question is critically addressed by experiments analyzing 
the kinetics of transcriptional arrest from methylated templates (Buschhausen et al, 1987). 
Both methylated and non-methylated versions of the herpes simplex virus thymidine 
kinase (HSV TK) gene are equally active during the first 8 hours after microinjection into 
rodent cells. It is only after longer time intervals (more than 8 hours) that the inhibitory 
effect of DNA methylation was exerted on the methylated reporter construct, as measured 
by the accumulation of HSV TK RNA. It is hypothesised that the injected DNA is not 
fully assembled into chromatin during the early stages, and that DNA methylation status 
has no effect on transcriptional activity in the absence of chromatin. Indeed, when an in 
vitro reconstituted chromatinised methylated reporter is introduced into the cells, it 
becomes transcriptionally inert. Subsequently Kass et al showed clear evidence for a time-
dependent repression of methylated template following injection into Xenopus oocytes 
(Kass et al, 1997). Loss of transcriptional activity from the methylated template coincides 
with the appearance of a nucleosomal array in the vicinity of the promoter, and 
disappearance of engaged RNA polymerases. The above studies demonstrate that' DNA 
methylation can lead to alteration of chromatin structure, and that in some cases, DNA 
methylation per se is not sufficient for transcriptional repression. 
1.9 How does DNA methylation repress transcription? 
A most simplistic model to explain why DNA methylation is inhibitory to transcription is 
that mCpG prevents transcriptional initiation by interfering with binding of transcription 
factors to their cognate recognition sites (Figure 1.9A). Indeed, the two basepair CG can 
be found in many transcription factor recognition sites, and DNA methylation has been 
shown to inhibit the binding activity of various proteins such as E217, NFiB, etc 
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Figure 1.9. How does DNA methylation repress transcription? 
5-meC inhibits the binding of transcription factors or basal transcription machinery to DNA. 
Indirect repression by MeCPs. 
MeCPs are proposed to contain two functional domains (transcriptional repression domain and 
methyl-CpG binding domain). MeCPs can either communicate with components of transcription 
apparatus or alter chromatin structure to silence gene expression. 20 
(reviewed in Tate and Bird, 1993). In addition, DNA methylation can also influence the 
translational positioning of nucleosomes on certain DNA sequences in vitro (Davey et al, 
1997). Methylation induced occlusion of essential regulatory elements by nucleosomes 
can in theory provide a way to repress transcription. It remains to be tested whether this 
mechanism actually operates in vivo. Repression through such mechanisms is also 
referred to as "direct" inhibition of transcription. 
Certain transcription factors such as Spl are however not affected by methylation within 
their recognition sites, and not all sequence-specific transcription factor sites contain CpG 
(Harrington et a!, 1988; Holler et al, 1988). Therefore, a second hypothesis needs to be 
invoked to explain how DNA methylation leads to transcriptional repression as well as 
protection of mCpG in mammalian nuclei (Antequera et al, 1990). Proteins with affinity 
for methylated DNA are attractive candidates for mediating indirect repression by DNA 
methylation (Figure 1.9 B). 
MeCP1 (methyl-CpG binding protein 1) was one of the first methyl-CpG binding activity 
detected in various mammalian nuclear extracts and can bind to 12 or more symmetrically 
methylated CpGs in any sequence context (Meehan et al, 1989). The molecular nature of 
MeCP1 is not defined, but the functional significance of this activity has been studied 
both in vitro and in vivo (Boyes and Bird, 1991). The extent of repression on methylated 
reporters in living cells correlates strongly with the density of methylation as well as in 
vitro affinity of MeCP1 for the methylated reporters. Repression on the methylated 
reporters can also be rescued by co-transfection of methylated ligands for MeCP I. More 
importantly, cells and extracts deficient in MeCP1 failed to repress the methylated 
reporters (Boyes and Bird, 1991; Levine et al, 1991). These studies implicate MeCP1 as a 
methylation-dependent transcriptional repressor. 
MeCP2 is another protein with an affinity for methylated DNA, but differs from MeCP1 
in that it can bind to a single methylated CpG pair (Lewis et al, 1992; Meehan et al, 1992; 
Nan et al, 1993). There is significant variation in the abundance of MeCP2. Murine brain 
nuclear extracts contain the highest levels of MeCP2 as revealed by Southwestern assay 
and immunoblotting with anti-MeCP2 antibodies (Meehan et al, 1992; Nan et al, 1997). 
MeCP2 is also a chromosomal protein that localised to mCpG-nched heterochromatin in 
mouse cells (Lewis et al, 1992; Nan et al, 1996). Deletion studies of MeCP2 led to the 
mapping of a 85 amino-acids methyl-CpG binding domain (MBD) (Nan et al, 1993). That 
the MIBD of MeCP2 is also required for methyl-CpG binding in vivo was critically 
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addressed by a later study to look at the in vivo localisation of MeCP2 (Nan et al, 1996). 
In mouse cells, ectopically expressed MeCP2-LacZ fusion protein was targeted to 
heterochromatin which is enriched with 5-methylcytosine. Deletion within the MBD 
region of MeCP2-LacZ fusion protein lead to inefficient targeting to heterochromatin. The 
results strongly suggest that the MBD of MeCP2 is required for preferential association 
with methyl-CpG in vivo. Beside binding to naked DNA, MeCP2 has also been shown to 
interact specifically with methylated chromatin (Nan et al, 1997). However, it is not 
certain if MeCP2 binds to the methylated, exposed linker DNA or interacts directly with 
methyl-CpGs on the surface of nucleosomes. More recently, MeCP2 was shown to 
footprint to specific methyl-CpG pairs on nucleosomal DNA in a highly defined system 
(Chandler et al, 1999). The results further strengthen the idea that MeCP2 is an integral 
component of chromatin and has abundant binding sites in the mammalian genome (Nan 
et al, 1997). 
Several other proteins have also been shown to bind methylated DNA. A methylated DNA 
binding protein (MDBP1) has been detected in nuclear extract from human placenta 
(Huang et al, 1984). Further characterisation of this activity reveals that in addition to 
methylation specificity, the protein also binds to specific fragments within the prokaryotic 
plasmid vectors, pBR322 and M13mp8 (Wang et al, 1986). The consensus binding 
sequence can be found in the mammalian genome and viral DNA, and methylation in 
these sequences enhances DNA binding but is not an absolute requirement. The 5-meC 
can also be substituted by T (5-methyluracil) for MDBP1 binding (Zhang et al, 1989). As 
MDBP1 is a sequence specific DNA binding protein, and is present in undifferentiated 
embryonal carcinoma cells which do not efficiently repress methylated reporters (Boyes 
and Bird, 1991; Levine et al, 1991), it is unlikely to play a role in the global repression of 
methylated sequences (Supakar et al, 1988). 
MIDBP2 is an avian protein that binds both in vitro and in vivo to the methylated promoter 
of avian vitellogenin II gene (Pawlak et al, 1991; Jost and Hofsteenge, 1992). The 
binding of MDBP2 is not sequence-specific and requires a minimum length of 30 bp with 
a symmetrically methylated CpG. Interestingly, MDBP2 turns out to be a histone Hi 
subtype (Jost and Hofsteenge, 1992). Phosphorylation of MDBP2 is crucial for its 
affinity towards methylated DNA, and more importantly, the phosphorylated form is 
shown to repress transcription of the vitellogenin II promoter in vitro (Bruhat and Jost, 
1996). However, it is not clear if MIBDP2 is an active repressor in vivo. The 
demonstration that an avain histone Hi subtype can bind specifically to methylated DNA 
22 
prompted an investigation of the methylated DNA binding property of mammalian histone 
Hi. The answer is still unclear and the findings are controversial. While two groups find 
that histone Hi had no preference for methylated nucleosomal or naked DNA 
(Nightingale and Wolffe, 1995; Campoy et al, 1995), some groups observed an effect of 
histone Hi on naked methylated DNA templates (Levine et a!, 1993; Johnson et al, 1995; 
McArthur and Thomas, 1996). 
An EST databases searching strategy was used to find novel proteins with homology to 
the methyl-CpG binding domain (MBD) of MeCP2. The rationale is that the MBD is 
likely to be a structurally conserved domain for recognition of methyl-CpG pairs. A 
family of novel mammalian proteins with homology to the MIBD (MBD1 to 4), has been 
identified using this approach (Cross et al, 1997; Hendrich and Bird, 1998). Northern 
analysis reveals that MIBD1 and MBD2 are expressed in a variety of tissues but the 
transcripts are deficient in ES cells. Transcripts for MIBD3 and MBD4 can however be 
detected in ES cells. Using bandshift assays, IVIBD1, MBD2 and MBD4 are shown to 
bind specifically to mCpG pairs in any DNA sequence context. The heterochromatin in 
mouse cells is enriched in heavily methylated major satellite DNA which is preferentially 
stained by DAPI. Ectopic expression of MBD 1, MIBD2 and MBD4 results in the 
localisation of these proteins to the DAPI bright spots, and suggests that these proteins 
bind to methylated DNA in vivo (Hendrich and Bird, 1998). Ectopically expressed MBD2 
and MBD4 failed to localise to heterochromatic foci in DNMT1 -I- ES cells with low 
levels of genomic methylation, indicating that methylation is an essential parameter for 
their localisation in the cells. With the same analysis, MIBD1 remains localised to DAPI 
bright spots, suggesting that protein factors may be involved in in vivo localisation, or 
MBDi is targeted by residual methylated sites. Although MBD2 and MBD3 are related as 
revealed by the high level of sequence conservation at the C-terminal region (including the 
MBD), MIBD3 does not bind to methylated DNA specifically either in vitro and in vivo 
using the same set of binding assays for MBD 1, MBD2 and MBD4. Therefore, among 
the mammalian methylated DNA binding proteins, only MeCP1, MeCP2, MBD1, MBD2 
and MBD4 bind to methylated DNA in a non-sequence specific manner, and exhibit strict 
requirement for mCpG. 
Until recently, the molecular mechanism by which DNA methylation represses 
transcription remained largely unknown. However, a few reports hinted at a connection 
between DNA methylation and histone deacetylation. In one instance, an inhibitor of 
histone deacetylase, sodium butyrate was shown to elevate the expression of a methylated 
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episomal reporter gene (Hsieh, 1994). It was also reported that both sodium butyrate and 
trichostatin A could substitute for the DNA demethylating agent, 5-aza-2'-deoxycytidine 
(5-aza-dC) in restoring transcription from previously methylated and silenced plant 
ribosomal RNA genes (Chen and Pikaard, 1997). The interchangeable effect of TSA and 
a DNA demethylating agent prompted the notion that DNA methylation and histone 
deacetylation may operate along a common mechanistic pathway to silence transcription. 
1.10 Post-translational modification of histones: lysine acetylation 
It is known that core histones can be subjected to several form of post-translational 
modification, e.g. methylation, phosphorylation, ubiquitination, and acetylation. Histone 
acetylation has attracted much attention based on an early observation that histone 
acetylation is linked to RNA synthesis, and it is proposed that one way to regulate 
transcription of chromatin templates is through acetylation of histones (Pogo et al, 1966). 
Using an antibody against acetylated histone H4, it was demonstrated that 
transcriptionally active genes are associated with acetylated core histones (Hebbes et al, 
1988). The link between histone acetylation and transcriptional activation is further 
substantiated by the finding that Tetrahymena histone acetyltransferase A is homologous 
to the yeast transcriptional activator, Gcn5p (Brownell et al, 1996). Both Tetrahymena 
histone acetyltransferase A and Gcn5p possess a novel histone acetyltransferase (HAT) 
activity that can acetylate core histones in vitro. Gcn5p is also shown to acetylate specific 
lysines of histones H3 and H4 in vivo (Kuo et al, 1996). Point mutations within the HAT 
domain abolish the capability of Gcn5p to direct histone acetylatioh and mediate 
transcriptional activation in vivo (Kuo et al, 1998). 
Many biological regulatory pathways make use of antagonising processes to achieve 
different states of activity, histone modification by acetylation is no exception. The 
removal of acetyl groups from core histones is catalysed by histone deacetylases (Libby, 
1970; Boffa et al, 1971; Krieger et al, 1974). Trapoxin is a fungal product that can inhibit 
histone deacetylase activity in vitro and can cause accumulation of hyperacetylated core 
histones in vivo (Kijima et al, 1993). A trapoxin affinity matrix was used to purify 
mammalian nuclear proteins with affinity for trapoxin. Intriguingly, one of the two 
proteins that binds to the trapoxin, HD 1 is related to the yeast transcriptional regulator, 
Rpd3 (Taunton et al, 1996). Deletion of yeast Rpd3 leads to an increase in acetylation of 
core histones H3 and H4 in vivo (Rundlett et al, 1996). Rpd3 interacts with another 
transcriptional corepressor Sin3 in vivo (Wang and Stillman, 1993; Kadosh and Struhl, 
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1997). Targeted recruitment of both Rpd3 and Sin3 to promoters leads to transcriptional 
repression, and repression is reduced or abolished in yeast strains with Rpd3 or Sin3 
mutations (Kadosh and Struhi, 1997). The yeast DNA binding repressor Ume6 is found 
to interact with the Rpd3/Sin3 complex, and repression of Ume6-regulated genes is 
sensitive to both Rpd3 and Sin3 mutation. Mutations within the putative catalytic motif of 
Rpd3 destroyed histone deacetylase activity in vitro and repression of Ume6 regulated 
genes in vivo (Kadosh and Struhl, 1998a). Therefore, histone deacetylase activity is 
essential for repression by Rpd3 in vivo. In addition to Ume6, a variety of mammalian 
DNA binding repressors are shown to interact with the mammalian mSin3/ Hil)AC1/ 
HDAC2 complex. mSin3 is the mammalian homologue of yeast Sin3 corepressor protein, 
while HDAC1 and HDAC2 are the mammalian homologues of yeast histone deacetylase 
RPD3. The proteins that interact with the mammalian mSin3 corepressor complex include 
the Mad/Max and MxilfMax heterodimers (Ayer et al, 1995; Schreiber-Agus et al, 1995; 
Laherty et al, 1997; Alland et al, 1997; Heinzel et al, 1997; Hassig et al, 1997; Zhang et 
al, 1997), unliganded nuclear hormone receptors (Heinzel et al, 1997; Nagy et al, 1997), 
AML 1-ETO fusion (Gelmetti et al, 1998; Lutterbach et al, 1998; Wang et al, 1998), PML-
RARcx and PLZF-RARcx fusion (Grignani et a!, 1998; He et al, 1998; Lin et al, 1998), 
Aiolos and Ikaros (Koipally et al, 1999), and neural-specific repressor, REST (Huang et 
al, 1999). 
The proteins mentioned in the above list have been shown to interact with the mSin3/ 
HDAC complex and in many cases repression can be relieved by histone deacetylase 
inhibitors (trichostatin A or trapoxin). However, only two reports demonstrate that 
tethering of the repressors (Rb, Aiolos and Ikaros) to the reporters leads to reduction in 
acetylated histones as revealed by chromatin immunoprecipitation experiments (Luo et al, 
1998; Koipally et al, 1999). As these experiments were performed by transient 
transfection of reporters into mammalian cells, it is not certain if the transfected DNA is 
assembled into proper nucleosomal arrays (Wu, 1997). Two independent studies using 
the yeast system show that targeting of Rpd3 to a promoter leads to localised deacetylated 
nucleosomal domain that spans one to two nucleosomes (Kadosh and Struhi, 1998b; 
Rundlett et a!, 1998). This result suggests that short range deacetylation of chromatin is 
sufficient to repress transcription, and begs the question as to how histone deacetylation 
represses transcription. 
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1.10.1 The mSin3 and NuRD histone deacetylase complexes 
Biochemical fractionation of Xenopus oocyte and mammalian nuclear extracts revealed 
two major histone deacetylase complexes, namely mSin3 and NuRD complexes (Figure 
1.10.1, Wade et al, 1998; Wade et al, 1999; Zhang et al, 1998a). The mSin3 complex as 
defined by immunoprecipitation with antibodies against different subunits, contains at 
least 7 subunits mSin3, HDAC1, HDAC2, RbAp48, RbAp46, SAP30, and SAP18 
(Zhang et al, 1997; Zhang et al, 1998b). The mammalian NuRD (Nucleosome 
Remodeling and eacetyIation) complex contains 7 subunits: Mi-2, MTA2, FIDAC 1, 
HDAC2, RbAp48, RbAp46, and M1BD3 (Zhang et al, 1998a; Zhang et al, 1999). 
HDAC1 and HDAC2 are the catalytic subunits found in both complexes. Co-
immunoprecipitation experiments established that HDAC1 and HDAC2 are associated in 
mammalian cells (Hassig et al, 1997; Zhang et al, 1997; Hassig et al, 1998). The two 
other common subunits RbAp46 and RbAp48, have been shown to bind directly to helix 
1 of histone H4 which is not accessible when H4 is incorporated into nucleosomes 
(Verreault et a!, 1998; Vermaak et al, 1999). This is consistent with the finding that the 
mSin3 complex is active in deacetylating core histone octamers, but unable to deacetylate 
nucleosomal histones (Zhang et al, 1998b). The probable explanation is that the histone 
binding subunits RbAp46 and RbAp48 are unable to access nucleosomal histones. 
The NuRD complex differs from the mSin3 complex by possessing a novel ATP -
dependent nucleosome remodeling activity, and the activity can be attributed to the 
presence of Mi2, a member of the SWIJ SNF2 helicase/ ATPase family (Zhang et al, 
1998a; Tong et al, 1998; Xue et al, 1998; Wade et al, 1998). Importantly, it is shown that 
ATP stimulates deacetylation of oligonucleosomal histones in vitro, suggesting that 
hydrolysis of ATP leads to nucleosome disruption and aids the deacetylases to access its 
substrates. Several proteins are known to interact with either the NuRD complex or a 
subunit of the complex. For example, the E7 oncoprotein of human papilloma virus type 
16 has been shown to interact with the Mi2 subunit of the NuRD complex using yeast two 
hybrid assay (Brehm et al, 1999). Ikaros, a lymphoid lineage-determining factor is also 
found associated with the NuRD complex in T cells as revealed by co-fractionation and 
co-immunoprecipitation (Kim et al, 1999). Upon T cell activation, both Ikaros and NuRD 
complex are co-localised to centromeric heterochromatin, suggesting that Ikaros brings 
about the silencing of inactive genes and centromeric heterochromatin in T cells through 
histone deacetylation. The same group also reported the interaction between Ikaros and 
mSin3 based on a yeast two hybrid assay and co-immunoprecipitation (Koipally et al, 
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Figure 1.10.1 mSin3 and NuRD histone deacetylase complexes. 
Both complexes share a core histone deacetylase complex (HDAC1, 
HDAC2, RbAp46 and RbAp48). Unique subunits of each complex are 
shown. 
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To determine whether methyl-CpG binding proteins repress transcription and to elucidate 
the mechanism of repression. 
The thesis centres on the functional studies of three methyl-CpG binding proteins, 
MeCP2, MBD2 and MBD1. Chapter 3 describes the mechanism of repression by 
MeCP2. Chapter 4 describes the identification of components of MeCP1 and how MBD2 
which is the methyl-CpG binding factor in MeCP1 represses transcription. Chapter 5 
describes the functional characterisation of MBD1. 
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Chapter 2: 	Materials and Methods 
2.1 General buffers 
TB 
10 mM Tris.HC1 (pH 8.0), 1 mM EDTA (pH 8.0) 
PBS 
8mM Na2HP041  1.5 mM KH2PO4, 147 mM NaCl, 3 mM KC1 
TAB 
40 mM Tris.acetate, 1 mM EDTA, pH 7.2 
TBE 
90 mM Tris base, 90 mM boric acid, 2 mM EDTA 
2.2 Growth and maintenance of Escherichia coil cells 
E. coli. cells were grown in Luria-Bertani (LB) medium (10 g bacto-tryptone, 5 g bacto-
yeast extract, 10 g NaCl per litre). The E.coli strain XL1 Blue (recAl, endAl, gyrA96, 
thi-1, hsdRl7, supE44, relAl, lac, [F proAB, lacPZt,M]5, TnlO (tet')]. )was routinely 
used for cloning and propagation of plasmids. BL21 (DE3) pLysS E. coli B F dcm 
ompT hsdS (rB MB-) gal XDE3 [pLysS Cam']. 
2.3 General methods 
2.3.1 	Agarose gel electrophoresis 
Horizontal agarose gel electrophoresis was used for analysing DNA molecules and 
restriction digests. DNA was loaded with 10 % volume of 10 x loading buffer (0.1 % 
orange G, 15 % ficoll type 400 in TE buffer) and separated at 100 V on agarose gel (0.5 
to 1.8 % depending on the size of DNA) in 1 X TAE buffer containing 0.5 tg/ ml 
ethidium bromide. The resolved DNA was visualised using a UV-transilluminator. 
2.3.2 	Recovery of DNA fragments 
After separation of DNA fragments (either PCR products or restriction fragments) by 
electrophoresis, the band of interest was located with a long-wavelength UV lamp, and 
excised from the gel using a razor blade. 3 volumes of QG buffer (Qiagen) was added to 
the gel slice, and heated to 50 OC to dissolve the gel. The mixture was then passed 
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through a Qiaquick Spin Column (containing a silica-gel based membrane for binding 
DNA under high concentration of chaotropic salt and low pH conditions). Loading of the 
column 2 more times was found to increase the amount of DNA bound to the column. 
The column was washed once with QG buffer and twice with PE buffer (Qiagen). DNA 
was eluted with either TE or 10 mlvi Tris.HC1 pH 8.5. 
	
2.3.3 	Purification of DNA fragment 
Cloning procedures routinely require the exchange of buffers and removal of restriction 
enzymes or other enzymes such as Klenow or calf intestinal phosphatase. Five volumes 
of PB buffer (Qiagen) was added to the DNA solution and passed through the Qiaquick 
Spin Column twice. The column was washed once with PB buffer and twice with PE 
buffer. DNA was eluted with either TE or 10 mM Tris.HC1 pH 8.5. 
2.3.4 	Restriction endonuclease digestion, dephosphorylation, and 
ligation 
Endonuclease digestion of DNA were performed under conditions and buffers 
recommended by the manufacturers. Typically, 1 ig of DNA was digested with 5 units of 
restriction enzyme in a 20 p1 reaction mixture. Calf intestinal alkaline phosphatase (CIP) 
was used to remove phosphate group from the 5' end of linerised vector DNA to prevent 
self-ligation. Typically two rounds of dephosphorylation were carried out to ensure 
minimal background resulting from self-ligation of vector DNA. Ligation was carried out 
with buffer supplied by the manufacturer. For sticky end ligation, the reaction was 
performed at 25 °C for 4 hours before transforming competent bacterial cells. For blunt 
end ligation, the reaction was incubated at 16 °C for 16 hours. 
2.4 Plasmid miniprepration 
A bacterial colony was picked and innoculated into 5 ml of LB (with the appropriate 
antibiotics for selection) for 16 hours at 37 °C. The bacterial cells were pelleted by 
centrifugation. The pellet was resuspended in 250 p.1 of P1 buffer (100 p.g/ml RNaseA, 50 
mM Tris.HC1, 10 mM EDTA, pH 8.0). 250 p.1 of P2 buffer (0.2 M NaOH, 1 % SDS) 
was added to lyse the bacteria, and this was followed addition of N3 buffer (Qiagen) to 
neutralise the lysate and precipitate genomic DNA and proteins. The lysate was clarified 
by centrifugation at 14 000 rpm for 10 min at room temperature. The supernatant was 
then loaded onto Qiagen Miniprep column. The column was washed once with PB buffer 
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and twice with PE buffer. The plasmid DNA was eluted with either TE or 10 mlvi 
Tris.HC1 pH 8.5. 
2.5 Large scale plasmid preparation 
Method 1 (ion-exchange column): 
A bacterial colony was picked and innoculated into 200 ml of LB and incubated 
overnight at 37 oc.  The bacterial cells were harvested by centrifugation and resuspended 
in 10 ml of P1 buffer. 10 ml of P2 buffer was added and mixed gently. After 5 min of 
incubation at room temperature, 10 ml of ice-cold P3 buffer (2.55 M sodium acetate, pH 
4.8) was added. The lysate was clarified by filtration and supernatant was loaded onto a 
pre-equilibrated Qiagen 500 column. The column was washed twice with QC buffer (1 M 
NaCl, 50 mM MOPS pH 7.0, 15 % ethanol). The bound plasmid DNA was eluted with 
15 ml of QF buffer (1.25 M NaCl, 50 mM MOPS pH 8.2, 15 % ethanol). The DNA was 
precipitated by addition of 10.5 ml of isopropanol. After centrifugation and 70 % ethanol 
wash, the dried DNA pellet was resuspended in TE buffer. 
Method 2 (CsC1 gradient): 
Bacterial cells from an overnight 500 ml culture was pelleted, and resuspended in 
10 ml of solution 1(50 mM glucose, 25 mM Tris.HCI, pH 8.0, 10 mM EDTA). Chicken 
egg white lysozyme (Boehringer) was added to a final concentration of 40 mg/mi. Lysis 
was allowed proceed for 10 min at room temperature. 20 ml of solution II (0.2 M NaOH, 
1 % SDS) was added and the mixture was incubated for 5 min at room temperature. 15 ml 
of ice-cold solution III (3M sodium acetate, pH 5.2) was added and the mixture was left 
on ice for 10 mm. Supernatant removed after centrifugation at 5000 rpm, was precipitated 
with 0.6 volume of isopropanol. The precipitate was recovered by centrifugation (5000 
rpm for 15 mm) and washed once with 70 % ethanol. The air-dried pellet was 
resuspended in 10 ml of TE. Cesium chloride and ethidium bromide were added to the 
solubilised pellet at final concentration of 1 g/ml and 0.8 mg/ml respectively. The solution 
was poured into two 5.1 ml Quick Seal polyallomer tubes (Beckman) which were 
subsequently sealed by heat. The tubes were spun in a NVT 90 rotor (Beckman) at 20 oc 
according to the following program: 
90000 rpm for 90 mm 
87 000 rpm for 15 mm 
83 000 rpm for 15 mm 
81000 rpm for 30 mm 
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80000 rpm for 30 mm 
The plasmid band was isolated from the tube by a sterile syringe and needle. The DNA 
solution was extracted for a few rounds with 10 ml of isoamyl alcohol. TB was 
sometimes added when the CsCl started to precipitate due to excessive dehydration by 
isoamyl alcohol. The DNA was precipitated by 3 volumes of 70 % ethanol at room 
temperature. The DNA pellet was washed in 70 % ethanol and resuspended in TE. A 
second round of ethanol precipitation was carried out with 2.5 volume of 100 % ethanol 
in the presence of 0.3 M sodium acetate pH 5.2. The pellet was washed again in 70 % 
ethanol, dried, and stored in TE. 
2.6 DNA sequencing 
Fluorescent dye-primer sequencing reactions were performed using a Perkin Elmer! 
Applied Biosystems ABI PRISM Dye Primer Cycle Sequencing Kit with AmpliTaq DNA 
polymerase. Each reaction contained 1 p1 primer (30 ng/ p1), 4 tl sequencing premix, and 
5 tl of DNA solution (500 ng of template). The reactions were subjected to 25 sequencing 
cycles of 98 °C for 60 s, 55 °C for 30 s, and 60 °C for 4 mm. The mixture (10 p1) was 
then precipitated by addition of 1 p1 of 3M sodium acetate (pH 4.8) and 25 j.il of 95 % 
ethanol. After centrifugation at 14 000 rpm for 20 mm, the DNA pellet was washed once 
with 70 % ethanol. The DNA samples were analysed using an automated 373 DNA 
sequencer (Applied Biosystems Perkin-Elmer). The data collected were analysed using 
the GeneJockey II software (Biosoft Cambridge). 
2.7 Radioactive labeling of DNA 
Kienow end filling method: 
Typically about 100 ng of CG1 1 sticky end fragment was labeled using 2 U of Klenow, 
in the presence of 2 jtl 3000 Ci! mmol [a 32P] dATP (20 iCi), 2 il 3000 Ci / mmol [a 
32P] dCTP (20 iCi), 2 p.1 3000 Ci! mmol [a 32P] dTTP (20 p.Ci), and 0.5 MM cold dGTP 
at 25 oc  for 1 hour. The reaction buffer was 50 mM Tris.HC1 (pH 7.5), 10 mM MgSO 4 , 
0.1 mM DTT in a total volume of 40 p.1. The reaction was stopped by adding 5 p.1 of 0.5 
M EDTA, and DNA was ethanol precipitated in the presence of 2 p.g of tRNA. The 
DNA/RNA pellet was washed two times with 70 % ethanol to remove unincorporated 
dNTPs. After drying at room temperature for 1 hour, the pellet was resuspended in TB 
buffer. 2 p.1 of the resuspended probes were aliquoted into scintillation vials and counted 




Reactions were performed using 200 ng of template DNA with specific primers at 0.1 
nmol in a 100 jil volume. Pfu DNA polymerase was used for amplification of inserts for 
cloning because of its proofreading activity that leads to reduced errors. Each reaction 
consisted of 200 pM of each dNTPs, 1.5 mM MgCl2, and 5 U of Pfu polymerase. The 
samples were overlaid with mineral oil (Sigma) and placed in a Techne PHC2 
thermoblock. 22 amplification cycles with parameters of 94 oc!  45 seconds, 55 oC/  45 
seconds, 72 oCt  10 seconds to 2 minutes (depending on the length of insert to amplify) 
per cycle was used. 
2.9 Preparation of electro-competent cells 
A bacterial colony was picked and innoculated into 50 ml of LB for 16 hours at 37 oc. 
The culture was expanded to 1 litre with addition of fresh LB. The cells were allowed to 
grow at 37 0C,  until mid-logarithmic phase (OD595  nm of 0.5). The flasks were chilled on 
ice for 10 min and cells were harvested by centrifugation at 4000 rpm for 15 min at 2 °C. 
The cell pellet was washed twice with 500 ml of ice cold sterile water. The cells were also 
washed twice with 25 ml of ice cold sterile 10 % glycerol. Finally the cells were 
resuspended in ice cold 10 % glycerol to a final volume of 2 ml. The resuspended cells 
were snap-frozen in liquid nitrogen in aliquots of 40 j.tl. 
2.10 Transformation 
Typically 1 il of ligation mixture was added to a thawed tube of electro-competent cells 
(40 j.tl). The mixture was transferred to a chilled 0.2 cm electroporation cUrvette and 
subjected to a 1.7 kilovolt pulse (25 gF, 200 c) using a Gene Pulser apparatus (BioRad). 
The time constant was typically 4.5 to 4.6 ms. 500 il prewarmed SOC medium (2 % 
Bacto-tryptone, 0.5 % Bacto-yeast extract, 10 mM NaCI, 2.5 MM KC1, 10 MM  MgCI21 
10 mlvi MgSO4, 20 mM glucose) was added immediately to the cells after electroporation. 
The cells were removed from the curvette and allowed to recover for 1 to 1.5 hr at 37 oC 
The cells suspension (100 to 200 jil) was finally plated on LB agar supplemented with 
antibiotics. 
2.11 Cloning 
For eukaryotic expression of GALA-fusion proteins: 
PCR products (after cutting with Bgl II or BamHT) were cloned into pCMV-Ga14 BamHI 
cut vector: Positive clones were screened by PCR and integrity of inserts were determined 
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by sequencing. All clones used for transfection assays have insert fused in-framed with 
GALA DNA binding domain ORF. 
For making mutation within the MBD: 
Primers harboring mutated nucleotides were used to amplify inserts for cloning. 
For prokaryotic expression of His-tagged or GST-fusion proteins: 
The desired fragments were amplified by PCR with primers with the appropriate 
restriction sites. PCR products were digested and cloned into pET6H, pCT2, pGEX2T, 
pGEX3x vectors. pET6H vector was used for expression of N-terminal 6xHis tagged 
protein (Cross et al, 1997). pCT2 vector was used for expression of C-terminal 6xHis 
tagged protein. pGEX2T and pGEX3x vectors (Pharmacia) were used for expression of 
GST-fusion proteins (Smith and Johnson, 1988). Positive clones were screened by PCR 
and integrity of inserts were determined by sequencing. 
For in vitro transcription and translation of 35S methionine labeled protein: 
The desired fragments were amplified by PCR with primers with the appropriate 
restriction sites. PCR products were digested and cloned into pCS2+MT vector (Laherty 
et al, 1997). This vector contains a SP6 polymerase binding site. Positive clones were 
screened by PCR and integrity of inserts were determined by sequencing. The vector can 
also be used for expression in mammalian cells, as the insert can be expressed by the 
CMV promoter upstream of the SP6 site. 
2.12 Protein guantitation 
Bradford assay: All reagents required for this assay were found in the Bradford assay kit 
(Biorad). Protein samples (1 - 10 il) and BSA standards (1 to 10 g) were added to 
diluted Bradford reagent (1 in 10 dilution of a stock solution), and incubated for 5 
minutes at room temperature. The mixtures were then transferred to plastic curvettes and 
OD 595 nm measurements were taken. The blank was diluted Bradford reagent without 
protein. The BSA standard calibration was included for every protein concentration 
measurement. 
2.13 sos polyacrylamide gel electrophoresis (PAGE) 
SDS-polyacrylamide gels (Laemmli, 1970) were cast using Bio-Rad protein mini-gel II 
system. The resolving gel typically contained 7%, 10%, or 12 % acrylamide/ 
bisacrylamide mixture (37.5:1), 375 mM Tris.HC1 pH 8.8, and 0.1 % SDS. The stacking 
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gel contained 4 % acrylamide/ bisacrylamide mixture, 125 mm Tris.HC1 pH 6.8, and 0.1 
% SDS. The resolving gel was poured into the space between the two glass plates. The 
gel was layered with water and allowed to polymerise for 1 hour. The water was decanted 
and stacking gel was layered on top of the resolving gel. Protein samples were adjusted to 
31 mM Tris.HCI pH 6.8, 1% SDS, 0.1 M 3-mercaptoethanol and 5% glycerol. The 
samples were subjected to 98 oc  for 3 minutes before loading into the protein gel. The 
gels were electrophoresed in 25 mM Tris, 250 mM glycine, and 0.1 % SDS buffer at 200 
V for 45 minutes. After electrophoresis, the gel was either staining in Coomassie blue 
solution (0.1 % Coomassie brilliant blue dye, 45 % methanol, 10 % acetic acid) or blotted 
using Bio-Rad TransBlot Submarine apparatus. 
2.14 Western blotting 
After SDS-PAGE, the protein gel was electroblotted to nitrocellulose membrane (20 .Lm 
pore size, Schleicher and Schuell) using Bio-Rad TransBlot submarine transfer apparatus 
(2 hr at 200 mA). Pre-stained molecular weight markers (New England Biolabs) were 
used to monitor the transfer of proteins onto the nitrocellulose membrane. The membranes 
were blocked overnight at 4 oc  in TBST buffer containing 5 % milk powder (w/v). The 
membranes were then rinsed in TBST buffer, and incubated with primary antibodies (at 
1:500 to 1: 5000) in binding buffer (TBST with 1 % milk powder) for 1 hr at room 
temperature. After three 15 min washes in the same binding buffer, the membranes were 
incubated with secondary antibodies (1:2000 to 1:15 000) for 45 mm. The secondary 
antibodies were either affinity purified anti-rabbit IgG-HRPO (Amersham), or 
monoclonal GT-34 anti-goat/ sheep IgG peroxidase conjugate (Sigma). The membranes 
were then washed three time in binding buffer, before detection with Enhanced 
Chemiluminescence (ECL) as described by the manufacturer (Amersham). 
2.15 Expression and affinity purification of recombinant proteins 
Expression and purification of GST-fusion proteins 
Single colony was picked and cultured overnight at 37 oc.  The overnight culture was 
diluted 1 in 100 in 500 ml of fresh LB. The bacteria were allowed to grow to an OD 595 n. 
of 0.5, and expression was induced for 3 to 5 hours by addition of 0.2 mlvi IPTG (final 
concentration). The bacterial cells were harvested by centrifugation and washed once with 
ice-cold PBS. The pellet were resuspended in 15 ml of lysis buffer (containing 50 mlvi 
Tris.HC1 (pH 8.0), 0.3 M NaCl, 0.1 % Triton X-100, 1 mM DTT, 10 % glycerol and 
protease inhibitors (0.5 mM PMSF, pepstatin A, leupeptin, chymotrypsin, and antipain at 
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5 g/ ml each) and lysed by ultrasound using BRANSON sonicator (set at power 4, 30 % 
cycle for 6 mm) on ice. The lysate was clarified by centrifugation on a SS34 rotor at 18 
000 rpm at 0 oc  for 45 mm. The supernatant was then incubated with 1 ml packed volume 
of rGSH-sepharose (Pharmacia) for 2 hr at 4 oc  on a rotating platform. The sepharose 
beads were pelleted by centrifugation at 500 rpm for 3 mm. The beads were washed three 
times in lysis buffer. Bound proteins were eluted in 15 mM rGSH in lysis buffer. 
Typically, three rounds of elution with rGSH were performed. The eluted fractions were 
analysed by SDS-PAGE. Purified proteins were stored in aliquots at -70 oc. 
Expression and purification of His-tagged MBD1 (MBD1 with C-terminal 
6 His tag) 
Clone CPI (pCT2-MBD1 in BL21 DE3 pLyS) was cultured overnight at 37 oc.  The 
culture was then grown in fresh media (under selection with 100 tg4il ampicillin and 34 
j.tg/pJ chioramphenicol) to an OD 595  of 0.5, and expression was induced for 3 hours by 
addition of 0.4 mM IPTG (final concentration). The bacterial cells were harvested by 
centrifugation and washed once with ice-cold PBS. The pellet were resuspended in lysis 
buffer (containing 50 mM HEPES.KOH (pH 7.9), 1 M NaCl, 0.1 % Triton X- 100, 10 
mM 3-mercaptoethanol, 10 % glycerol and protease inhibitors (0.5 mM PMSF, pepstatin 
A, leupeptin, chymotrypsin, and antipain at 5 pg/ ml each) and lysed by ultrasound using 
BRANSON sonicator (set at power 4, 30 % cycle for 6 mm) on ice. The lysate was 
clarified by centrifugation on a SS34 rotor at 18 000 rpm at 0 oc  for 45 mm. The 
supernatant was supplemented with imidazole (final concentration of 25 MM) and loaded 
onto Ni 2 -NTA superfiow (Qiagen) column (pre-equilibrated with lysis buffer plus 25 
mM imidazole). The column was washed stepwise with lysis buffers containing (0.8 M, 
0.5 M, 0.3 M NaC1 and 25 mM imidazole). The bound proteins were eluted in 50 MM 
HEPES.KOH (pH 7.9), 0.25 M imidazole, 0.3 M NaCl, 0.1 % Triton X-100, 10 MM - 
mercaptoethanol, and 10 % glycerol. The eluted sample which contained four major 
proteins, was loaded directly onto Fractogel EMD SO3e65O  (M) (Merck) strong cation-
exchange column pre-equilibrated with 50 mM HEPES.KOH (pH 7.9), 0.3 M NaCl, 0.1 
% Triton X-100, 10 mM -mercaptoethanol, and 10 % glycerol. At this concentration of 
salt, only the full-length MIBD1 protein preferentially bound to the column. The column 
was washed sequentially with the same buffer containing 0.3 M NaCl and 0.5 M NaCl. 
The full-length protein was eluted with 1 M NaCl, and dialysed sequentially against 
dialysis buffer (50 mM HEPES.KOH (pH 7.9), 0.1 % Triton X-100, 10 MM 0-
mercaptoethanol, and 10 % glycerol) containing 0.75 M NaCl, 0.5 M NaCl, and 0.25 M 
NaCl. The final concentration of protein was typically 50 ng/ p1. The optimal amount of 
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cation-exchanger was crucial for selective adsorption of full-length product. A bacterial 
protein of about the same size as full-length M1BD1 was found to co-purify with MBD1. 
The purification procedure was monitored by analysing all the samples by SDS-PAGE. 
Purified proteins were stored in aliquots at -70 oc. 
2.16 Antibody production 
Recombinant proteins purified from E.coli were used for immunisation of animals (either 
rabbits or sheeps). Only protein preparations that were judged to be 98 % pure were used. 
Approximately 150 to 200 gg of proteins were used for each immunisation (either for 
priming or subsequent boost). The animals were primed by injection of antigen mixed 
with complete Freund's adjuvant. Boost injections were carried out at 3 weeks intervals 
with antigen and incomplete Freund's adjuvant. The animals were bled on the 7th day 
after each injection for serum donation. Injection of proteins into animals and processing 
of sera were carried out by Scottish Antibody Production Unit (SAPU). 
2.17 Affinity purification of antibodies 
When sufficient antigens were available (more than 5 mg of purified proteins), affinity 
purification of the antisera was carried out. The choice of matrix (Affi- 10 or Affi- 15, Bio-
Rad) depends on the iso-electric point of the protein of interest. Acidic proteins (as 
predicted based on amino acid composition) were coupled to Affi-15 activated matrix, 
while basic proteins were coupled to Affi-10 activated matrix. Typically, 8 mg of protein 
was coupled to 500 j.tl of matrix. 
2.18 Maintenance of cell cultures 
HeLa cells, F9 EC cells, mouse L929 fibroblast cells were routinely cultured in 
Dulbecco's Minimal Eagles medium (DMEM, Gibco-BRL), supplemented with 10 % 
bovine calf serum, 100 U/mi penicillin and 100 g/ml streptomycin at 37 oc  in an 
atmosphere of 5% CO2 . 
2.19 Making frozen stocks of cultures 
70-90 % confluent adherent cells were trypsinised, resuspended in fresh medium (with 
bovine calf serum to quench the activity of trypsin), pelleted by centrifugation at 1000 
rpm for 3 minutes. The cell pellet was resuspended in 10 % DMSO/ DMEM with 10 % 
bovine calf serum and frozen at - 80 °C for 24 hours before storage in liquid nitrogen. 
2.20 Thawing of frozen stock 
Frozen stocks were thawed rapidly at 37 oc,  and the contents were transferred into a 15 
ml Falcon tube with 12 ml of fresh medium (prewarmed at 37 °C). The cells were 
collected by centrifugation at 1000 rpm for 5 minutes. The cell pellet was then 
resuspended in prewarmed fresh medium and seeded in culture flasks at high density. 
2.21 Transfection of mammalian cells 
Liposome-mediated transfection: 
Transfection of adherent HeLa cells and F9 EC cells was carried out using Lipofectamine 
(Gibco-BRL) according to the manufacturer's instructions. 1.5 p1 lipofectamine and 2 jig 
of plasmid DNA were used for transfecting a 35 mm dish of HeLa cells at 50 % 
confluence. 5 jig of plasmid DNA and 2 p1 lipofectamine were used for transfecting a 60 
mm dish of F9 EC cells at 30 % confluence. 
DEAE-dextran mediated transfection: 
Mouse L929 fibroblast cells were seeded at a density of 5 x 105 per 60 mm (diameter) 
tissue culture dishes a day before transfection. Reporter plasmid (2 jig) were cotransfected 
with different amounts of effector plasmids. The total amount of plasmids per transfection 
was kept at 6 jig by including pCMV-BamNeo plasmid as carrier. 
2.22 Cell staining 
HeLa cells were seeded onto 20 x 20 mm coverslips in 6-well tissue culture plate and 
allowed to grow to 80 % confluence overnight. The cells were rinsed in PBS before 
fixation with 3.7 % paraformaldehyde (Fluka)/ PBS pH 7.0 for 10 minutes at room 
temperature. After three washes with PBS, the cells were permeabilised with PBS 
supplemented with 0.2 % Triton X-100 for 12 minutes. Non-specific sites were blocked 
by incubation in 10 % rabbit serum in PBS for 10 minutes at room temperature. The 
coverslips were incubated with primary serum (anti-MBD1 or preimmune) at 1:200 
dilution in PBS with 10 % rabbit serum for 1 hour at room temperature. After primary 
antibody binding step, the coverslips were washed three times in PBS. The coverslips 
were then incubated with secondary anti-sheep-FITC antibodies (Vector Laboratory) in 
1:100 dilution in PBS with 10 % rabbit serum for 45 minutes at room temperature. After 
three washes with PBS, the coverslips were mounted with Vectashield media 
supplemented with DAPI (Vector Laboratory). Immunofluorescence was visualised and 
photographed on a Zeiss Axioplan POT fitted with Photometrics cooled CCD camera. 
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2.23 Reporter assays 
The cells were harvested 60 hours post-transfection. J3-galactosidase activity or luciferase 
activity was measured using kits from Promega. For f3-galactosidase assay, the substrate 
was o-nitrophenyl-3-D-ga1actopyranoside, and the value for each 3-ga1actosidase 
measurement was subtracted against the 3-galactosidase reading for lysate obtained from 
mocked transfected cells. For the luciferase assay, the substrate was luciferin, and the 
value for each luciferase measurement was subtracted against the background light 
reading for lysate obtained from mocked transfected cells. 
2.24 Isolation of nuclei from cells 
Cells grown as suspension culture were spun down at 1500 rpm for 5 minutes in 50 ml 
Falcon tubes. The cell pellets were washed two times with ice-cold PBS. The cell pellets 
were then resuspended lysis buffer (10 mM Tris.HC1 pH 7.5, 10 mM NaCl, 2 mM 
MgCl2). 1 % NP40 (80 jtl/ ml) was then added to the resuspension to initiate cell lysis. 
Cell lysis was monitored under phase contrast microscopy to check for the release of 
nuclei. The nuclei were spun down at 3000 rpm at 0 oc  in swing-out rotor JS 13.1 in 30 
nil Corex tube for 5 minutes. The supernatant was then removed by vacuum suction. The 
nuclear pellet was resuspended in lysis buffer and layered onto 15 ml of 1.2 M sucrose in 
lysis buffer. The nuclei were pelleted by centrifugation at 5000 rpm at 0 °C for 5 minutes. 
The procedure was repeated again to purify the nuclei from detergent. The nuclear pellet 
was finally resuspended in nuclear freezing buffer (50 mM Tris.HC1 pH 8.3, 5 MM 
MgCl2, 0.1 mM EDTA pH 8.0, 42 % glycerol). 
2.25 Preparation of nuclear extracts 
Nuclear extracts of mammalian cells were prepared according to the method by Dignam et 
al (1983). The procedure was carried out at 0 °C to 4 oC  in the cold room to prevent 
protein denaturation and degradation. Freshly prepared or frozen nuclei were thawed on 
ice water. The nuclei were then pelleted by centrifugation at 1000 rpm for 10 minutes at 0 
°C. The nuclear pellet was resuspended in 1.5 x packed volume of ice-cold extraction 
buffer (20 mM HEPES.KOH pH 7.9, 1.5 mM MgC121  0.2 mlvi EDTA, 0.5 mlvi DTT, 25 
% glycerol, 0.42 M KC1, 0.5 mM PMSF) by Dounce homogenizer (loose fit, 15 
strokes). Nuclear proteins were extracted for 30 minutes at 0 oc  with constant mixing. 
Chromatin and non-soluble proteins were pelleted by centrifugation for 45 minutes at 17 
500 rpm at 0 °C in a SS34 rotor (Beckman). The supernatant was dialysed against 3 
ME 
changes of 1 litre of dialysis buffer (20 mM HEPES.KOH pH 7.9, 1.5 MM MgC121  0.2 
mM EDTA, 0.5 mM DTF, 20 % glycerol, 0.1 M KC1, 0.5 mlvi PMSF). The dialysed 
extract was cleared again by centrifugation for 30 minutes at 17 500 rpm at 0 oc  in a SS34 
rotor. The supernatant was aliquoted into small volume, snap-frozen in liquid nitrogen 
and stored at - 80 oc.  The concentration of the proteins was typically 5 mg/ml using BSA 
as standard. 
2.26 Bandshift 
Bandshift reactions with nuclear extracts were carried out with 4 to 6 jig of extracts in 
binding buffer (final volume of 30 j.tl; 20 mM HEPES.KOH pH 7.9, 1 mM EDTA, 3 mM 
MgC121  10 mM -mercaptoethanol, 4 % glycerol, 0.05 % bromophenol blue, 0.05 % 
xylene cyanol, and 1 % digitonin) containing 1 to 2 jig of sonicated E.coli competitor 
DNA (Cross et al, 1997) . 32  P-labeled probe (approximately I fmol or 0.1 ng) was added 
to the extracts. The mixtures were then incubated on ice for 30 minutes before 
electrophoresis in 1.5 % agarose gel at 4 oc  and 120 V in 0.5 x TBE buffer. The gel was 
dried onto Whatman DE81 paper before exposure onto X-ray film at -70 oc.  The same 
protocol was used for bandshift assays with recombinant proteins, except that the amount 
of competitor DNA was varied. For antibody supershift experiments, 0.5 to 1 jil of 
antiserum was added to each reaction and incubated for 2 hours on ice before addition of 
the labeled probe. In certain experiments, 5 % polyacrylamide gel was used instead of 1.5 
% agarose gel to resolve the DNA/ protein complex. 
2.27 Immunoprecipitation 
Antibodies (monoclonal or affinity purified polyclonal antibodies) or serum was bound 
first to 25 j.tl of protein G sepharose (Pharmacia) at 4 °C for 1 hour on a rotating platform. 
Unbound antibodies or serum proteins were removed by washing the beads three times 
with PBS supplemented with 0.1 % Triton X- 100. The beads were then incubated with 
HeLa nuclear extracts (100 jig to 200 jig) 4 oc  for 5 hour on a rotating platform. The 
beads were then washed 5 times with wash buffer (50 mM Hepes.KOH pH 7.9, 150 mM 
NaCl, 10 % glycerol, 0.5 mM EDTA, 0.1 % Triton X-100, 1 mM DTT). The bound 
proteins were eluted by adding 12 jil of 2 x SDS loading buffer and heated at 98 oc  for 5 
minutes. The supernatant was then loaded onto SDS protein gel for subsequent Western 
blot analysis. 
41 
2.28 Coupled in vitro transcription and translation in TNT reticulocyte 
lysates (Promega) 
In vitro protein synthesis was carried out in 25 j.tl volume using components supplied by 
the Promega TNT kit: 
8 jil nuclease free water 
12.5 J.il TNT reticulocyte lysates 
1 tl TNT buffer 
0.5 p1 SP6 or T7 RNA polymerase 
0.5 Jil amino-acids mixture (1 mM, without methionine) 
1 p1 35S methionine (Amersham, in vitro translation grade, 1000 Ci! mmol) 
0.5 gil RNasin (40 U/gil) 
1.5 p1(1 pg) DNA 
The reaction was incubated for 1 to 1.5 hours at 30 OC  The labeled mixture can be stored 
at - 70 OC 
2.29 GST puildown assays 
Pulidown of nuclear proteins: 
GST-fusion or GST protein (6 gig) was first immobilised onto GSH-sepharose beads 
(Pharmacia). HeLa nuclear extract (60 gtg) was then added and allowed to mix with the 
beads for 4 hours at 4 °C on a rotating platform. Unbound proteins were removed by 
washing the beads for five times with wash buffer (20 mM HEPES.KOH pH 7.9, 150 
mM NaCl, 10 % glycerol, 0.5 mM EDTA, 0.1 % Triton X-100, 1 mM DTT). The bound 
proteins were eluted by adding 12 p1 of 2 x SDS loading buffer and heated at 98 °C for 5 
minutes. The supernatant was then loaded onto SDS protein gel for subsequent Western 
blot analysis. 
Puildown of in vitro translated 35S labeled proteins: 
GST-fusion or GST protein (3 gig) was immobilised onto GSH-sepharose beads 
(Pharmacia). The slurry was then incubated with 1 gil of in vitro translated mixture in 100 
gil of pulldown buffer (50 mM HEPES.KOH pH 7.9, 250 mlvi NaCl, 0.1 % Triton X-
100, 1 mM DTT, 0.5 mM EDTA, 10 % glycerol, 0.5 gig/ gil of BSA) for 2 hours at 4 °C 
on a rotating platform. After three washes with pulldown buffer, the bound proteins were 
eluted by adding 12 gil of 2 x SDS loading buffer, fractionated by SDS-PAGE, and 
detected by autoradiography. 
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Puildown of core histories: 
GST-fusion (4 jig) or GST protein (6 jig) was immobilised onto GSH-sepharose beads 
and blocked in binding buffer (50 mM HEPES.KOH pH 7.9, 200 mM NaCl, 0.1 % 
Triton X-100, 2 mM DTT, 0.5 mM EDTA, 10 % glycerol, 0.5 jig/ jil of BSA, 0.5 mlvi 
PMSF). The beads were then incubated with 12 jig of calf thymus core histones (or 30 jig 
of lysozyme in control experiments) in a 120 jil volume for 3 hours at 4 oc  on a rotating 
platform. The core histones (H2A, H2B, H3 and H4) were purchased from Boehringer. 
After four washes with binding buffer (the last wash did not contain BSA), the bound 
proteins were eluted by adding 12 jil of 2 x SDS loading buffer, fractionated on a 16.5 % 
SDS protein gel. 
2.30 In vitro transcription assay 
Bacterially expressed GST-MBD2a or GST-MBD2b fusion proteins were incubated at 
room temperature for 30 mins in 19.5 jig of buffer containing 8.2 mM HEPES.KOH (pH 
7.9), 41 mlvi KC1, 3 MM  MgCI21  0.08 mM EDTA, 0.2 mlvi DTT, and 8.2 % glycerol in 
the presence of 100 ng AdML promoter constructs (pAdomal either mock methylated or 
HhaI methylated, and pAdBXN as internal control). The amount of DNA was normalised 
to 1 jig by using pGEX3x as carrier. 8 units of HeLa nuclear extract (Promega) was 
added and incubated for 10 mins. Transcription was initiated by adding 2.5 jil of NTP 
mix (5 mM each of ATP, CTP, GTP, and UTP) and further incubated for 1 hr at 30 oc 
The reactions were terminated by adding 100 jil of stop solution (20 MM EDTA pH 8.0, 
0.2 M NaCl, 1 % SDS, and 0.25 jig/jil glycogen) and 300 p1 of 0.3 M sodium acetate 
(pH 4.8). The samples were deproteinised by phenol/chloroform extraction and ethanol 
precipitated. The samples were dissolved in 5 p1 of water. The amount of transcripts from 
the two promoter constructs were quantified by primer extension assay (Promega). The 
primer used was TAGCGCAGAAGTCATGCCCGCTTT. The 32P end-labeled primer 
was allowed to anneal with the transcripts at 52-54 °C. Reverse transcription was then 
carried out using Superscript reverse transcriptase (Gibco, BRL). Transcription from the 
pAdomal construct gives a primer extension product of 87 bases in length, while 
transcription from the pAdBXN construct gives a primer extension product of 103 bases 
in length. Primer extension products were analysed on denaturing 7% polyacrylamide gel. 
Quantification of transcription products was determined by Phosphor Imager (Molecular 
Dynamics) using ImageQuant ver 3.3 software. 
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Chapter 3: Mechanism 	of transcriptional 	repression 	by 
methyl-CpG binding protein 2, MeCP2 
3.1 Introduction 
In addition to the methyl-CpG binding activity MeCP1 (Meehan et a!, 1989), a second 
methyl-CpG binding activity (MeCP2) was also detected in many mammalian nuclear 
extracts (Lewis et al, 1992). This activity was purified, and the cDNA encoding the 
protein was subsequently cloned (Lewis et al, 1992). MeCP2 contains two important 
functional domains expected of a methylated DNA binding transcriptional repressor (Nan 
et al, 1993; Nan et a!, 1997). 
The methyl-CpG binding domain (MBD) of MeCP2 was mapped by methylated DNA 
binding assays using a panel of truncated recombinant MeCP2 proteins (Nan et a!, 1993). 
A minimal region of 85 amino acids was shown to bind specifically to a single methyl-
CpG pair in vitro. That the MBD of MeCP2 is also required for methyl-CpG binding in 
vivo was critically addressed by a later study to look at the in vivo localisation of MeCP2 
(Nan et al, 1996). In mouse cells, ectopically expressed MeCP2-LacZ fusion protein was 
targeted to heterochromatin which is enriched with 5-methylcytosine. Deletion within the 
MIBD region of MeCP2-LacZ fusion protein lead to inefficient targeting to 
heterochromatin. The localisation studies strongly suggests that the MBD of MeCP2 is 
required for preferential association with methyl-CpG in vivo. 
The second functional domain is the transcriptional repression domain (TRD). 
Recruitment of the TRD to a reporter gene via a GALA-DNA binding domain leads to 
transcriptional repression (Nan et a!, 1997). The TRD is highly basic and not homologous 
to other known nuclear proteins. The contents in this chapter deal with the studies on the 
mechanism of repression by MeCP2. 
3.2 Results and discussion 
3.2.1 	MeCP2 can bind to mSin3A and HDACs: mapping of co- 
repressor interacting region 
Previous work carried out in this laboratory defined a transcriptional repression domain in 
MeCP2 that can repress transcription of a reporter when tethered to the DNA via a GALA- 
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DNA binding domain. As MeCP2 is a chromosomal protein, it is speculated that MeCP2 
may make use of chromatin modifying repressor to repress transcription. An attractive 
candidate for MeCP2 interacting repressor is the mSin3A co-repressor complex required 
for a variety of DNA binding repressors (e.g. Yeast Ume6, Mad-Max heterodimer, 
unliganded nuclear hormone receptors). An in vitro GST-pulldown assay was used to test 
this hypothesis. GST and GST-MeCP2 fusion proteins were first coated onto GSH-
sepharose beads. GST protein alone served as a negative control. The beads were then 
incubated with HeLa nuclear extract for more than 2 hours at 4°C to allow interaction 
between GST-fusion proteins with other nuclear proteins. After extensive washes of the 
GST fusion-sepharose beads, bound proteins were analysed by Western blotting using 
antibodies against mSin3A, HDAC1 and HDAC2. mSin3A, HDAC1 and HDAC2 were 
found to interact with GST-MeCP2 (Figure 3.2. 1A). GST control did not bind to these 
co-repressor proteins. Using a panel of different GST-MeCP2 fragments, a co-repressor 
interacting region (CIR) was delineated. The co-repressor interacting region overlaps 
substantially with the T.RD mapped using the GAL4-fusion in vivo repression assay 
(Figure 3.2.1B). 
3.2.2 	MeCP2 is associated with mSin3A and histone deacetylases 
The immunoprecipitation and histone deacetylase experiments described in this section 
were carried out by Dr Xinsheng Nan (University of Edinburgh) and Dr Cohn Johnson 
(University of Birmingham), respectively. Rat brain nuclear extract which is enriched 
with MeCP2 was used for both assays. It was found that anti-MeCP2 antibodies (670 and 
674) can both co-immunoprecipitate mSin3A protein, in addition to MeCP2 itself (Figure 
3.2.2A). Preimmune antibodies did not immunoprecipitate mSin3A or MeCP2 proteins. 
Conversely, reciprocal immunoprecipitation experiment with different anti-mSin3 
antibodies also revealed that MeCP2 and mSin3 proteins exist in a complex. In addition, it 
was found that anti-MeCP2 antibodies can also immunoprecipitate histone deacetylase 
activity (Figure 3.2.2B). The substrate for the histone deacetylase assay is a synthetic 
peptide corresponding to the 18 N-terminal residues of histone H4, chemically acetylated 
using 3H-labeled acetic anhydride. Treatment of the inimunoprecipitates with a histone 
deacetylase inhibitor Trichostatin (TSA), abolished the activity. The result indicates that 
MeCP2 is associated with a catalytically active histone deacetylase complex. 
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Figure 3.2.1. Interaction between mSin3A/HDAC1/HDAC2 and MeCP2 
Western blot analysis of proteins that interact with different fragments of 
MeCP2. The numbers shown correspond to amino-acid position in the protein. 
The HDAC2 band in lane 108-392 migrates aberrantly due to co-migration of GST-
fusion protein with HDAC2. mSin3A antibody was K20 (Santa Cruz), HDAC1 
antibody was raised against a peptide corresponding to the C-terminal domain of 
HDAC1 (obtained from Dr. Bryan Turner), HDAC2 antibody was obtained form 
Dr. Ed Seto. 
Summary of MeCP2 / mSin3A co-repressor complex interaction 































I I I I 
Figure 3.2.2. Co-immunoprecipitation of MeCP2, mSin3, and histone deacetylase 
activity from rat brain nuclear extracts 
Western blot proteins immunoprecipitated by anti-MeCP2, and anti-mSin3 
antibodies. 
The antibodies used for immunoprecipitation were indicated in the brackets. AK11, 
1(20, AK12 were obtained from Santa Cruz. RE was obtained from Dr. Robert 
Eisenman. The blot was probed with mSin3A antibody (RE) and anti-MeCP2 (670 
and 674). 
Immunoprecipitation of histone deacetylase activity with MeCP2, HDAC1, and 
mSin3A antibodies. Preimmune and CDK7 antibodies were controls. + indicates 
pre-incubation of the immunoprecipitates in the presence of 5 ng/ml TSA. 
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3.2.3 	MeCP2 can bind to in vitro synthesised mSin3A but not HDACs 
The mSin3A corepressor complex contains at least 7 subunits: mSin3A, HDAC1, 
HDAC2, RbAp46, RbAp48, SAP30 and SAP 18 (Zhang et al, 1997; 1998). From in vitro 
protein-protein interaction studies, the largest known subunit mSin3A appears to serve as 
a scaffold protein which other subunits interact (Zhang et al, 1998; Laherty et al, 1998). 
The next question to ask is which subunit does MeCP2 interact with. To address this 
question, mSin3A, HDAC1 and HDAC2 were in vitro synthesised and labeled with 31  S-
methionine using rabbit reticulocyte lysates. The labeled proteins were then tested for the 
affinity with GST-CIR (amino acids 108-392 of rat MeCP2). GST-CIR interacts strongly 
with mSin3A, as more than 15 % of the mSin3A input material was found to be retained 
by GST-MeCP2 (Figure 3.2.3). The interaction with HDAC1 or HDAC2 was weak but 
significant. The interaction between GST-MeCP2 and mSin3A is specific because GST 
control did not bind to mSin3A under the same experimental condition. 
3.2.4 	Mapping of MeCP2 interacting regions within mSin3A 
Further work was carried out to map the region in mSin3A that can interact with GST-
CIR in vitro. A panel of truncated mSin3A protein was synthesised using rabbit 
reticulocyte lysate. GST-pulldown assays revealed that two regions in mSin3A appears to 
mediate binding to MeCP2 (Figure 3.2.4). The first region is the N-terminal half of the 
histone deacetylase interaction domain (HID, Laherty et al, 1997). The binding of 
mSin3A to GST-CIR was drastically reduced upon removal of C-terminal 200 amino 
acids of mSin3A, it is inferred that the C-terminal of mSin3A contains a second MeCP2 
interacting site. Furthermore, removal of the HID region did not destroy the interaction 
between MeCP2 and mSin3A. The interaction between CIR of MeCP2 and HID of 
mSin3A suggests MeCP2 may block the interaction between mSin3A and histone 
deacetylase. This possibility is unlikely based on the result of co-immunoprecipitation 
experiments which indicate that MeCP2 is associated with both mSin3A and histone 
deacetylases. 
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Figure 3.2.3. CIR interacts strongly with mSin3A, but weakly with HDAC1 and HDAC2. 
mSin3A, HDAC1, and HDAC2 were in vitro translated and labelled with 35S methionine. 
The labeled proteins were incubated with either GST or GST-CIR. Input is 20 % of total. 
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Figure 3.2.4. Interaction between CIR and mSin3A. 
Different fragments of mSin3A were synthesised and labeled with 35S methionme. 
The labeled proteins were incubated with either GST or GST-CIR. Input is 10 % of total. 
Maps of different mSin3A deletion constructs. The thick black lines indicates the 
regions of mSin3A that bind strongly to dR. 
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3.2.5 	Ternary complex between MeCP2I mSin3A/ HDAC2 cannot be 
assembled in vitro 
As the CIR of MeCP2 interacts in vitro with previously identified HID (Laherty et al, 
1997), this raises the question of whether mSin3A can bind simultaneously to MeCP2 
and HDAC1 or HDAC2. mSin3A, HDAC2, luciferase or MeCP2 were in vitro co-
translated and labeled with 35S-methionine. mSin3A was then inimunoprecipitated using 
anti-myc 9e10 monoclonal antibody that recognises five myc epitopes that the N-terminal 
of mSin3A. Binding of in vitro translated proteins to anti-myc antibody/protein G 
sepharose was dependent on the presence of myc epitopes as HDAC2 and MeCP2 did not 
bind to the antibody-protein G sepharose beads (Figure 3.2.5A). It is found that HDAC2 
can co-immunoprecipitate with mSin3A. The interaction between mSin3A and HDAC2 is 
specific because the luciferase in the same reaction did not co-immunoprecipitate with 
mSin3A and HDAC2 (Figure 3.2.513). MeCP2 was absent in the immunoprecipitates. 
Co-translation with increased amount of MeCP2 construct to yield more MeCP2 did not 
result in co-immunoprecipitation of MeCP2 with mSin3A/ HDAC2. Therefore, no ternary 
complex between MeCP2/ mSin3AI HDAC2 can be formed in vitro. It is plausible that a 
co-factor for mediating the ternary interaction was missing in the reaction, or in vitro 
synthesised MeCP2 was not folded properly. 
3.2.6 	Repression by GAL4-MeCP2 TRD is sensitive to histone 
deacetylase inhibitor, TSA 
Biochemical evidences described in section 3.2.1 to 3.2.3 established an association 
between MeCP2 and mSin3A/ histone deacetylases complex. An important question is 
whether repression by TRD is dependent on histone deacetylation. Experiments were 
carried out to test whether repression by TRD is sensitive to a specific inhibitor of histone 
deacetylases, trichostatin A (TSA). The relative reporter activity (G5/GO) was used as a 
measure of the specific transcriptional repression by GAL4-TRD on the reporter construct 
with Ga14 binding sites. Each G5/GO value is the ratio of 3-galactosidase activity from 
separate transfection of cells with either G5 reporter (containing 5 upstream Ga14 binding 
sites) or GO reporter (with no Ga14 binding site). The relative reporter activity in the 
absence of Ga14-MeCP2 remains close to 1 as the Ga14-binding sites do not affect the 3-
actin promoter activity. The presence of GAL4-TRD reduced the relative reporter activity 
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Figure 3.2.5. Failure to reconstitute a ternary mSin3A/ HDAC2 / MeCP2 complex in vitro 
Anti-myc antibody immunoprecipitates only myc-tagged mSin3A, and not untagged 
HDAC2 and MeCP2. Mock immunoprecipitation does not contain antibody. 
Immunoprecipitation of in vitro co-translated mSin3A/Luciferase/HDAC2 or 
rnSin3A/HDAC2/ MeCP2. 1:1:1 indicates the ratio of plasmids used for in vitro 
translating the three different proteins. In 1:1:3 mixture, the amount of MeCP2 contruct 
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Figure 3.2.6. Repression by TRD is sensitive to histone deacetylase inhibitor, TSA 
Mouse L cells were transiently transfected with GAL4-TRD (207-492 amino-acids of 
MeCP2) and reporter with or without 5 Ga14 binding sites (G5 or GO). Relative 3-gal 
activity was used to determine the specific repression by TRD. Transfected cells were 
treated with 100 ng/ml TSA for 24 hours before harvest. The result shown are based 
on three independent experiments. The G5 reporter and GAL4-TRD effector 
constructs used for the experiment were shown. 
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relative reporter activity was increased by 2 to 3 fold (Figure 3.2.6). Similar TSA 
treatment did not affect the relative reporter activity in the absence of GAL4-TRD. It is 
concluded that GAL4-TRD can repress transcription in a deacetylation dependent manner. 
3.2.7 	HeLa cells is deficient in MeCP2, but can repress methylated 
reporter construct in a deacetylation dependent manner 
Repression by DNA methylation is well-studied for HeLa cells (Boyes and Bird, 1991). 
Transfection of methylated genes into this cell-line result in transcriptional silencing, and 
MeCP1 is implicated as a mediator of methylation dependent repression. However, the 
finding that MeCP2 is also a transcriptional repressor with an affinity for methyl-CpGs 
evokes the possibility that MeCP2 may also be responsible for repression of methylated 
DNA in HeLa cells. A western blot of HeLa nuclear extract with anti-MeCP2 antibody 
(R670) failed to detect MeCP2 (Figure 3.2.7A). Control experiment with anti-mSin3A 
antibody showed that mSin3A proteins were present in both HeLa and rat brain nuclear 
extracts. As the anti-MeCP2 antibodies was raised against GST-rat MeCP2, it is possible 
that the antibodies did not recognise human MeCP2 due to sequence variation between 
species. The same anti-MeCP2 antibody was tested on human liver and kidney extracts, 
and it detected proteins of 80 kDa, which is likely to be MeCP2 (Figure 3.2.7B). The blot 
was also probed with anti-MBD1 (S751) antibody as a control for loading of extracts. 
The R670 anti-MeCP2 antibody was raised against rat MeCP2 spanning amino-acids 207-
492, and the similar region in human MeCP2 shares a 93% identity over 286 amino-acids 
compared to the rat MeCP2. The result indicates that MeCP2 is below the level of 
detection, and is either absent or not abundant in HeLa cells. Therefore, MeCP2 is 
unlikely to mediate repression of methylated genes in this cell-line, and other methyl-CpG 
binding proteins are implicated. 
The next question to ask is whether the repression of methylated reporter in the absence of 
MeCP2 is dependent on histone deacetylation. It has previously been shown that 
repression of methylated reporters in HeLa cells is dependent on DNA methylation 
density, and the repression is very likely to be mediated by another methyl-CpG binding 
activity, MeCP1 (Boyes and Bird, 1991; 1992). Therefore a reporter construct, pGL2-
CG1 1 (Figure 3.2.8B, constructed by Xinsheng Nan) was used to address this question. 
CG1 1 is a 150 bp CpG rich probe used for detecting MeCP1 bandshift activity (Meehan 
et al, 1989). The 6 kb parent plasmid pGL2 consists of a SV40 promoter driving a 
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Figure 3.2.7. HeLa cells are deficient in MeCP2 
Western blot analysis of nuclear extracts from HeLa or rat brain nuclei. The blot were 
probed with anti-MeCP2 (R670) or anti-mSin3A (K20) antibodies. 
Anti-MeCP2 (R670) antibody can detect MeCP2 in human liver and kidney extracts. 




























Figure 3.2.8. HeLa cells can repress methylated reporter in a deacetylation 
dependent manner. 
HeLa cells were transfected with either mock-methylated (M-) or HhaI-
methylated (M+) pGL2-CG11 luciferase reporter. Transfected cells were either 
treated with 100 ng/rnl TSA for 24 hours or left untreated. Relative activity of the 
luciferase activity was normalised with (i-gal activity from a co-transfected 13-gal 
reporter driven by SV40 promoter. The result shown are based on three 
independent experiments. 
Map of pGL2-CG11 construct. The positions of 45 HhaI sites are shown. 
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with an ampicillin resistance gene. In pGL2-CG1 1 construct, a CG  I cluster is located 
upstream of the SV40 promoter. The CG  1 which is methylatable at 27 methyl-CpGs, is 
designed to "attract" endogenous MeCP1 to the vicinity of the promoter. Hpall 
methylated pGL2 construct (at 25 "CCGG"sites) was repressed to a greater extent than 
HhaI methylated pGL2 construct (at 25 "GCGC"sites) in mouse L fibroblasts (Xinsheng 
Nan, personal communication). However, the difference between mock-methylated pGL2 
construct and HhaI methylated pGL2 construct was minimal (Xinsheng Nan, personal 
communication). The result indicates that HpaH methylation caused direct inhibition of 
transcription, and it is very probable that the binding of certain transcription factors to 
their cognate recognition sites were affected by Hpall methylation. It is also suspected 
that methylation of the pGL2 construct at all CpGs (including Hpall and HhaI sites) by 
SssI methyltransferase will also bring about direct effect of repression. In order to study 
the genuine effect of "tethered" MeCPs on transcription of a promoter, I decided on using 
HhaI methylated pGL2-CG1 1 construct. By methylating the construct with HhaI 
methyltransferase, a densely methylated region of 20 methyl-CpGs over 150 bp was 
created. The rest of the 6 kb plasmid is only methylatable at 25 methyl-CpG sites. 
The HhalI methylated pGL2-CG1 1 luciferase reporter was repressed to 30 % of the mock 
methylated reporter in HeLa cells (Figure 3.2.8A). These values were obtained after 
correcting for transfection efficiency by co-transfection of a non-methylated pSV40-LacZ 
reporter (SV40 promoter driving LacZ reporter gene). TSA treatment of transfected HeLa 
cells restored the relative activity (Luciferase/ 3-galactosidase activity) of HhaI methylated 
pCL2-CG reporter to approximately 70 % of the mock methylated reporter. The result 
indicates that DNA methylation dependent repression in HeLa cells is dependent on 
deacetylation. Therefore, TSA sensitive repression of methylated reporter can occur in the 
absence of the known methyl-CpG binding repressor MeCP2, and MeCP1 is implicated 
for this effect. 
3.3 Conclusion 
MeCP2 has previously been shown to repress transcription in vitro and in vivo, and 
repression activity has been mapped to a region central in MeCP2 (Nan et a!, 1997; Kudo, 
1998). Using GST-pulldown assays, a region in MeCP2 that was found to interact with 
components of the mSin3A co-repressor complex such as mSin3A, HDAC1 and 
HDAC2. Importantly, the corepressor interacting region (CIR) outlined by the in vitro 
pulidown assay overlaps substantially with the previously identified transcriptional 
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repression domain delineated using an in vivo repression assay. The interaction between 
MeCP2, mSin3A and histone deacetylases was further confirmed by reciprocal 
immunoprecipitation using anti-MeCP2 and anti-mSin antibodies. Anti-MeCP2 can 
immunoprecipitate both mSin3A and histone deacetylase activity from rat brain nuclear 
extract, and anti-mSin3A antibodies can immunoprecipitate MeCP2. GST-CIR interacts 
preferentially with in vitro synthesised mSin3A, and poorly with in vitro synthesised 
HDAC 1 and HDAC2. The result suggests that MeCP2 binds directly to mSin3A which in 
turn interacts with HDAC1 and HDAC2 (Laherty et al, 1997; Zhang et al, 1998). GST-
CIR binds to two regions within mSin3A. Attempt to assemble a ternary complex 
between MeCP2, mSin3A and HDAC2 was unsuccessful, suggesting that additional co-
factor may be required for reconstitution of the MeCP2 corepressor complex. Most 
importantly, repression by GAL4-TRD can be partially relieved by histone deacetylase 
inhibitor Trichostatin A, indicating that deacetylation contributes to in vivo repression by 
TRD of MeCP2. 
The interaction between MeCP2 and the Sin3A histone deacetylase complex was 
independently verified by Wolffe and colleagues (Jones et al, 1998). Xenopus MeCP2 
was found to co-purify with the Xenopus Sin3A, HDAC1 and HDAC2. Co-
immunoprecipitation experiments confirmed that they exist in a complex. Importantly, the 
transcriptional repression domain of Xenopus MeCP2 can repress transcription in a 
deacetylation dependent manner as revealed by TSA relief experiment. I 
The finding that MeCP2 is associated with the chromatin modifying complex, Sin3I 
HDAC co-repressor complex is intriguing, as the interaction can potentially provide the 
molecular mechanism for the long-standing relationships between DNA methylation, 
transcriptional repression and histone deacetylation. Collectively, the data suggest a model 
in which MeCP2 interacts with the mSin3A histone deacetylase complex, deacetylates 
core histone tails and leads to transcriptional repression (Figure 3.2.9). 
Is MeCP2 the only player in mediating transcriptional repression by DNA methylation? In 
certain cell-lines such as HeLa cells, MeCP2 is below the limit of detection by Western 
blot analysis. Methylated reporters can however be efficiently repressed when transfected 
into HeLa cells (Boyes and Bird, 1991). In addition, repression of methylated reporter is 
sensitive to TSA, indicating that deacetylation dependent repression of methylated genes 
can occur in the apparent absence of MeCP2. Interestingly, HeLa cells contain methyl-
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Figure 3.2.9. A model for transcriptional repression by MeCP2. 
The mSin3A/ HDAC co-repressor complex is targeted to 
methylated DNA by MeCP2. It is proposed that this complex 
deacetylates core histone tails at the vicinity of chromatin bound 
MeCP2. Question marks represent unknown interaction between the 
MeCP2/ mSin3A/ HDAC complex with the basal transcription 
machinery. Deacetylation of core histone tails presumably lead to 
transcriptional silencing. 
Chromatin associated with non-methylated DNA is however 
associated with hyperacetylated histones and transcriptionally 
active. 	
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mediating repression. MBD2 is the subject of the work described in Chapter 4, and 
functional studies of MIBD 1 are presented in Chapter 5. 
ZE 
Chapter 4: MBD2 is a component of the transcriptional 
repressor MeCPI 
4.1 Introduction 
The work described in Chapter 3 indicates that MeCP2 can repress transcription via an 
interaction with the mSin3/ histone deacetylases complex. Therefore, the transcriptional 
repression mechanism by MeCP2 seems sufficient for the explanation of the longstanding 
relationship between DNA methylation and chromatin modification (Bestor, 1998; Razin, 
1998). However, certain cell-types such as HeLa cells are deficient in the known 
repressor MeCP2 (see Chapter 3), and can still silence methylated genes (Boyes and Bird, 
1991). It is clear that other methyl-CpG binding proteins are responsible for mediating 
repression of methylated sequences in the absence of MeCP2. 
The purification of MeCP1 activity has been met with severe technical difficulties. With 
the rationale that component(s) of MeCP1 may have a methyl-CpG binding region 
homologous to the MBD of MeCP2, the EST database' was searched to identify proteins 
with similar domain. The database search resulted in the identification of four novel 
mammalian proteins (MIBD1, MBD2, MBD3, and IMIBD4) with MBD-like region (Cross 
et al, 1997; Hendrich and Bird, 1998). Interestingly, MBD1 contains two cysteines-rich 
regions which are also found in the DNA cytosine methyltransferase 1 (DNMT1) and the 
mammalian trithorax-like protein ALL1 (Cross et al, 1997). Studies on the 
characterisation of MBD1 are presented in Chapter 5. MBD2 is highly similar to MBD3 at 
the C-terminal region, and possesses a basic N-terminal extension with a run of glycine-
arginine repeats. MBD4 has no significant homology to MBD 1, MBD2 and MIBD3 apart 
from the MIBD-like region. Interestingly, MIBD4 has a region similar to the glycosylase 
domains of various DNA repair proteins. Functional studies of MBD4 uncover a novel 
G/T mismatch glycosylase activity within the glycosylase domain of the protein (Hendrich 
et al, 1999). Thus, MBD4 is unlikely to be the mediator of transcriptional repression by 
DNA methylation. MBD1, MBD2 and MIBD4 can bind specifically to methylated DNA in 
vitro (Cross et al, 1997; Hendrich and Bird, 1998). In mouse cells, ectopically expressed 
MBD 1, MIBD2 and MBD4 were targeted to DAPI-bright spots which are enriched in 
heavily methylated major satellite DNA. Localisation of MBD2 and MIBD4 to these DAPI-
bright spots were disrupted in mouse cells with low level of 5-methyl cytosines. These 
studies demonstrated that MIBD2 and MIBD4 can bind to methylated DNA in vivo. MIBD3 
61 
failed to bind specifically to methylated DNA in vitro, and did not localise to DAPI-bright 
foci in vivo. 
These other methyl-CpG binding proteins (MBD1 and MBD2) are therefore attractive 
candidates for MeCP1. This chapter concerns the characterisation of MIBD2. 
4.2 Results and discussion 
4.2.1 	Characterisation of antibodies raised against MBD2 
In order to facilitate the biochemical studies of MBD2, three antibodies were raised 
against different MBD2 fragments. 
4.2.1.1 	S752 antibody 
S752 antiserum (S specifies the host animal which is a sheep) was raised against an 
internal fragment of human MBD2 (corresponding to amino acids 232 to 394 of murine 
MBD2a). The immune antiserum detected a doublet band of approximately 47.5 kDa and 
a much weaker 28 kDa band of same mobility as MBD2b, a shorter version of full-length 
MIBD2 (Figure 4.2.1.1 A and Q. Preimmune serum did not light up these bands. 
Attempts to express full-length MBD2 as a His-tagged protein were unsuccessful, 
therefore IvlBD2b was used as a size marker as well as a positive control for Western 
analysis. 
An alternative assay was used to test the specificity of this antibody. The immune 
antiserum was incubated with either GST-sepharose or GST-MBD2(antigen)-sepharose. 
This step is to deplete the antiserum of anti-GST and anti-MBD2 antibodies. The treated 
antisera were then used for Western probing. Pre-incubation with GST-MBD2(antigen)-
sepharose removed both the 47.5 Wa and 28 kDa bands, while incubation with GST-
sepharose alone had no effect (Figure 4.2.1.1 B). This result indicates that the 47.5 Wa 
and 28 kDa proteins were bound by antibodies against MIBD2 antigen. 
The MIBD2 cDNA can potentially encode 2 ORFs starting from 2 different ATG sites 
(Figure 4.2.1.1 Q. The shorter ORF, MIBD2b was originally deduced from various 
cDNAs found in EST databases. Therefore it is not certain if MBD2a or MIBD2b is the 
correct product of MBD2 gene. In vitro transcription and translation of the MIBD2 cDNA 
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Figure 4.2.1.1. Characterisation of anti-MBD2 S752 antibody 
S752 antiserum detected proteins of 47.5 kDa and 28 kDa (indicated by 
arrows) on a Western blot of HeLa nuclear extract. Preimmune serum did not 
cross-react with similar bands on a Western blot. 
The 47.5 kDa and 28 kDa proteins are MBD2-specific. 
Left, the S752 antiserum was preincubated with GST-sepharose before Western 
blot analysis. Right, the S752 antiserum was depleted of anti-GST and anti-MBD2 
antibodies by pre-incubation with GST-MBD2 antigen. The depleted signals are 
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Figure 4.2.1.1. Characterisation of anti-MBD2 S752 antibody 
Construct used for in vitro transcription and translation of MBD2. 
The MBD2 cDNA can potentially generated MBD2a and MBD2b proteins through 
two ATG start sites. 
A 47 kDa protein (indicated by arrow) was generated from the construct showed 
in C. 
The MBD2 cDNA was transcribed using SP6 RNA polymerase, and followed by 
translation in the presence of 35S-methionine to label the protein. Both mock and 
MBD2 translation mixtures were resolved by SDS-PAGE and the labeled proteins 
were detected by autoradiography. IVT is in vitro transcription /translation mixture. 
The 47 kDa protein (indicated by arrow) reacted with anti-MBD2 antibody. 
Both mock and MBD2 translation mixtures were probed with anti-MBD2 (S752) 
antiserum. The 47 kDa protein was the only product derived from full-length MBD2 
cDNA, and the 28 kDa (MBD2b version) protein was not detected by in vitro 
translation of MBD2 RNA. 
gave a major 35S labeled product of 47.5 kDa (Figure 4.2.1.1 D). The S752 antibodies 
also detected a protein of 47.5 Wa in the same in vitro translated mixture (Figure 4.2. 1.1 
E). This protein was not found in a mock in vitro translated mixture. It is concluded that 
the major protein product that can be produced from the MBD2 cDNA is MBD2a. 
Furthermore, the in vitro translated MBD2a is of the same mobility as the 47.5 Wa band 
on Western blot of HeLa nuclear extract, indicating that the anti-MIBD2 antibody can 
detect MBD2-specific protein. 
The S752 antibodies were affinity purified using a His-tagged MBD2b - AffiGel 10 
column. The affinity purified antibodies detected the 47.5 kDa doublet bands as well as 
the 28 kDa band on western blot of HeLa nuclear extract (Figure 4.2.1.1 F). 
The specificity of the antiserum was also tested for its ability to differentiate between 
recombinant MBD2b, MBD1, and MBD4. The antiserum did not recognise MIBD1 and 
MBD4 (Figure 4.2.1.1 G). Based on these series of experiments, it is concluded that the 
47.5 kDa protein is MBD2a. It is not certain whether the 28 Wa band (denoted as 
MIBD2b?) is a protein product (MBD2b version) of the MBD2 gene, a degraded product 
of MIBD2a or a MBD2b related protein. 
The S752 antibody was also tested for its ability to recognise native MBD2 proteins in an 
extract by immunodepletion assay. Preimmune or immune antibodies were immobilised 
on protein G sepharose beads. The coated beads were then incubated with HeLa nuclear 
extracts. Western blot analysis of the unbound extracts revealed that the antibodies did not 
deplete IVIIBD2 (Figure 4.2.1.1 H). It was not possible to analyse the immunoprecipitate 
for MBD2 because the co-eluted IgG migrates with the same mobility as MBD2a on the 
protein gel. It is inferred that this antibody does not recognise native MBD2. 
The effect of anti-MBD2 antibody on MeCP1 bandshift activity was also tested an in 
attempt to address whether MBD2 is a component of MeCP1. The methylated CG1 1 
probe was used for this experiment. The CG 11 fragment can be released from the parent 
plasmid pCG1 1 by cutting with restriction enzymes Asp718 and BamBI. The 5' 
overhangs of both ends allow radiolabeling of the probe by end-filling with Klenow. 27 
symmetrically methylated CpG can be created by methylating the CG  I fragment with 
Sss 1 CpG cytosine methyl-transferase. The antibodies obtained from different bleeds did 
not affect the mobility of MeCP1 bandshift activity (Figure 4.2.1.11). 
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Figure 4.2.1.1. Characterisation of anti-MBD2 S752 antibody 
Affinity purified anti-MBD2 antibodies detected both the 47.5 kDa and 28 kDa 
protein. 
Left panel, Western blot of HeLa nuclear extract probed with crude S752 
antiserum. 
Center panel, Western blot of HeLa nuclear extract probed with serum after 
adsorption on MBD2b affinity column. 
Right panel, Western blot of HeLa nuclear extract probed with affinity purified 
anti-MBD2 antibodies. A non MBD2-specific band is indicated, this is likely due 
to cross-reactivity of the secondary anti-sheep antibodies. 
The S752 antiserum only detected recombinant MBD2b, but not recombinant 
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Figure 4.2.1.1. Characterisation of anti-MBD2 S752 antibody 
S752 antibody cannot immunodeplete MBD2 from HeLa nuclear extracts. 
Different amounts of preimmune or immune S752 antibodies (2 Pd or 5 ill of serum) 
were immobilised on protein G-sepharose beads. The beads were then incubated with 
HeLa nuclear extracts, and the supernatants were analysed by Western blotting using 
anti-MBD2 (S752) antiserum. 
S752 antiserum did not supershift MeCP1 bandshift activity. 
1 Li! of serum (preimmune serum or immune sera from different bleeds) was added to 
HeLa nuclear extracts. The mixtures were then incubated with 32  P-labeled MeCG11 
probe (a 135 bp probe with 27 methyl-CpGs). The DNA/protein complexes were 
resolved on 1.5 % agarose gel. 	
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4.2.1.2 	S923 and R593 antibodies 
As S752 antibody did not recognise native MBD2, it cannot be used for 
immunoprecipitation experiments. Further attempts to make anti-MBD2 antibody focused 
on raising antibodies against larger regions of MBD2. 
S923 antiserum was raised against full-length MBD2 (MBD2a form). The immunogen 
used was purified GSTMBD2a fusion protein. This preparation contained mostly C-
terminal truncation products (Figure 4.2.1.2 A, left panel). Based on the size of the 
degraded products, it is estimated that the site of truncation occurred before the MBD 
region (Figure 4.2.1.2 A, right panel). Therefore, majority of the antigen will not contain 
1M[BD2b sequence. 
S923 antibody recognised M1BD2a on a Western blot of HeLa nuclear extract (Figure 
4.2.1.2 B, left panel). The reactivity of this antibody towards recombinant MBD2b and 
the 28 kDa band of HeLa nuclear extract is weak compared to another anti-MBD2 
antibody R593 (see below). The S923 antibody did not cross-react with M1BD1 and 
MBD4 (Figure 4.2.1.2 B, right panel). 
R593 (R specifies the host animal which is a rabbit) was raised against MBD2b. This 
antibody detected both MIBD2a and the 28 kDa protein on a Western blot of HeLa nuclear 
extract (Figure 4.2.1.2 C, left panel). Under the same intensity of MIBD2a bands, the 
R593 antibody recognised recombinant MBD2b and the 28 kDa protein more efficiently. 
The R593 antibody did not cross-react with MBD1 and MBD4 (Figure 4.2.1.2 C, right 
panel). The 70 kDa band in the MIBD1 lane is a bacterial protein that co-purifies with 
several recombinant proteins purified from E.coli. The additional bands greater than 47.5 
kDa on the Western blots detected with S923 and R593 antibodies are unlikely to be 
MIBD2 specific because they were not detected with the S752 antibody. 
Both S923 and R593 antisera were tested for the ability to differentiate between two 
highly related proteins, MBD2b and MIBD3 (71 % identity). 30 ng of MBD2b and MBD3 
were loaded for Western analysis. Under identical condition, S923 antiserum did not 
detect recombinant MIBD3 while R593 antiserum reacted with recombinant MIBD3 (Figure 
4.2.1.2 D). No band was detected in the MBD3 lane with S923 antiserum even after 
prolonged exposure. It is however not certain if the S923 antibodies can recognise larger 
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Figure 4.2.1.2. Characterisation of anti-MBD2 S923 and R593 antibodies 
Antigen for raising S923 antibody was enriched with N-terminal MBD2a 
fragments. 
The approximate site of truncation based on the sizes of GST-MBD2a products is 
before the MBD-like region. 
S923 antiserum detected the 47.5 kDa MBD2a, and cross-reacted weakly with the 
28 kDa protein (left panel). S923 antiserum did not cross-react with MBD1 or MBD4 
(right panel). 
R593 antiserum detected both the 47.5 kDa MBD2a and 28 kDa protein (left 
panel). R593 antiserum did not cross-react with MBD1 or MBD4 (right panel). The 
antiserum also detected a co-purified bacterial protein in the MBD1 preparation. A 
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Figure 4.2.1.2. Characterisation of anti-MBD2 S923 and R593 antibodies 
S923 antiserum (right panel) had minimal cross-reactivity with MBD3 (a protein 
with 71% identity compared to MBD2b). R593 antiserum (left panel) cross-reacted 
with MBD3. In addition, R593 antiserum also detected two proteins larger than 28 
kDa on Western blot of HeLa nuclear extracts. As these two bands were not 
detected by S923 antiserum, they are likely to be MBD3. 
S923 antiserum can immunoprecipitate MBD2a. 
Different amount of antibodies (S923 immune, S923 preimmune, S752 immune, and 
S752 preimmune) were used to immunoprecipitate nuclear proteins from HeLa 
nuclear extracts. The immunoprecipitates were analysed by Western blot using 
R593 antiserum. Only MBD2a was immunoprecipitated by S923 antibodies. S752 
antibodies bound very low level of MBD2a. 	
70 
amount of recombinant MBD3. Both antisera recognised the 28 kDa "MBD2b?" band, but 
with different efficiency. It is likely that the additional bands greater than 28 kDa are 
MBD3 proteins (Figure 4.2.1.2 D). As R593 antibody cross-reacts with MBD3, it is not 
characterised further and not used for experiments addressing MIBD2. 
Two anti-MBD2 antibodies (S923 and S752) were tested for their ability to 
immunoprecipitate native MIBD2 from HeLa nuclear extracts. The immunoprecipitates 
were probed with R593 antiserum which bound both MIBD2 and MBD3. It is found that 
the S923 antibodies can efficiently bind MBD2a, while S752 antibodies 
immunoprecipitated very low level of MIBD2a (Figure 4.2.1.2 E). In addition, the S923 
antibodies only immunoprecipitate MBD2a, but not the other smaller proteins detected by 
the R593 antiserum. It is likely that the epitopes recognised by S752 antibodies were not 
exposed in the HeLa nuclear extract, and can account for the different ability of the two 
antibodies in immunoprecipitating MBD2a. The MIBD2 bands were displaced downward 
in certain lanes (e.g. lane 3,4,7) due to co-migrating IgG. It is concluded that S923 
antibodies can recognise native MBD2. 
The properties of these three antibodies are summarised in Figure 4.2.1.2 F. 
4.2.2 	MBD2 is a component of MeCPI 
It is of interest to test whether MIBD2 is responsible for MeCP1 activity. As shown in the 
previous section, S923 antiserum was most efficient in iminunoprecipitating native MBD2 
from HeLa nuclear extracts. Therefore, S923 antiserum was used for MeCP1 supershift 
experiment. 
The S923 antiserum can quantitatively supershift HeLa MeCPI activity, while the 
preimmune antiserum had no effect on the mobility of MeCP1 (Figure 4.2.2 A). Both the 
immune and preimmune antisera did not affect the DNA/protein complex on the non-
methylated version of CG  1 probe. The nature of the DNA/protein complex on non-
methylated CG1 1 is not known, and this activity has also been observed previously by 
Boyes and Bird (1991). 
Another antibody S752 raised against an internal fragment of MBD2 (corresponding to 
amino acids 232 to 394 of murine MIBD2a) was not effective in immunoprecipitating 
native MIBD2, and failed to supershift the MeCP1 activity (see Figure 4.2.1.1 I). Thus, 
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Antibody Antigen 	Properties of antibody 
I 	 II 	 • 	, 	[ MBD2a (414 aa) 	S923 
	





Recognises native MBD2a (able to self-IP) 
Able to supershift, immunodeplete MeCP1 
Minimal cross-reactivity with MBD3 
Recognises native MBD2a poorly 
Unable to supershift MeCP1 
Unable to immunodeplete MBD2 
M11111111115 . . 	 j MBD2b (262 aa) 
71 % identity 
Il 	 1 MBD3 (285 aa) 
R593 	His-tagged Cross-reacts with MBD3 
MBD2b 
Figure 4.2.1.21 Summary of anti-MBD2 S752, S923 and R593 antibodies. 
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Figure 4.2.2. MBD2 is a component of MeCP1. 
S923 antiserum can supershift HeLa MeCP1 activity. 
Different amount of serum (preimmune (P1) or immune) were added to HeLa 
nuclear extracts before subsequent incubation with methylated (MeCG1I) or non-
methylated (CG11) probes. S923 antiserum specifically supershifted the MeCP1 
activity, but not the DNA/protein complex on the non-methylated probe. The 
preimmune serum did not affect the mobility of MeCP1 or the DNA/protein 
complex on the non-methylated probe. 
S923 antiserum can also supershift MeCP1 activity of DD7 nuclear extract. 
1 p.1 of preimmune (PT) or immune (I) serum was added to HeLa nuclear extracts 
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Figure 4.2.2. MBD2 is a component of MeCP1. 
Immunodepletion of MBD2 from HeLa nuclear extracts with S923 antiserum (2.5, 
5, and 10 jil) resulted in the loss of MeCP1 bandshift activity. Preirnmune sera did 
not deplete MeCP1 activity. The DNA/protein complexes of the non-methylated 
probe were not affected by immune (I) or preimmune (P1) antibodies depletion. 
S923 antiserum can also supershift MeCP1 activity of tissue nuclear extracts. 
Nuclear extracts were made from rat kidney, rat brain and rat liver. 1 1d of 
preimmune (PT) or immune (I) S923 serum was added to each bandshift reaction. 
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there is a correlation between the ability of the antibodies to bind native MBD2 and 
supershift MeCP1 activity. 
The S923 antiserum was also tested for its ability to supershift MeCP1 activity derived 
from another human cell-line, DD7. DD7 is a human lymphoblastoid line containing a 
balanced X/9 translocation. Again, the immune antiserum can supershift DD7 MeCP1 
activity, while the preimmune serum did not affect the mobility (Figure 4.2.2 B). 
Immunodepletion experiments were also carried out to determine whether the antiserum 
S923 can deplete HeLa MeCP1 activity. Different amounts of the immune and preimmune 
IgG were first bound to protein G sepharose. The beads were then mixed with HeLa 
nuclear extracts. Supernatants were subsequently separated from the beads, and assayed 
for MeCP1 bandshift activity. Immune IgG were found to deplete MeCP1 in a 
quantitative manner (Figure 4.2.2 Q. Preimmune IgG had no effect on MeCP1. Both 
immune and preimmune IgG did not deplete the non-specific complex on the non-
methylated CG1 1 probe. 
This series of experiments leads to the conclusion that M1BD2 is a component of MeCP1 
in HeLa cells. 
Interestingly, S923 antiserum can also supershift MeCP1 activity of nuclear extracts 
derived from rat brain and kidney tissues (Figure 4.2.2 D). Preimmune antiserum did not 
affect the mobility of MeCP1 activity in the same bandshift assay. It is notable that the 
supershift by the immune serum was different from HeLa MeCP1 supershift. The 
retarded 'supershifted' complexes were of much lower mobility. In addition, the immune 
antiserum did not shift a remaining portion of the MeCP 1 activity. The result suggests that 
other methyl-CpG binding proteins may potentially contribute to the composite MeCP1 
activity derived from somatic tissue extracts. 
4.2.3 	F9 embryonic carcinoma (EC) cells are deficient in M13132 
Although DNMT1 is crucial for the mouse embryogenesis, it is not required for the 
survival and proliferation of embryonic stem cells, and these cells can also tolerate very 
low levels of DNA methylation (Li et a!, 1992). Interestingly, ES and EC cells are 
deficient in MeCP1 activity (Meehan et a!, 1989; Boyes and Bird, 1991). The lack of 
MeCP 1 in F9 embryonic carcinoma cell-line correlates with the reduced ability of these 
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Figure 4.2.3. F9 embryonic carcinoma cells which lack MeCP1 activity are 
deficient in MBD2. 
F9 EC nuclear extract (25 jxg), rat liver nuclear extract (25 tg), HeLa nuclear 
extract (30 j.tg), and rat brain nuclear extract (22 .tg) were analysed by Western 
blot using S923 antiserum. The position of MBD2a is indicated. The blot was 
also probed with anti-mSin3A (K20) antibody for loading control. 
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cells to silence methylated reporter constructs. This data strongly suggests that MeCP1 is 
the mediator for transcriptional repression by DNA methylation (Boyes and Bird, 1991). 
The level of MIBD2 mRNA was also found to be drastically reduced in ES cells (Hendrich 
and Bird, 1998). 
Western blot analysis using anti-IvIBD2 antibody was carried out on nuclear extracts made 
from rat liver and F9 embryonic carcinoma cells. It was found that there is no detectable 
MIBD2 in F9 nuclear extract (Figure 4.2.3). However, these extracts contained 
comparable levels of the mSin3A corepressor protein, thus the lack of MBD2 in F9 
nuclear extract was not due to unequal loading of proteins. It is also apparent that rat brain 
nuclear extract which is enriched in MeCP2 has lower level of MIBD2 compared to rat 
liver nuclear extract, this suggests that there may be a tissue-specific variation in the 
abundance of these MeCPs. 
4.2.4 	MBD2 is associated with histone deacetylases 
MeCP2 had been shown to interact with the mSin3AI histone deacetylases complex. It is 
of interest to see if MBD2 is also associated with histone deacetylases. S923 antiserum 
was used to immunoprecipitate nuclear proteins. This antibody was chosen because of its 
ability to recognise native MI13132. The immunoprecipitated materials were separated by 
SDS-PAGE, and followed by Western blotting analysis to detect co-immunoprecipitated 
proteins. HDAC1, HDAC2 and RbAp48 were immunoprecipitated by antibody S923 
(Figure 4.2.4 A). Control preimmune antibody did not immunoprecipitate these proteins. 
The western blot was also probed with anti-retinoblastoma and anti-p150 (the largest 
subunit of chromatin assembly factor 1) antibodies. Retinoblastoma protein (Rb) is 
known to interact with histone deacetylases (HDAC1 and HDAC2), but was not 
immunoprecipitated by anti-MBD2 antibody (Brehm et al, 1998; Luo et al, 1998; 
Magnaghi-Jaulin et al, 1998). Chromatin assembly factor 1 complex contains the core 
histone binding protein, RbAp48 (Verreault et al, 1996; 1998). Although RbAp48 protein 
was found in anti-MIBD2 immunoprecipitate, p150 subunit of CAM was not detected. 
The absence of Rb and p150 in anti-MBD2 immunoprecipitates indicates that the antibody 
can specifically bringing down MBD2 associated proteins. 
Does the anti-MBD2 inimunoprecipitate contain histone deacetylase activity? This 
question was answered by experiments carried out by our collaborator Dr Cohn Johnson 










Figure 4.2.4. MBD2 is associated with histone deacetylases. 
A) Anti-MBD2 antibody can immunoprecipitate histone deacetylases 
HDAC1, HDAC2, and histone-binding protein RbAp48 from HeLa 
nuclear extracts. Preimmune antibodies did not immunoprecipitate these 
proteins. Anti-MBD2 antibody did not immunoprecipitate HDAC1 










0_ 	•- o •- - c.J o '•- 0 	c'i 	0 
0CO 0 CO 
CO D 





:• 	..—H DA 
HDAC1*+MBD2 
MBD3 
E - - -7. 




Figure 4.2.4. MBD2 is associated with histone deacetylases. 
Anti-MBD2 antibodies immunoprecipitated histone deacetylase activity from HeLa 
crude cell extracts, but preirnmune, anti-CDK7 and anti-MBD1 antibodies did not. 
MBD2 is present in affinity-purified 1-IDAC1 complexes. 
A silver-stained gel showing the proteins retained on HDAC1 ((XHDAC1) and GST 
((xGST) antibody columns. Mass spectrometric and sequence analysis of the 43 kDa 
band identified a peptide contained in HDAC1, as well as a 39 amino-acids peptide that 
matches MBD2 sequence. Known components of the complexes are indicated on the 
right. 
MBD2 is not present in previously characterised NuRD or mSin3 complexes. 
Affinity purified (aMTA2, (xHDAC1, aSAP30) or native (NuRD) complexes were 
analysed by Western blotting using anti-Mi2, anti-mSin3, anti-MTA2, anti-HDAC1, anti-
HDAC2, anti-RbApl 6, anti-RbAp48, and anti-MBD2 antibodies. 
The experiments were performed by Drs. Cohn Johnson and Yi Zhang. 	 79 
deacetylase activity can be immunoprecipitated by anti-MBD2 antibody (Figure 4.2.4 B). 
Control antibodies such as preimmune, anti-CDK7, or anti-MBD1 antibodies did not 
bring down histone deacetylase activity. 
Although anti-MBD2 antibody can imrnunoprecipitate histone deacetylases and 
deacetylase activity, it is not certain if this is due to cross-reactivity of the antibody 
towards components of histone deacetylase complexes. Therefore, reciprocal 
immunoprecipitation experiments are essential to confirm the interaction between MIBD2 
and histone deacetylases. Our collaborator Dr Yi Zhang (New Jersey) found that affinity 
purified HDAC1-containing complexes contain MIBD2 (Figure 4.2.4 Q. This was 
determined by microsequencing of a 43 kDa band from the silver-stained gel. A derived 
peptide sequence of 39 amino acids 
(GLQGVGPGSNDETLLSAVASALHTSSAPITGQVSAAVEK) was identical to 
sequence of MIBD2. Microsequencing also showed that the 43 Wa silver-stained band 
contained sequences derived from HDAC 1. Western blotting of the affinity purified 
HDAC1 complexes with anti-MBD2 antibody independently corroborated the interaction 
between JVIIBD2 and HDAC1 (Figure 4.2.4 D). Interestingly, MIBD2 was not found in 
affinity purified NuRD (anti-MTA2 lane) and mSin3 (SAP30 lane) complexes. This 
suggests that MIBD2 is found in a novel HDAC 1-containing complex. 
One prediction based on the MBD2/ HDAC1 association is that anti-HDAC1 antibody 
should immunodeplete MeCP1 activity. Indeed, anti-HDAC1 antibody could 
quantitatively reduce the level of both MeCP1 and MIBD2 (Figure 4.2.4 E). Control anti-
SAP30 antibody had no significant effect on either MeCP1 or MBD2. The two non-
specific bands (indicated by asterisks) bound by S923 anti-MBD2 antiserum were not 
depleted by HDAC 1 antibodies, and thus serves as internal negative controls for the 
specific depletion of MeCP1 and MBD2 using anti-HDAC1 antibodies. This result further 
substantiates the links between MIBD2, MeCP1 and HDAC1. 
Curiously, a panel of antibodies directed against components of the HDAC1/2 complexes 
(anti-HDAC1, anti-HDAC2, and anti-RbAp48) did not supershift the MeCP1 bandshift 
activity (Figure 4.2.4 F). Given the observation that anti-HDAC1 antibodies can 
immunodeplete both MBD2 and MeCP1 activity, it is proposed that the MeCP1 bandshift 
activity contains only the DNA binding component which is MBD2. It is conceivable that 
the MBD2/ HDAC complex may have dissociated during the process of electrophoresis. 
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Figure 4.2.4. MBD2 is associated with histone deacetylases. 
Anti-HDAC1 antibodies (10 j.tl, 20 jil, 30 jil) immunodepleted both MBD2 
and MeCP1 activity. Control anti-SAP30 did not deplete MBD2 or MeCP1 
activity. The asterisks indicate two non-MBD2 specific bands which are 
bound by anti-MBD2 S923 antiserum. These bands were not depleted by 
HDAC1 or SAP30 antibodies. 
Effect of anti-MBD2, anti-HDAC1, anti-MTA2, anti-Mi2, anti-SAP30, anti-. 
mSin3A, and anti-RbAp48 antibodies on MeCP1 bandshift activity. The 
amount of serum added to the bandshift reactions is indicated. 
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Alternatively, the conditions for the bandshift assay may lead to the dissociation of M1BD2 
/ HDAC complex. 
	
4.2.5 	Interaction between MBD2 and other components of HDACl/2 
complex 
HDAC1, HDAC2, RbAp48 and M1BD2a were synthesised in vitro, labeled with 31  S-
methionine and tested for interaction with GST-MBD2a. It is found that GST-MIBD2a can 
interact very weakly (less than 5 % of input was bound) with HDAC 1, HDAC2 and 
RbAp48 (Figure 4.2.5). On the other hand, MBD2a bound efficiently to GST-MBD2a 
(more than 10 % of input was bound). These interaction appear to be specific, as the GST 
control did not bind to the in vitro translated proteins. The self-interaction of MBD2a is 
interesting because it may facilitate the binding of MBD2a complex (MeCP1) to densely 
methylated DNA. It is perhaps not surprising that MIBD2a can interact with at least four 
proteins in vitro, because a highly related protein, MBD3, can bind directly to four 
proteins, namely MTA2, HDAC1, RbAp46 and RbAp48 (Zhang et a!, 1999). However, 
the possibility that a yet unknown protein(s) in the in vitro translation mixture mediates 
the interaction cannot be excluded with the GST-pulldown assay. 
4.2.6 	MBD2 exists in a high molecular weight complex 
Previous work had demonstrated that MeCP1 migrates with a large molecular weight 
(from 400 to 800 kDa) on a gel-filtration column. When native HeLa extract was 
fractionated on a Superose 6 gel-filtration column, MBD2 eluted in high molecular weight 
fractions (Figure 4.2.6). It is estimated that MBD2 migrates at about 800 kDa. The result 
is consistent with the finding that MBD2 can interact with multiple proteins in vitro and is 
found in a multiprotein HDAC1/2 complex. Unfortunately, MeCP1 activity could not 
detected in all the fractions, therefore in this experiment the relationship between MBD2 
and MeCP1 cannot be critically determined. 
4.2.7 	MBD2 can repress transcription in vitro 
Previously, MeCP2 was shown to repress transcription of a methylated template 
specifically in vitro (Nan et al, 1997). The same assay was used to test whether MBD2 
can repress transcription in a cell-free system. Recombinant GST-MBD2a or GST- 
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Figure 4.2.5. MBD2 interacts weakly with HDAC1, HDAC2, RbAp48, but 
strongly with itself. 
HDAC1, HDAC2, RbAp48, and MBD2a were in vitro translated and labeled 
with 35  S methionine. The labeled products were incubated with GST or 
GST-MBD2a. Bound proteins were eluted, separated by SDS-PAGE, and 
detected by autoradiography. In vitro translated MBD2a contained 5 myc 
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Figure 4.2.6. MBD2 exists in a high molecular weight complex. 
HeLa nuclear extract was fractionated by Superose 6 gel-filtration column. The 
fractions were analysed by Western blotting using anti-MBD2 S923 antiserum. 
MBD2 was found in fractions 7 and 8 (indicated by asterisks) corresponding to 
approximately 800 kDa. The column was calibrated with known molecular weight 
markers. Identical result was obtained using anti-MBD2 S752 antiserum (data not 
shown). 
M13D2b was incubated with pAdomal template (construct driven by adenovirus major late 
promoter) methylated at 44 HhaI sites (Figure 4.2.7). HeLa nuclear extracts and NTPs 
were then added to the mixture to initiate transcription from the reporter template. A 
mock-methylated pAdBXN template (pAdomal with 18 bp insertion downstream of 
transcription start site) was included as an internal positive control in these assays. Due to 
the extra 18 bp insertion in pAdBXN reporter, the RNA product is 18 nucleotides longer 
than that transcribed from the pAdomal reporter. The RNA transcripts derived from the 
pAdomal and pAdBXN reporters were determined by primer extension assay. In the 
absence of recombinant GST-MIBD2 protein, the relative transcription of the HhaI 
methylated template (ratio of M-/ M+) was close to 1. Addition of 1 jig and 2 jig of GST-
M1BD2a resulted in 2 fold and 4 fold repression of the methylated template respectively. 
GST-MBD2b was found to abolish transcription from the methylated template. The 
preparation of GST-MBD2a contained mostly C-terminal truncation products, and 
therefore deficient in products with the MBD region. This is likely to account for the 
weaker repression observed using the full-length MIBD2. 
It is however not possible to distinguish whether M1BD2 is repressing the methylated 
template by sterically blocking the access of transcription factors or through an active 
repression mechanism. Therefore the next experiment is designed to address if MBD2 can 
function as a transcriptional repressor in vivo when tethered to specific sites of a reporter. 
4.2.8 	MBD2 can repress transcription in vivo 
GAL4-MBD2a fusion construct was co-transfected with a reporter gene containing Ga14 
binding sites upstream of the promoter (G5). The GALA-MIBD2a fusion protein is 
tethered to the reporter construct in vivo, and the influence of MIBD2 on the promoter can 
be assayed. A reporter without Ga14 binding sites (GO) was used as a control in separate 
co-transfection experiments. GAL4-MBD2a repressed the G5 reporter to a greater extent 
compared to the GO reporter (Figure 4.2.8 A, top graph). After normalising the - 
galactosidase activity of the G5 or GO reporters with the luciferase activity from an 
internal pGL2 reporter, it is clear that the repression of GAL4-M1BD2a depends on the 
presence of Ga14 binding sites (Figure 4.2.8 A, bottom graph). Strangely, increasing 
amounts of co-transfected effector did not reduce the relative activity of the G5 reporter 
further. Western blot analysis of the lysates from transfected cells with anti-GAL4 
antibodies indicated that expression of GAL4-MBD2a from the effector construct was not 
saturated (Figure 4.2.8 Q. 
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Figure 4.2.7. Methylation dependent repression by recombinant MBD2. 
Recombinant MBD2a and MBD2b specifically repress the methylated pAdomal 
promoter in vitro. 
Different amounts of recombinant MBD2a and MBD2b (1 i.'g  or 2 j.tg) were incubated with 
mock methylated pAdBXN or HhaI methylated pAdomal reporters. HeLa nuclear 
extracts and NTPs were then added to the mixtures to initiate transcription from the two 
reporters. The level of transcription was quantitated by primer extension assays. No 
recombinant protein was added in lane 1. The ratio of M-/M+ was calculated for lane 1 
to 3 using values obtained by Phospholmager. The values for fold repression on the 
methylated reporter in the presence of MBD2a are shown. 
Contructs used in A. The location of transcription start site, HhaI sites and primer are 
shown. The 18 bp insertion is shown as a gray box. 
HhaI and CpG sites for pAdomal reporter are shown. Regions outside the 
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Figure 4.2.8. Transcriptional repression by MBD2. 
GAL4-MBD2a specifically represses a reporter with Ga14 binding sites. 
Increasing amounts of GAL4-MBD2a effector was co-transfected with GO or G5 
reporters (human 13 actin promoter driving lacZ gene) in the presence of 
luciferase reporter as an internal control. Top graph, 13-gal reporter activities are 
shown. Bottom graph, normalised reporter activity (13-gal/luciferase)  are shown. 
Contructs used in A. 
The effector construct expressed a GAL4-MBD2a fusion protein of the correct 
size as revealed by Western blot analysis using anti-GAL4 antibodies. ++ (2 jig) 
contains double amount of effector used compared to + (1 jig). 	
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The effect of GAL4-MBD2a was also tested on another reporter driven by the human 
DNA polymerase 3 promoter. The repression of the human DNA polymerase 0 promoter 
was weaker compared to that of the human 13-actin promoter (Figure 4.2.8 D). Saturation 
of repression on the G5 reporter was again observed. Different preparation of DNA 
(cesium chloride or Qiagen ion exchange) did not affect the repression activity of GAL4-
MBD2a (data not shown). The reason for the modest repression on both the human 3-
actin promoter and human DNA polymerase 13  promoter is not known. It is plausible that 
the presence of two DNA binding domains (methyl-CpG binding domain and GALA 
DNA binding domain) may lead to mistargeting of the GAL4-MBD2a fusion protein. 
Alternatively, full repression activity of MBD2a may require chromatinised templates, and 
such chromatin conformation may be absent in transiently transfected DNA templates 
(Wu, 1997). 
	
4.2.9 	Trichostatin A (TSA) can relieve repression on the human DNA 
polymerase 13  promoter 
As MBD2a was found associated with histone deacetylases and can repress transcription 
in a transient transfection assay, an inhibitor relief experiment will allow one to address 
whether repression is dependent on deacetylation in vivo. Transfected cells were 
incubated in media with 100 ng/ml TSA or 200 ng/ml TSA for 24 hours before collection 
for reporter assays. It is found that repression on the human 13-actin promoter was not 
sensitive to TSA (Figure 4.2.9, left panel), while ISA abolished repression on the human 
DNA polymerase 13  promoter (Figure 4.2.9, right panel). Promoter-specific derepression 
upon TSA treatment has previously been documented (Luo et al, 1998; Koipally et al, 
1999). 
4.2.10 	Mapping of a repression domain? 
It is of interest to map the region in MBD2a that is responsible for the repression observed 
in section 4.2.8. A panel of GAL4-MIBD2 fusion constructs was generated (Figure 
4.2.10). The GAL4 fusion protein with amino-acids 215 to 414 aa of MBD2 repressed 
transcription of both GO and G5 reporters, and showed no apparent specificity towards 
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Figure 4.2.8. Transcriptional repression by MBD2. 
GAL4-MBD2a specifically represses a reporter with Ga14 binding sites. 
Increasing amounts of GAL4-MBD2a effector was co-transfected with GO or G5 reporters 
(human DNA polymerase 13  promoter driving luciferase gene) in the presence of lacZ 
reporter as an internal control. Normalised reporter activity (luciferase/13-gal) are shown. 
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Figure 4.2.9. Effect of histone deacetylase inhibitor, TSA on repression by GAL4-MBD2a. 
Repression on the 0 actin promoter by GAL4-MBD2a is not sensitive to TSA. 
Repression on the DNA polymerase 3 promoter by GAL4-MBD2a is sensitive to TSA. 
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Figure 4.2.10. Mapping of a repression domain in MBD2a. 
The effect of different GAL4-MBD2 fusions (A to F) was tested on GO and G5 reporters 
(human 3 actin promoter driving lacZ gene). Repression profiles on GO and G5 
reporters are shown. 
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full-length MIBD2. It is likely that the repression property of MBD2 is sensitive to 
deletion, as in the case of yeast histone deacetylase, RPD3 (Kadosh and Struhi, 1998a). 
4.2.11 	Is MBD3 a methyl-CpG binding protein? 
The remarkable similarity between MBD2 and MBD3 prompted the reinvestigation of 
whether MBD3 is a methyl-CpG binding protein. MBD3 was expressed in E.coli. as a 
His-tagged protein. The purified protein was used for bandshift experiments using 
methylated and non-methylated version of CG  1 (0.1 ng of labeled probe). A titration 
experiment with increasing concentration of protein in the absence of competitor DNA 
demonstrated that MIBD3 has a preference for methylated DNA (Figure 4.2.11 A). The 
mobility of the DNA/protein complex at a particular concentration was different between 
the methylated and non-methylated probes. A change in detergent used in the bandshift 
assays from digitonin (1 %) to Triton X-100 (0.1 %) did not alter the DNA binding 
property of MBD3 (data not shown). 
Increasing amounts of non-methylated E.coli. competitor DNA included in the bandshift 
assay also lead to the preferential formation of complex with the methylated probe (Figure 
4.2.11 B). Under certain conditions (e.g. 100 ng and 200 ng of competitor DNA), only 
the methylated probe was shifted by MBD3. A similar conclusion is reached that MBD3 
has a preference for methylated DNA in vitro. 
In collaboration with Dr. Danny Reinberg (New Jersey), we studied the DNA binding 
property of MBD3 expressed and purified from baculovirus infected insect cells. Two 
versions of MBD3 (a and b) were tested for binding to methylated DNA (Figure 4.2.11 
Q. MBD3a contains the full MBD-like region, and MIBD3b is a splice variant with only 
half of the MBD-like region (Zhang et al, 1999). Initial bandshift experiment was carried 
out with increasing amounts of protein and in the absence of competitor DNA (Figure 
4.2. 11 D). At certain protein concentration, MBD3a bound both the methylated and non-
methylated CG  1 probes. However, similar to the result obtained from E.coli expressed 
protein, M13D3a exhibited a preference for methylated DNA. For example, at 100 ng of 
MBD3a, only the methylated CG  1 probe was shifted. 
These series of experiments showed that MBD3 has a preference for methylated DNA in 
vitro. In addition, the MBD-like region is important for selectivity as MBD3b, which does 
not 	have the full MED-like region 	did not bind 	to 	DNA. 
92 
4ft •.ø— Wells 
100 	300 	100 	300 
0 	200 	0 	200 	MBD3 (ng) 
CG11 	MeCG11 
•— Wells 
- 2 5 10 20 100200 - 2 5 10 20 100200 E.coIi DNA (ng) 




Figure 4.2.11. Methyl-CpG binding property of MBD3 
Increasing amounts of recombinant MBD3 (expressed in E.coli.) were incubated 
with either non-methylated or methylated CG11 probes in the absence of competitor 
DNA. The DNA /protein complexes were resolved on 1.5 % agarose gel. The position 
of the wells is indicated. 
Increasing amount of E.coli. DNA as added to 100 ng of MBD3 before incubation 
with either non-methylated or methylated CG11 probes. The asterisks indicate 
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Figure 4.2.11. Methyl-CpG binding property of MBD3 
Two variants of MBD3 used in bandshift experiments shown in D. MBD3a contains 
a MBD-like region shown as a box. MBD3b contains C-terminal half of the MBD-like 
region. 
Increasing amount of MBD3a or MBD3b (expressing and purified from baculovirus 
infected insect cells) was incubated with either non-methylated or methylated CG11 
probes in the absence of competitor DNA. The DNA/protein complexes were resolved 
on 5 % polyacrylamide gel. The position of the wells is indicated. 
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The specificity of the MBD3a/ MeCG1 1 complex was next tested by competition 
experiments with methylated and non-methylated competitor DNA. It was found that the 
MIBD3a/ MeCG1 1 complex is very sensitive to competition by non-methylated DNA, as 
the DNA binding activity was completely abolished by the addition of 100 ng of E.coli 
DNA (Figure 4.2.11 E, compare lane 1 and lane 3). When the bandshift reactions were 
challenged with equal amount of non-methylated or methylated DNA, no clear difference 
was evident (Figure 4.2.11 E, compare lanes 4 &5, 6&7, 8 & 9, 10 & 11, 12 & 13, 14 & 
15). It is concluded that the specificity of MBD3 towards methylated DNA is weak. 
As MBD3 is identified as a component of the Nucleosome Remodelling and histone 
eacetyiation complex (NuRD) (Zhang et al, 1999; Wade et al, 1999). A more relevant 
question is whether the native NuRD complex has an affinity for methylated DNA. Under 
conditions with no non-methylated competitor DNA, the NuRD complex bound both the 
methylated and non-methylated DNA (Figure 4.2.11 F, lanes 3 and 6). Addition of non-
methylated competitor DNA (300 ng) abolished the DNA/protein complexes (see Figure 
4.2.11 H, lane 4). Therefore, no methylated DNA binding specificity was detected for the 
NuRD complex. In addition to MBD3, Wade et al (1999) showed that a MTA1-like 
protein in the Xenopus NuRD complex has an affinity for methylated DNA using a 
Southwestern assay. The human homolog of MTA1-like protein, MTA2 bound both the 
non-methylated and methylated probe, indicating that MTA2 binds non-specifically to 
DNA independent of methylation (Figure 4.2.11 G). 
Although MBD2 is not a component of the NuRD complex, it can however interact with 
the NuRD complex in vitro as revealed by GST pulldown assay (Zhang et al, 1999). 
Incubation of GST-MBD2a with the purified NuRD complex (300 ng) also resulted in the 
formation of a DNA/ protein complex with lower mobility (Figure 4.2.11 H, compare 
lanes 2 and 3). Under the same assay condition, the addition of 3 jig of BSA (10 fold 
more than the amount of NuRD used) did not alter the mobility of the DNA/ protein 
complex (Figure 4.2.11 H, compare lanes 6 and 7). 
4.3 Conclusion 
Several antibodies were raised against MBD2. Antibody R593 cross-reacts with a related 
protein MBD3, which did not show a marked preference for methylated DNA in vitro and 
in vivo (Hendrich and Bird, 1998). As MBD3 is a component of the NuRD complex, the 
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Figure 4.2.11. Methyl-CpG binding property of MBD3 
E) The MeCG11/MBD3 complex was challenged with non-methylated or methylated 
competitor DNA (lanes 2 to 15). pCG11 is a pUC19 plasmid containing a CG11 insert. 
pHsr11.9 is a pUC9 with a 11.9 kb human rDNA EcoRT fragment. The plasmids were 
methylated at all CpG sites using SssI methylase. The DNA/protein complexes were 
resolved on 5 % polyacrylainide gel. 
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Figure 4.2.11. Methyl-CpG binding property of NuRD complex and MTA2 
Increasing amounts of purified NuRD complex were incubated with non-
methylated or methylated CG11 probes in the absence of competitor DNA. The 
DNA/protein complexes were resolved on 1.5 % agarose gel. HeLa nuclear extracts 
were included as controls. 
Increasing amounts of recombinant MTA2 (expressed in E.coli.) were incubated 
with either non-methylated or methylated CG11 probes in the absence of competitor 
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Figure 4.2.11. Interaction between MBD2 and NuRD 
H) Addition of NuRD complex can alter the mobility of MBD2/MeCG11 complex. 
The binding reactions contained 300 ng of E.coli. competitor DNA, and/or 200 ng of 
GST-MBD2a, and/or 300 ng of NuRD complex (lane 2 to 4). Addition of 300 ng of 
E.coli. competitor DNA to the NuRD bandshift mixture abolished the DNA binding 
activity completely (lane 4). 10 fold excess of BSA did not alter the mobility of 
MBD2/MeCG11 complex (lane 6). 
R593 antibody was not used in studies addressing MBD2 interacting proteins. Although 
the two other antibodies (S752 and S923) can discriminate between MBD 1, M13132, and 
MIBD4, only antibody S923 can efficiently recognise native MBD2 from HeLa nuclear 
extracts as revealed by immunoprecipitation assay. Antibody S752 recognised native 
MBD2 poorly, suggesting that the C-terminal epitopes are not exposed. These two 
antibodies were tested for the ability to interact with the méthyl-CpG binding activity in 
HeLa cells, MeCP1. Antibody S923 can supershift and immunodeplete MeCP1 activity in 
HeLa cells. Antibody S752 did not affect MeCP1 activity under similar assays. A 
correlation between the ability of these antibodies to recognise native MBD2 and interact 
with MeCP1 was observed, and the result suggests that MBD2 is a component of 
MeCP1. In addition, S923 antibody was able to supershift MeCP1 activity from nuclear 
extracts derived from rat brain, kidney, liver and a human lymphoblastoid cell-line, DD7. 
Co-immunoprecipitation experiments using S923 antibody indicate that MBD2 is 
associated with HDAC1, HDAC2 and RbAp48. These proteins are common subunits of 
histone deacetylase complexes found in mammalian cells (Hassig et al, 1997; Laherty et 
al, 1997; Zhang et a!, 1997; Zhang et al, 1998). In addition, S923 antibody can 
immunoprecipitate histone deacetylase activity from HeLa cell extracts. Reciprocal 
immunodepletion and immunoprecipitation experiments using anti-HDAC1 antibody 
confirmed the interaction. Anti-HIDAC1 antibodies were able to immunodeplete both 
MBD2 and MeCP1. Affinity purified HDAC1 containing complexes also contained 
MBD2. Based on the work with our collaborators (Drs Yi Zhang and Danny Reinberg), 
MBD2 is not found in previously characterised mSin3 or Mi2/ NuRD histone deacetylase 
complexes. Using GST-pulldown assay, MBD2 was shown to interact weakly with 
HDAC1, HDAC2 and RbAp48. Interestingly, MBD2 can also interact with itself under 
the same assay. Homodimerisation may provide the MBD2 complex with extra binding 
affinity for methylated DNA. Consistent with the finding that MIBD2 exists in a 
multiprotein complex, the native size of MBD2 as revealed by gel filtration 
chromatography is in the range of 800 kDa. 
GAL4-MBD2 can repress transcription from reporter constructs containing Ga14 binding 
sites upstream of human DNA polymerase P promoter or human -actin promoter. 
Repression on the human DNA polymerase 3 promoter is sensitive to TSA, indicating that 
deacetylation is involved in repression of this promoter. Repression on the human 13-actin 
promoter was not relieved by TSA, suggesting that MIBD2 can repress transcription 
through deacetylation independent pathway. It is notable that repression on the two 
promoters was not strong. It is possible that chromatinised template is required for full 
repression activity. 
Interestingly, it is reported that a truncated version of MIBD2 (MBD2b) contains a 5-meC 
demethylase activity (Bhattacharya et al., 1999). MBD2b was shown to catalyse the 
removal of methyl group from 5-meC. Unfortunately, this novel activity cannot be 
reproduced by two laboratories (Ng et al, 1999; Wade et al, 1999). 
As M1BD3 is identified as a component of the Xenopus and mammalian NuRD complex 
(Zhang et al, 1999; Wade et al, 1999), the issue of whether MBD3 is a methyl-CpG 
binding protein was re-investigated. Bandshift experiments with M1BD3 expressed from 
E.coli using a densely methylated probe showed that MIBD3 has a preference for 
methylated DNA. The bandshift experiments were also repeated using affinity purified 
M1BD3 derived from baculovirus infected insect cells. Full-length MBD3 (MBD3a) bound 
preferentially to methylated probe in the absence of competitor DNA. However, the non-
methylated probe was also shifted in the presence of more protein. A shorter version of 
Iv[BD3 with half the MBD-like domain deleted did not bind to either the non-methylated or 
methylated probes. Both the full-length MIBD3 expressed in E.coli and insect cells 
showed preference for methylated DNA. It should however be emphasised that the 
methylated DNA! protein complex is very sensitive to competition with non-methylated 
DNA. Furthermore, addition of non-methylated or methylated DNA did not yield a 
specific DNA/ protein complex. 
The DNA binding activity of mammalian NuRD complex was also studied. The native 
NuRD complex shifted both the non-methylated and methylated probe in the absence of 
competitor DNA. Addition of non-methylated competitor DNA abolished the DNA 
/protein complex. A component of the NuRD complex, MTA2 also bound to DNA in a 
methylation independent manner. Therefore, unlike the Xenopus MIBD3 and MTA1-like 
protein, the mammalian homologues do not bind specifically to methylated DNA. 
GST-MBD2 can pull-down all the subunits of the NuRD complex (Zhang et al, 1999). In 
addition, the NuRD complex can 'supershift' the MBD2/ DNA complex. The result 
indicate that MIBD2 can interact with the Mi2 containing NuRD complex in vitro. It should 
however be emphasised that there is currently no evidence that the interaction between 
MIBD2 and NuRD can occur in vivo. The result can also be explained by the possibility 
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that MIBD2 interacts directly with certain subunits of the NuRD complex, e.g. HDAC1, 
HDAC2 or RbAp48. 
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Chapter 5: MBDI is a transcriptional repressor 
5.1 Introduction 
MBD1 (formerly known as PCM1) was originally identified by searching the EST 
databases for proteins with methyl CpG binding domain of MeCP2. The N-terminal of 
MBD1 contains a MIBD-like region (Cross et al, 1997). In addition, this protein has two 
cysteine-rich regions (termed the CxxC motifs) also found in DNA methyltransferase 
protein 1 (DNMT1) and mammalian trithorax-like protein HRX. The HRX, also known 
as MLL (mixed lineage leukemia) and ALL] (acute lymphoblastic leukemia) is frequently 
translocated in acute leukemia. A region encompassing the CxxC motif in DNMT1 has 
been shown to bind zinc (Bestor, 1992; Chuang et al, 1996). 
An antibody raised against MBD1 was able to supershift the MeCP1 activity, this 
suggests that MBD1 is a component of the long sought MeCP1 (Cross et al, 1997). When 
an in vitro transcription extract was supplemented with recombinant MBD 1, the 
transcription from a methylated template was preferentially repressed. The result from the 
in vitro experiment suggests that MBD1 is a mediator of transcriptional repression by 
DNA methylation. 
The work described in this chapter concerns the functional characterisation of the methyl-
CpG binding protein, MBD 1. 
5.2 Results and discussion 
5.2.1 	Full-length MBDI binds selectively to methylated DNA in vitro 
MBD1 is susceptible to degradation when expressed in E.coli (Cross et al, 1997; 
Hendrich and Bird, 1998). When the N-terminal His-tagged MBD1 was purified over a 
Ni2 -NTA column, the majority of the eluted proteins contained only the N-terminal 
fragments. It was found that a combination of affinity purification of C-terminal His-
tagged MBD1 and strong cation-exchange chromatography can preferentially enrich for 
full-length MIBD1 (Figure 5.2.1 A). The first step of purification over a Ni 2 -NTA 
column yielded three major products. The two smaller proteins of approximately 70 Wa 
are likely to be degraded MBD1 lacking the basic N-terminal parts. When the eluate was 
applied to a strong cation-exchange Fractogel EMD S0 3  e_650(M) column at 0.3 M NaCl, 
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Figure 5.2.1 Affinity of intact MBD1 for methylated DNA in vitro 
Purification of C-terminal tagged MBD1 over Ni 2 -NTA and cation exchange column. 
Full-length MBD1 binds specifically to methylated probes. 
HpaII methylated CG11 probe contains 7 methyl-CpG pairs. HhaI methylated CG11 probe 
contains 20 methyl-CpG pairs. M- probe was mock-methylated. 
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only the full-length protein was retained. The eluted protein was judged to be 95 % pure 
by Coomassie blue staining and Western blotting (Figure 5.2.1 A and 5.2.3 A). 
Bandshift assays were carried out using the full-length MBD1. MBD1 bound to the Hpall 
methylated and Hhal methylated CG  1 probes, but not the non-methylated probe (Figure 
5.2.1 B). 
5.2.2 	The N-terminal of MBDI is sufficient for binding to methylated 
The MIBD-like region in MBD1 shares a 43.6 % identity with IvIIBD of MeCP2 over a 55 
amino-acids sequence (Figure 5.2.2 A). Since the minimal region in MeCP2 required for 
specific interaction with methyl-CpG pair spans 85 amino-acids (Nan et al, 1993), it is 
curious to test whether this homologous region is sufficient for specific binding to 
methylated DNA. The first 67 amino-acids of MIBD1 was expressed as a GST-fusion 
protein. The purified recombinant protein bound specifically to 17 mer AB 17 probe with a 
single methyl-CpG pair, and not to the control non-methylated or hemi-methylated probes 
(Figure 5.2.2 B). 
Proline at the 38 position is conserved between the MBD of different methylated DNA 
binding proteins (MeCP2, MBD1, MBD2, and MBD4). Using PCR-directed 
mutagenesis, the codon coding for proline was mutated to encode alanine or lysine. The 
purified GST-MBD1 (1-67 aa) with these amino-acid substitutions failed to bind 
methylated DNA as demonstrated using bandshift assay (Figure 5.2.2 Q. The result 
indicates that the N-terminal 67 amino-acids of MBD1 is a methyl-CpG binding domain. 
The NMR structure of the MBD of MeCP2 has been solved, and the corresponding 
proline in MBD of MeCP2 was found at a sharp turn between two strands of beta sheets 
(Wakefield et a!, 1999). The amino acids around this proline did not undergo a chemical 
shift upon DNA binding, suggesting that it is not in contact with DNA. Conversion of the 
proline to alanine or lysine is likely to perturb the local structure of the MBD by removing 
the unique chain bending property of proline. 
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Figure 5.2.2. Methyl-CpG binding domain of MBD1 
Sequence comparison between MBD of MeCP2 and MBD-like region in MBD1. A conserved 
proline is highlighted in bold. 
The N-terminal 67 amino-acids of MBD1 binds specifically to a symmetrical methyl-CpG pair. 
Mutation in proline 38 abolished methyl-CpG binding. 	
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5.2.3 	Characterisation of an antibody raised against MBDI 
To facilitate the functional studies of MBD 1, an antibody was raised against a GST-fusion 
of MBD1 (spanning amino acids 351 to 556) in sheep. The C-terminal fragment of MBD1 
was chosen to minimise cross-reactivity towards other MBD or CxxC domain-containing 
proteins. The S571 immune antiserum is specific for MIBD1 and does not cross-react with 
MBD2b or MBD4. When a Western blot of HeLa nuclear extracts was probed with this 
antibody, two bands were detected (the bands correspond to 83 and 75 Wa; see Figure 
5.2.3 A, left panel). Two lines of evidence indicate that the two bands are specific for 
MBD1. First, the preimmune serum did not detect these proteins (data not shown). 
Second, the specific antibodies in the immune antiserum can be depleted by pre-
incubation with GST-MIBD1 coupled to GSH-sepharose beads (Figure 5.2.3 A, left 
panel). GST-GSH-sepharose beads did not deplete the MBD1 signal (Figure 5.2.3 A, 
right panel). The two proteins of different molecular weight are possibly spliced variants 
of M1BD1 (see Figure 5.2.7 A for two spliced versions: MBD1 and MBD1*).  It is very 
likely that the 83 Wa M1BD1 protein contains 3 CxxC motifs while the 75 kDa protein 
contains only 2 CxxC motifs. An additional CxxC motif of about 68 amino-acids can 
account for an increase of 5 kDa in size. mRNA encoding for 2 or 3 CxxC motifs can be 
detected in HeLa cells by RT-PCR (data not shown). Affinity purified antibody also 
detected the same bands as the crude antiserum, therefore the 83 and 75 Wa bands are 
MBD1-specific (Figure 5.2.3 B). Furthermore, the antiserum only recognised MIBD1 but 
not MBD2b or MBD4 (Figure 5.2.3 Q. 
Beside specificity, the antibody was also examined for sensitivity. Different amounts of 
His-tagged antigen (amino acids 351 to 556 of MBD1) were blotted and challenged with 
either preimmune or immune antisera (Figure 5.2.3 D). The immune antiserum detected 
even 500 picograms of antigen. 
Next, the S751 antibody was tested for its ability to recognise native MBD 1. Anti-MED 1 
antibodies, together with control preimmune antibodies, was used to immunoprecipitate 
nuclear proteins from HeLa nuclear extracts. The presence of MBDI in the anti-MIBD1 
immunoprecipitate indicates that the antibody can recognise native MBD1 (Figure 5.2.3 
E). 
The S751 antiserum was also tested on rat liver nuclear extract (containing both MeCP 1 
and MeCP2), and mouse F9 embryonic carcinoma nuclear extract (deficient in MeCP 
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Mock GST depleted serum 
	
GST-MBD1 depleted serum 
Figure 5.2.3.A. Western blot of HeLa nuclear extract with anti-MBD1 S751 antiserum. 
Left panel: the antiserum was preincubated with GST. MBD1 specific signals are 
indicated. The non-specific band was due to cross-reactivity with secondary anti-sheep 
antibody. 
Right panel: the antiserum was preincubated with GST-MBDI to deplete MBD1 
specific antibodies. The residual band in recombinant MBD1 lane is probably a co-




















Figure 5.2.3. Specificity of 5751 antiserum 
Affinity purified anti-MBD1 antibody detected both 83 and 75 kDa nuclear proteins. 
HeLa NE is HeLa nuclear extract. 
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Figure 5.2.3. S751 antiserum 
S751 antiserum can detect picograms of antigen. Preimmune serum was used as a 
control. 
S751 antiserum can recognise native MBD1 from a HeLa nuclear extract. 
Both preimmune and immune S751 sera were used to immunoprecipitate nuclear proteins 
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Figure 5.23. S751 antiserum 
F) Anti-MBD1 antibody cross-reacts poorly with murine MBD1. 
Western blot of HeLa, rat liver, mouse P9 EC nuclear extracts were probed with S751 
antiserum. The blot was also probed with anti-mSm3A (K20) antibodies as a control 
for loading. 
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bandshift activity). The antiserum detected a band of 83 kDa for rat liver nuclear extract, 
albeit very weakly (Figure 5.2.3 F). Since the conservation in amino acid sequences 
between the human and mouse MBD1 is not high (55 % identity and 61 % similarity over 
the region of 206 amino-acids used to raise the S751 antibody), it is suspected that the 
antibody was not efficient in recognising the murine protein, and the weak signal is 
unlikely due to the lack of MIBD 1 in the murine tissue extract. 
5.2.4 	MBDI is not a component of MeCPI 
The discovery of three novel methyl-CpG binding proteins (MBD 1, MBD2 and MBD4) 
raises the possibility that these proteins may contribute to the MeCP1 activity. Previous 
work using an antibody raised against full-length MBDI was able to supershift HeLa 
MeCP1 activity, suggesting that MIBD1 is a component of MeCP1 (Cross et al, 1997). 
With a specific antibody against MIBD1, the relationship between IVIBD1 and MeCP1 is 
studied. 
Immunodepletion experiments described in Chapter 4 (section 4.2.2) was carried out. The 
HeLa nuclear extract after immuno-absorption with MIBD1 antibodies had reduced level of 
MBD1, but the MeCP1 bandshift activity was not affected (Figure 5.2.4 A and B). The 
non-specific complex on the non-methylated probe was not affected by similar treatment. 
Antibody "supershift" experiments were also carried out. Addition of preimmune or 
immune sera (1 p1) to HeLa nuclear extracts slightly altered the mobility of MeCP 1 
complex as compared to bandshift reaction with no added serum (Figure 5.2.4 C, 
compare lanes 8, 9 and 11). When half the amount of serum (0.5 p1) was added to the 
bandshift reactions, no alteration in mobility of MeCP1 was observed (Figure 5.2.4 C, 
compare lanes 8, 10, 12). No difference between the effects of preimmune and immune 
sera on MeCP1 was detected. 
MIBD2 was demonstrated to be a component of MeCP1 (based on work described in 
Chapter 4). Therefore, if IvIBD1 is also a component of MeCP1, MBD1 and MIBD2 
should co-exist in a same complex. Immunoprecipitation experiments revealed that MBD1 
is not associated with MBD2, as MIBD2 was not detected in MIBDI immunoprecipitate 
and MIBD2 immunoprecipitate did not contain Iv[BDI (Figure 5.2.4 D). 
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Figure 5.2.4. MBD1 and MeCP1 
Immunodepletion of MBD1 with anti-MBD1 antibodies. 
HeLa nuclear extracts were incubated with either preimmune or immune S751 sera. The 
unbound extracts were separated from the antibodies and analysed on a Western blot to 
detect MBD1. HeLa NE is non-treated HeLa nuclear extract. 1 il, 5 p1, and 10 il of sera were 
used. Depletion of the 83 kDa MBD1 was not efficient. 
Reduction in MBD1 does not lead to loss of MeCP1. 
The immunodepleted extracts were analysed for MeCP1 bandshift activity. PT is 
preimmane antibodies depleted extract. I is anti-MBD1 antibodies depleted extract. M+ 
CGI1 is CG11 probe methylated at 27 methyl-CpGs. M- CG11 is mock-methylated probe. 












Figure 5.2.4. MBD1 and MeCP1 
C) Anti-MBD1 antibodies do not supershift MeCP1 activity. 
Different amount of preimmune and immune S751 sera were added to bandshift reactions 
as indicated. No serum was added to lanes 2 and 8. No nuclear extract was added to lanes 
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Figure 5.2.4. MBD1 and MeCP1 
MBD1 and MBD2 are not associated in the same complex. 
Immunoprecipitates of S923 (preimmune or immune anti-MBD2) and S751 (preimmune or 
immune anti-MBD1) were probed with anti-MBD1 or anti-MBD2 antibodies. MBD1 was 
not immunoprecipitated by anti-MBD2 antibodies, and vice versa. 
MBD1 is not associated with HDACI complexes. 
Nuclear extracts were immunodepleted with anti-MTA2 (component of NuRD complex), 
anti-HDAC1, and anti-SAP30 (component of mSin3 complex) antibodies. Anti-MTA2 
antibodies did not deplete mSin3A, MBD1 or MBD2. Anti-HDAC1 antibodies depleted 
both mSin3A and MBD2. Anti-SAP30 antibodies depleted mSin3A but not MBD2 or MBD1. 




•:,.; 	 im.iS 
114 
As MeCP2 and MBD2 are both associated with HDAC1 complexes, the relationship 
between MIBD1 and HDAC1 was also examined. It was found that under conditions in 
which MBD2 and mSin3A were specifically depleted by anti-HIDAC1 antibodies (Figure 
5.2.4 E), the level of MBD1 in the HDAC 1-depleted extracts was unaffected. Neither 
anti-MTA2 nor SAP30 antibodies depleted MBD2, consistent with the finding that MBD2 
is not associated with NuRD or mSin3 complexes (Figure 4.2.4 Q. Collectively, the data 
indicate that M1BD1 is not associated with MIBD2/ MeCP1 complex or other HDAC1-
containing complexes. 
5.2.5 	Biochemical characterisation of MBDI 
A HeLa nuclear extract was passed over a Superose 6 gel-filtration column to determine 
the native size of MIBD 1. Western blot analysis of the fractions that elute from the column 
revealed that MBD1 migrates at the range of 200 kDa (Figure 5.2.5 A). The calculated 
molecular weight for MIBD1 is 66 kDa, therefore it is likely that MBD1 interacts with 
itself or other nuclear proteins to form a higher molecular weight complex. MIBD1 did not 
co-migrate with MBD2, as MBD2 eluted in fractions 7 and 8 under the same conditions 
(see Figure 4.2.6). 
The abundance of MBD1 in HeLa nuclei was estimated by Western blotting of known 
amount of recombinant MBD1 and nuclei (Figure 5.2.5 B). The MIBD1 signal from 4 ng 
of recombinant protein and 1.4 x io nuclei was judged to be roughly equal (compare 
lanes 2 and 7). Based on this estimation, each nucleus is calculated to contain 2500-5000 
molecules of MBD1. Therefore, MBD1 is not abundant in HeLa cells. 
Experiments were also carried out to determine how tightly bound MBD1 was in HeLa 
nuclei. A typical 0.42 M KC1 extraction was sufficient to elute MIBD1 from the nuclei 
(Figure 5.2.5 C, lane 3). However, it was found that a significant amount of IVIBD1 was 
still retained in the insoluble chromatin pellet (lane 4). Dialysis of the 0.42 M KC1 extract 
resulted in the precipitation of a fraction of 0.42 M KC1 soluble MBD1 (lane 1), indicating 
that MIBD1 is unstable under low salt condition. Thus, MBD1 exhibits character of 
chromatin-associated proteins such as MeCP2, which require high salt for efficient 
extraction from the nuclei (Meehan et al, 1992). The result suggests that MBD 1 is tightly 
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Figure 5.2.5 Biochemical characterisation of MBD1 
A) MBD1 migrates at a molecular weight of 200-400 kDa. 
HeLa nuclear extract was fractionated on a Superose 6 gel-filtration column. The 
eluted fractions were analysed by Western blotting to detect MBD1. The column was 
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Figure 5.2.5. Biochemical characterisation of MBD1 
MBD1 is not abundant in HeLa cells. 
HeLa nuclei were solubilised in SIDS loading buffer and analysed by Western 
blotting using anti-MBDI antibody (lane 7 contained 1.4 x 107  nuclei). Lanes 6, 5, 
and 4 contained 2x, 3x, and 4x the number of nuclei in lane 7, respectively. Known 
amounts of recombinant MBD1 were loaded for estimating the abundance of 
MBD1. 
MBD1 is tightly bound in the nuclei. 
HeLa nuclei were extract with 0.42 M KC1 (lane 3, 26.5 tg of protein). 0.42 M KC1 
insoluble chromatin fraction was resuspended in 0.9 M KC1 and sonicated before 
SDS-PAGE (lane 4,23.5 p.g of protein). MBD1 can be found in 0.1 M KCI insoluble 
fraction after dialysis (lanes 1 and 2; 23 p.g of protein was loaded in lane 2). 
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5.2.6 	MBDI can repress transcription in a DNA methylation 
dependent manner in vivo 
Although MBD1 is not a component of the MeCP1 repressor complex, previous work 
from this laboratory showed that recombinant MIBD1 can repress transcription of a 
methylated template in an in vitro system. It is therefore of interest to determine whether 
MBD1 can repress transcription of methylated reporter in vivo. 
Methylated reporters are inevitably silenced when transfected into many mammalian cell-
lines (Boyes and Bird, 1991; Levine et al, 1991). Two main parameters that dictate the 
transcriptional fate of the methylated reporters are: direct repression due to exclusion of 
transcription factor(s) and indirect repression due to methyl-CpG binding repressors. The 
presence of endogenous methyl-CpG binding repressors imposes a major hindrance to 
analysis of repression on methylated reporters by a protein of interest. It is also known 
that embryonic stem (ES) cells or embryonic carcinoma (EC) cell-lines are deficient in 
methyl-CpG binding proteins, e.g. MeCP1 (MBD2) and MeCP2 (Meehan et al, 1989; 
Boyes and Bird, 1991; Tate, 1996). The RNA transcripts of MIBD1 and MBD2 are not 
detected in ES cells (Hendrich and Bird, 1998). The lack of methyl-CpG binding activity 
in F9 EC cells also correlates with the failure of these cells in repressing methylated 
reporters (Boyes and Bird, 1991; Levine et al, 1991). Therefore, co-transfection of a 
construct expressing MIBD1 and differentially methylated reporters into F9 EC cells 
should allow one to test whether MBD1 can selectively repress the methylated reporter. 
Consistent with previous studies, the HhaI methylated pf3G5Bglll reporter (human -actin 
promoter driving the -galactosidase gene) was not significantly repressed compared to 
the mock methylated version (see Figure 5.2.6 A). In contrast, the same HhaI methylated 
reporter retained less than 20 % activity (compared to the non-methylated version) upon 
transfection into mouse L fibroblasts (Nan et al, 1997). The result suggests that 
repression on HhaI methylated reporter can be attributed to methyl-CpG binding 
repressors in mouse L cells. 
Two concentrations of effector (construct for expression of MIBD 1) were tested for 
repression of reporters with different levels of methylation. At 0.25 jig of effector 
concentration, similar level of expression from mock-methylated and Mal-methylated 
reporters was observed (Figure 5.2.6 A, compare bars 1 and 3). When MIBD1 was co-
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Figure 5.2.6.A Methylation dependent repression by MBD1 
MBD1 (0.25 jig or 1.5 jig) was co-transfected either mock-methylated or 
methylated reporter. Methylation was introduced at all HhaI sites. Relative 
activity is the ratio of 3-gal activity in the absence of co-transfected MBD1 / P-  
gal activity in the presence of MBD1 (e.g. value of column 1 / value of column 
2). Reporter construct and HhaI methylation sites at the promoter and reporter 
gene are shown. 	
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reduced to 67 % (Figure 5.2.6 A, bar 2). The -galactosidase activity of the methylated 
reporter in the presence of MBD1 was repressed to 24 % (Figure 5.2.6 A, bar 4). As 
MBD1 binds specifically to methylated DNA in vitro (see Figure 5.2.1 B), it is suspected 
that the reduction in activity of the non-methylated reporter upon co-transfection of MIBD1 
expressing construct is due to a toxic effect of MBD1. Therefore, the 2.8 fold difference 
in the relative reporter activity between non-methylated and methylated reporters can be 
attributed to the only difference in one parameter: DNA methylation. Increasing the 
amount of effector construct from 0.25 jig to 1.5 jig, resulted in even higher level of 
repression on non-methylated reporter, and the p-galactosidase activity was reduced to 20 
% relative to the 3-galactosidase activity when no effector was co-transfected (Figure 
5.2.6 A, bar 6). With 1.5 jig of transfected effector, the relative reporter activity of the 
HhaI methylated reporter was 2 % (Figure 5.2.6 A, bar 8). More than 20 fold difference 
in relative reporter activity between the non-methylated and methylated reporter was 
observed. Therefore, the result showed that MBD1 can preferentially repress the 
methylated reporter. Furthermore, M1BD1 repressed the methylated reporter in a dose-
dependent manner (2.8 fold at 0.25 jig of effector and 20 fold at 1.5 jig of effector). 
It is of interest to test whether MIBD1 can still repress transcription in a methylation 
dependent manner when the promoter is activated by potent transcriptional activators such 
as the VP16, E2F1, Spi activation domain (Blau et al, 1996; Emili et al, 1994; Sadowski 
et al, 1988; Triezenberg et al, 1998). The pI3G5Bglll reporter (mock methylated or HhaI 
methylated) was co-transfected into F9 cells along with constructs for expression of 
GAL4-VP 16 and MIBD 1. The relative reporter activity of the mock methylated reporter 
was 72.4 %, and that of the HhaI methylated reporter was 21.9 % (Figure 5.2.6 B, bars 
1 to 4). Again, a toxic effect on the non-methylated reporter in the presence of MBD1 was 
observed. There is a 3 fold difference in the relative reporter activity between non-
methylated and methylated reporters. The level of repression on the methylated reporter 
(based on fold difference) is surprisingly very similar to the result when the reporters 
were not transactivated by GAL4-VP16 (Figure 5.2.6 A, 0.25 jig of effector). As the 
Ga14 binding sites (5 x CGGAAGACTCTCCTCCG) do not have HhaI methylation 
(GCGC) sites (Giniger et al, 1985; Lin et al), it is not likely that HhaI methylation 
prevents binding of GAL4-VP16 to the Ga14 binding sites and leads to reduced reporter 
activity. In addition, the HhaI methylated reporter was activated to similar extent as the 
mock methylated reporter by GAL4-VP16 (see also below). The effect of two other 
activators (E2F1 and Spi) on repression by MIBD1 was also tested. Similar to the GAL4-
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Figure 5.2.6.B. Effect of MBD1 on reporters activated by different activation domains. 
Methylation was introduced at all HhaI sites. The results are derived from average of 
duplicates. Relative activity is the ratio of 3-gal activity in the absence of co-transfected 
MBD1/ [-gal activity in the presence of MBD1 (e.g. value of column 1/ value of column 2). 
GAL4-AD is GAL4-Activation domain fusion. 
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(either mock-methylated or HhaI-methylated) and effector (for expression of M13131). 
Strangely, the HhaI methylated reporter was not selectively repressed in the presence of 
GAL4- E2171 or GAL4-Spl (Figure 5.2.6 B, bars 5 to 12). The result suggests that 
repression by M13D1 is only targeted towards certain classes of activators. 
During the course of this work, Fujita et al (1999) also showed that MIBD1 can repress 
transcription in a methylation-dependent manner in COS cells and Drosophila cells. 
5.2.7 	MBDI contains a potent transcriptional repression domain 
As the HhaI methylation sites occurred throughout the whole pI3G5Bglll reporter plasmid 
(including promoter and lacZ gene), it is not certain if repression due to MBD1 was the 
results of steric blocking of transcriptional initiation and/ or elongation (see Figure 5.2.6 
A). Therefore, a more informative assay is required to ask if MIBD1 can actively repress 
transcription when tethered to sites remote from the promoter region. An inkling that 
MIBD1 may repress transcription comes from functional studies of the HRX protein 
(Figure 5.2.7 A). A CxxC containing region in HRX has been reported to repress 
transcription in vivo using a GAL4 fusion assay (Prasad et al, 1995; Zeleznik-Le et al, 
1994), therefore it is of interest to test whether the similar CxxC domains in MBD1 can 
also repress transcription. 
A GAL4 fusion repression assay was used to address this possibility. Constructs with 
different fragments of MBD1 fused to cDNA encoding the GALA DNA binding domain 
were generated. To avoid mis-targeting of the GAL4 fusion proteins to methylated sites in 
the genome, the first 43 amino-acids of MBD1, corresponding to half of the MBD, was 
omitted from all constructs. These effector constructs were separately co-transfected into 
mouse L929 fibroblasts with a 3-galactosidase reporter (with or without 5 Ga14 binding 
sites upstream of the human -actin promoter; GO or G5). Approximately 60 hours (two 
and a half days) after transfection, the cells were harvested and extracts were assayed for 
3-galactosidase activity. For each construct, titration of at least 3 concentrations of effector 
was carried out. 
As a pilot experiment to address whether the CxxC domains can repress transcription, 
three GALA-MIBD1 constructs (81-556 aa, 261-556 aa, 350-556 aa) were tested for 
transcriptional repression activity. If the repression property of CxxC domain is also 
retained in MBD1, the first two constructs with CxxC domain(s) (81-556 aa and 261-556 
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Figure 5.2.7 A. Is MBD1 a transcriptional repressor? 
The cysteine-rich (CxxC domain) transcriptional repression domain of ALL1 can 
also be found in DNIvIT1 and MBD1. Two forms of MBD1 that can be expressed 
by the human gene: MBD1 and MBD1*  (Cross et al, 1997; Hendrich et al, 1999a). 
MBD1 contains two CxxC domains, while MBD1*  has three CxxC domains. The 
two shaded regions in ALL1 has been shown to contain transcriptional 
repression activity (indicated by +; Prasad et al, 1995). The CxxC domains are 
shaded in hatch. 
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aa) should repress transcription of a reporter with Ga14 binding sites (G5). Unexpectedly, 
all three effectors, including the construct encoding MBD1 without CxxC domains (350-
556 aa), repressed the G5 reporter (Figure 5.2.7 B). The two constructs containing the 
CxxC domain also repressed the reporter without Ga14 binding sites (GO). It is concluded 
that the C-terminal of M1BD1 can repress transcription and repression is dependent on 
interaction with the promoter. It is not clear whether the CxxC-containing effectors can 
repress transcription specifically or if their expression is toxic to the cells leading to loss 
of reporter activity. 
In the next experiment, an internal control reporter (SV40 promoter driving luciferase 
gene) was included in the transfection assay for normalising the -galactosidase activity. 
Again, the 8 1-556 effector repressed the GO reporter (Figure 5.2.7 Q. It should also be 
noted that the G5 reporter was consistently repressed to a greater extent than the GO 
reporter by 81-556 aa effectors. The C-terminal fragment of MBD1 (350-556 aa) however 
specifically repressed the G5 reporter. 
A detailed mapping experiment was performed to delineate the C-terminal transcriptional 
repression domain, TRD (Figure 5.2.7 D, E, F). As the human and mouse MIBD1 have 
two or three CxxC domains similar to that of ALL 1, it is of particular interest to know if 
they can all repress transcription (see Figure 5.2.7 A and G). A 33 amino-acids region at 
the C-terminal of MBD1 was identified as the TRD. It is notable that only the second 
CxxC domain (273-340 aa) can repress transcription (Figure 5.2.7 H). Related N-
terminal CxxC domains (161-228 aa of MBD1 and 161-221 aa of MBD1*)  did not 
repress the reporters. The CxxC region of the DNA cytosine 5-methyl transferase also did 
not repress. Western blotting using anti-GAL4 antibodies indicates that the GAL4-fusion 
proteins were expressed, although GAL4-CxxC1 (161 to 221 aa of MBD1*)  was poorly 
expressed (Figure 5.2.7 I). The results suggest that, despite of the significant sequence 
conservation among the CxxC domains, their functions in different proteins may differ. 
5.2.8 	Characterisation of the C-terminal TRD (Mutagenesis; Long 
distance repression; TSA sensitivity) 
Comparison between the human and mouse MIBD1 revealed that the TRD is conserved 
with 66.7 % identity and 78.6 % similarity over a 33 amino-acids region. The TRD is 
















V 	'IV 	DV 	a 	WV IU 











aa 261-556 (1 CxxC) 
IVV evv IIVV 'WV 0VV OVU 
GAL4 fusion construct (ng) 












01. 	 .1 
0 	200 400 600 800 1000 1200 
GAL4 fusion construct (ng) 
o G5 reporter (with Ga14 binding sites) 
o GO control reporter (no Ga14 binding sites) 
Figure 5.2.7. MBD1 is a transcriptional repressor 
B) An effector lacking the CxxC domains can specifically repress transcription of a reporter 
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Figure 5.2.7. MBD1 is a transcriptional repressor 
C) GAL4-MBD1 (81 to 556 aa) repressed both the GO and G5 reporters. 
The 3-gal activity was normalised with luciferase activity froma co-transfected luciferase 
reporter. GAL4-MBD1 (350-556 aa) repressed only the G5 reporter. The lacZ reporter is 
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o G5 reporter (with Gal4 binding sites) 
o GO control reporter (no Ga14 binding sites) 
Figure 5.2.7. MBD1 is a transcriptional repressor 
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Figure 5.2.7. MBD1 is a transcriptional repressor 
E) Mapping of fragments of MBD1 with transcriptional repression activities. Two regions 
with distinct repression profile on GO and G5 reporters are identified (gray, and hatched). 
The minimal hatched region repressed the G5 reporter specifically, and is denoted as the 
transcriptional repression domain (TRD). A CxxC domain repressed both the GO and G5 
reporters (gray). 128 
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Figure 5.2.7. MBD1 is a transcriptional repressor 
F) Expression of different GAL4-MBD1 fusions proteins as detected by anti-GAL4 
antibodies. Certain constructs e.g. 261-346 aa were poorly expressed. All constructs 
expressed GAL4-fusions of the correct expected sizes. 
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Figure 5.2.7. MBD1 is a transcriptional repressor 
Sequence alignment of CxxC domains from MBD1, DNMT1, and HRX (also known as 
ALL1). 
Repression profile on the G5 and GO reporters by various CxxC domains. 
Expression of GAL4-CxxC domains as detected by anti-GAL4 antibodies. 
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F, valine-V): 33 % and glycine: 15.1 % (Figure 5.2.8 A). Database searching with the 33 
amino-acids TRD did not uncover similarity with known transcriptional regulators. 
To test the importance of the conserved amino acids, three TRD mutations with single 
amino-acid substitution were generated (Figure 5.2.8 A). Conversion of hydrophobic 
residues 1527 and L530 to basic residue arginine (R) abolished the repression activity of 
TRD. Substitution of polar residue T525 to lysine (K) lead to partial loss of repression 
activity. Western blot analysis using anti-GAL4 antibodies indicated that the expression of 
these GALA-TRD mutants was comparable to the wild-type TRD fusion protein. 
The next question to ask is whether the TRD can repress transcription from a distance. 
Two reporters (p3-887-G5 and p-1774-G5) with the 5 Ga14 binding sites located 1.3 kb 
and 2.1 kb away from the translation start site were used to address this question (Figure 
5.2.8 B). The TRD repressed the activity of p3G5BglII reporter (G5 reporter with 5 Ga14 
binding sites 400 bp upstream of the translation start site) to about 10 %. Under the same 
effector concentration (250 ng), the activity of p43geoNIB reporter (GO reporter without 
Ga14 binding site) was not affected. The GAL4-TRD also efficiently repressed both the 
p3-887-G5 and p3-1774-G5 reporters to 12 %. The result indicates that TRD can mediate 
long distance repression. This finding contrasts the significant reduction with distance in 
the efficiencies of activation by GAL4-VP16 and of repression by the GAL4-TRD of 
MeCP2 in the same assay. 
The association between methylated DNA, transcriptional repression and hypoacetylated 
histones raised the possibility that MIBD1 may also repress transcription via interaction 
with histone deacetylases. TSA treatment restored the relative reporter activity by 
approximately two to three fold, suggesting that deacetylation may be involved (Figure 
5.2.8 Q. The repression by the CxxC domain was however not sensitive to TSA (data 
not shown). MIBD1 was not depleted by HDAC1, SAP30, or MTA2 antibodies under 
conditions where MBD2 was specifically depleted by HDAC1 antibodies (see Figure 
5.2.4 E). Therefore, it is unlikely that MBD1 is associated with HIDAC1 complexes. 
Previous experiments showed that anti-MED 1 antibody did not immunoprecipitate histone 
deacetylase activity from crude HeLa cell extract (Figure 4.2.4 A). As the extract was 
prepared by lysing the cells with NP40 detergent in the presence of 150 MM NaCl, it is 
not certain if MBD1 was effectively extracted under the low salt condition (see Figure 
5.2.5 Q. Thus, the low abundance of MIBD1 in the low salt extract may help to explain 
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Figure 5.2.8. Characterisation of TRD 
A) The TRD is conserved between the human and mouse MBD1. Mutation of two 
hydrophobic residues (1527 and L530) abolished transcriptional repression property of the 
TRD. Substitution of T525 residue only lead to partial loss of activity. The result shown are 
based on three independent transfection. 




































Figure 5.2.8. Characterisation of TRD 
B) The TRD can repress transcription from a distance. 
250 ng of effector (GAL4-TRD) was used. The reporter constructs and the location of Ga14 
binding sites relative to the transcription start site are shown. The result shown are based 
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Figure 5.2.8. Characterisation of TRD 
C) The TRD repressed transcription in a deacetylation dependent manner. 
Transfected cells were incubated with TSA (100 ng/ml) for 24 hours before harvest. 
Two concentration of effector (100 ng and 200 ng of GAL4-TRD) were transfected. The 
result shown are based on three independent transfection. TSA did not affect the 
relative activity of the reporters (G0/G5) in the absence of GAL4-TRD. 
134 
5.2.9 	MBDI is a chromosomal protein 
As the S751 antibody can recognise native MBD1 in a nuclear extract, indirect 
immunofluorescence with this antibody was used to look at localisation of endogenous 
MBD1 in HeLa cells. Nucleoplasmic staining with the exclusion of nucleoli was detected 
(Figure 5.2.9 A). Preimmune antibodies gave only background staining (data not 
shown). Affinity purified anti-MIBD1 antibodies gave the same staining pattern as crude 
immune serum (data not shown). The staining of MBD1 on mitotic chromosomes was 
weak and it was not possible to analyse the chromosomal localisation of MBD1 on 
aneuploid HeLa cells. 
In collaboration with Dr. Peter Jeppesen (Western General Hospital, Edinburgh), we 
used this antibody to look at localisation of M1BD1 on human metaphase chromosomes 
prepared from human DD7 lymphoblastoid cell-line (Figure 5.2.9 B). The major sites of 
labeling are centromeric heterochromatin on chromosomes 1, 9, 15 and 16. In addition, 
M1BD1 was also detected at the satellites on acrocentrics (rDNA), and some telomeres. 
The staining pattern is specific because locus specificity was observed (staining on both 
chromatids). Preimmune serum gave only background staining (data not shown). Affinity 
purified MBD1 antibodies also gave the same staining pattern as the immune serum. The 
localisation of MIBD1 is also consistent with the staining pattern of sites of methylation 
using anti-5-meC antibody (Barbin et al, 1994). 
To further analyse the relationship between M1BD1 and constitutive heterochromatin or 
facultative heterochromatin (e.g. inactive X-chromosome), metaphase chromosomes of a 
primary female fibroblast line HF19 (Jeppesen and Turner, 1993) were co-stained with 
anti-MIBD1 and anti-acetylated H4 sera (Figure 5.2.9 C, performed by Dr. Peter 
Jeppesen). MIBD1 was found to be concentrated at centric constitutive heterochromatin 
which is deficient in acetylated histories (Jeppesen et al, 1992). The localisation of MBD1 
on both active and inactive X chromosomes was however not significantly different, 
though the inactive X chromosome was hypoacetylated. The likely explanation is that the 
overall methylation status of the X chromosomes are not very different (Barbin et al, 
1994). In addition, low-level and non-uniform labeling of euchromatic chromosome arms 
was observed. The result suggests that the primary factor governing the chromosomal 





Figure 5.2.9. Localisation of MBD1 
A) MBDI is a nuclear protein. 
HeLa cells were stained with anti-MBD1 S751 antiserum. 
B) MBD1 can be found on mitotic chromosomes. 	
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Figure 5.2.9. Localisation of MBD1. 
D) MBD1 is a chromosomal protein. 
Metaphase chromosomes of DD7 lymphoblastoid cells were stained 
with affinity purified anti-MBD1 antibodies (green). The spread was 
counterstained with DAPI for DNA (blue). The major sites of MBD1 
are centric heterochromatin of chromosomes 1, 9, 15, and 16. MBD1 
was also detected at the satellites on acrocentrics (rDNA), and some 
telomeres. 









Figure 5.2.9. Localisation of Iv[BD1. 
E) MBD1 is a chromosomal protein 
Top panel: 
Metaphase chromosomes of female human HF19 cell-line were 
stained with anti-MBD1 antiserum (red). 
Middle panel: 
Merged image of top and bottom panels. The spread was 
counterstained with Hoechst 33258 for DNA (blue). Several 
chromosomes were identified based on Hoechst and H4 acetylation 
patterns. Xi is inactive X chromosome, while Xa is active X 
chromosome. 	 - 
Bottom panel: 
The chromosomes were simultaneouly stained with anti-acetyl lysine 
12 H4 antiserum (green). 
MBD1 is concentrated at pericentromeric heterochromatin of 
chromosomes 1, 9, 15, and 16. In addition, significant staining of 
MBD1 was observed at euchromatic chromosome arms. This 
experiment was performed by Dr. Peter Jeppesen. 
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5.2.10 	MBDI has an affinity for core histones 
In order to probe the mechanism of repression by MBD 1, candidate interacting proteins 
were identified. Different regions of MBD 1 were tested for their affinity for core histories 
for two reasons. Firstly, the transcriptional repression domain of yeast Ssn6/Tupl global 
repressor has been shown to interact directly with histone H3 and H4 tails (Edmondson et 
al, 1996). Secondly, MBD1 is a chromosomal protein in vivo (see section 5.2.7), and it 
is therefore of interest to examine its affinity with components of chromatin. 
A GST-pull down assay was used to address whether the TRD of MBD1 has affinity for 
core histones in solution. In this assay, immobilised GST-MBD1 (different regions) 
fusion was incubated with highly purified calf thymus core histones in the presence of 
BSA (to reduce non-specific interaction). After extensive washing of the GST fusion-
sepharose beads, bound proteins were eluted by boiling in SDS loading buffer, and 
analysed by SDS-PAGE. It was found that although different C-terminal fragments 
containing TRD did not bind to core histones, a fusion containing the CxxC domain can 
bind directly to core histones (predominantly histone H3 and H4, see Figure 5.2. 10 A). A 
mapping study using more fragments of MBD1 was performed. Two regions of MBD1 
can interact directly with core histones (Figure 5.2. 10 B and Q. It was notable that when 
a strong binding was detected, all four core histones were bound. Only CxxC2 domain of 
MBD1 interacted with core histones, the CxxCl domain of IVIBD1 and the CxxC domain 
of DNMT1 did not bind to core histories. The interaction is specific and not likely due to 
highly basic nature of core histones, because GST alone did not interact with histones, 
and different GST-MBD1 fusions did not interact with a highly basic protein lysozyrne 
under the same condition (Figure 5.2.10 D). However, it is curious that full-length 
MBD 1 did not interact with the histones (Figure 5.2. 10 E). One plausible explanation is 
that the full-length protein is not folded in the correct conformation. Attempts to determine 
which core histones are the direct binding partners failed because certain histones bind 
non-specifically to GST protein (data not shown). 
In order to test for interaction between full-length MBD1 and core histones, a HeLa 
nuclear extract was incubated with calf thymus core histones column. The column was 
washed extensively to remove unbound proteins and bound proteins were eluted in SDS 
loading buffer. Immunoblotting with anti-MBD1 antiserum showed that tVIIBD1 was 
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Figure 5.2.10. MBD1 can bind to core histones 
A) CxxC2 domain of MBD1 (273-340 aa) interacts preferentially to histones H3 and H4 
in vitro, with more than 10 % of input bound. GST control and several C-terminal 
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Coomassie blue stained gel 
Figure 5.2.10. MBD1 binds to core histones 
B) Mapping of core histones binding domains using different GST-MBD1 fusions. 
Only strong interaction (with recovery of more than 10 % of input) were scored as 
positive. A weak interaction (less than 5 % of input) was detected for GST-295-
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Figure 5.2.10. MBD1 binds to core histones 
C) Summary of the interaction between core histones and different GST-MBD1 
fusions. Only strong interaction (with recovery of more than 10 % of input) was 
scored as positive. Fragments of MBD1 that bound more than 10 % of input were 
highlighted in gray. (-) indicates weak binding. GST alone did not interact with 
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Figure 5.2.10. MBD1 binds to core histones 
D) GST-MBD1 fusions did not interact with lysozyme (a 14.4 kDa highly basic protein 
from hen egg white). 
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Figure 5.2.10. MBD1 binds to core histones 
E) Core histones did not bind to recombinant full-length MBD1. 
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Figure 5.2.10. MBD1 binds to core histones 
G) In vitro translated MBD1 binds to GST-core histones. 
Full-length MDB1 (top panel) or a truncated MBD1 without the methyl-CpG 
binding domain (bottom panel) were in vitro translated and incubated with 
GST-H2A, GST-H2B, GST-H3 or GST-H4. Bound proteins were eluted, 
fractionated on SDS-PAGE and detected by autoradiography. 
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GSH-sepharose column. The core histone column not incubated with HeLa nuclear 
extract did not contain MBD 1. 
Full-length MBD1 was synthesised in vitro and labeled with 35 S methionine. The labeled 
protein was then incubated with different histone GST-fusion proteins. M1BD1 bound to 
all core histones but not to GST control (Figure 5.2. 10 G). MBD1 without methyl-CpG 
binding domain (93-556 aa) exhibited similar binding activity towards all core histones, 
thereby excluding the possibility that the interaction is mediated by nucleic acids. 
However, it is possible that the interaction between MIBD 1 and histones may be indirect, 
and bridged by proteins present in the reticulocyte lysate. 
These results established an in vitro interaction between MBD 1 and core histones. 
5.3 Conclusion 
An antibody highly specific towards MIBD1 was used to evaluate the relationship between 
MBD1 and MeCP1. Anti-MBD1 antibody did not supershift or immunodeplete MeCP1 
activity, suggesting that IvIBD1 does not contribute to MeCP1 bandshift activity derived 
from HeLa cells. The work described in Chapter 4 showed that another methyl-CpG 
binding protein, M13D2 is a component of MeCP 1. MBD 1 is however not associated with 
MBD2/ HDAC complex as revealed by co-immunoprecipitation experiments. In addition, 
MBD1 and MBD2 do not co-migrate on a gel-filtration column. 
Although MBD 1 is not a component of MeCP 1, it can nevertheless repress transcription 
in a methylation dependent manner in F9 embryonic carcinoma cells. It is however 
possible that MBD1 is repressing transcription indirectly by blocking access of 
transcription factors to methylated sites. A GAL4 fusion repression assay was used to 
address this question. Fragments of MBD1 are fused to GAL4 DNA binding domain, and 
their effect on transcription can be assayed with reporter harboring Ga14 binding sites 
upstream of the promoter. A CxxC domain in MIBD1 repressed the reporter with or 
without Ga14 binding sites, suggesting that this domain is toxic to transcription in a non-
specific manner. A novel transcriptional repression domain (TRD) was also mapped to the 
C-terminal of MBD 1. The TRD preferentially repress transcription of a reporter with Ga14 
binding sites. Repression by the TRD can occur at a distance and several hydrophobic 
residues are important for the repression activity. The repression is sensitive to histone 
deacetylase inhibitor TSA, suggesting that histone deacetylase may be involved. 
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Immunolocalisation studies indicate that MIBD1 is bound at sites enriched with 5-
methylcytosine on human chromosomes (Barbin et al, 1994). The major sites are centric 
heterochromatin on chromosomes 1, 9, 15 and 16. Using GST-pulldown assay, an 
interaction between two regions of MIBD1 and core histones was detected. MBD1 was 
also found to bind to core histone column. The result suggests a mechanism in which 
MBD1 might be anchored tightly onto chromatin. 
In summary, functional analysis of MIBD1 delineated a methyl-CpG binding domain, a 
CxxC domain which represses transcription independent of binding to the promoter and a 
C-terminal transcriptional repression domain. Like MeCP2, MBD1 is also a chromosomal 
proteins that is concentrated at centric heterochromatin. 
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Chapter 6: General discussion 
One well known consequence of CpG methylation in vertebrates is transcriptional 
silencing. As the vertebrate genomes are heavily methylated, 5-meC can be found in 
transcription factor recognition sites and impair the recruitment of transcription factors or 
basal transcription machinery to regulatory elements. However, many transcription factor 
recognition sites do not contain CpG and some transcription factors are not sensitive to 
methylation at their cognate binding sites, therefore indirect repression by methyl-CpG 
binding proteins is invoked to explain methylation induced repression. Indeed, methyl-
CpG binding activities have been detected in mammalian extracts (MDBP1, Huang et al, 
1984; MeCP1, Meehan et al, 1989; MDBP2, Pawlak et al, 1991; MeCP2, Lewis et al, 
1992). 
Apart from its preference for methylation, MDBP1 binds DNA in a sequence specific 
manner, with recognition site of more than two basepairs. Furthermore, its binding 
activity does not exhibit strict requirement for 5-meC. Therefore, MDBP1 is unlikely to 
mediate global repression by methylation. MIDBP2 is an avian histone Hi subtype, and 
binding to DNA requires a minimum length of 30 bp with a symmetrically methylated 
CpG. However, whether mammalian histone Hi has similar affinity for methylated DNA 
is still unclear in light of opposing findings (Nightingale and Woiffe, 1995; Campoy et al, 
1995; Levine et al, 1993; Johnson et al, 1995; McArthur and Thomas, 1996). On the 
other hand, MeCP1 is shown to bind specifically to methylated DNA, and binding affinity 
is dependent on methylation density (Meehan et al, 1989). The protein(s) responsible for 
this activity was not known until recently (see Chapter 4 of this thesis). MeCP2 is a 
second DNA binding activity discovered after MeCP1 (Lewis et al, 1992). Cloning of the 
cDNA for MeCP2 provides a headway for the characterisation of this methyl-CpG 
binding protein and understanding of the biological consequences of DNA methylation. 
Gene targeting experiments demonstrate that MeCP2 is essential for embryonic 
development (Tate et al, 1996). Chimaeric embryos derived from ES cells with MeCP2 
gene disrupted, failed to developed normally and did not survive beyond weaning stage. 
Functional analysis of MeCP2 resulted in the mapping of a methyl-CpG binding domain 
(MBD) and a transcriptional repression domain (Nan et al, 1993; Nan et al, 1997). 
The EST database screening effort has been fruitful in identifying four novel mammalian 
proteins (MBD1 to 4) with MBD-like region (Cross et al, 1997; Hendrich and Bird, 
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1998). Previous work from this laboratory showed that MBD1, MIBD2 and MIBD4 bind 
specifically to methylated DNA. 
This thesis addresses the fundamental question of how DNA methylation represses 
transcription. The work described in this thesis provide insight into the mechanisms of 
repression of three of these methyl-CpG binding proteins (MeCP2, MBD2 and MIBD1). 
MIBD4 is shown to be a T/G glycosylase and therefore unlikely to be involved in 
mediating silencing by DNA methylation (Hendrich et a!, 1999). 
Table 6.1 summarises the current understanding of how methyl-CpG binding proteins 
repress transcription. 
MeCP2, MBD2 and MBD1 can actively repress transcription when recruited to sites 
upstream of the promoter. MeCP2 interacts with the HDAC1/2 containing mSin3 co-
repressor complex, and MBD2/ MeCP1 associates with a HDAC1I2 containing complex 
which is distinct from the mSin3 co-repressor complex and the Mi2 containing NuRD 
complex. On the other hand, MBD1 is not associated with a HDAC1/2 containing 
complex. However, TSA sensitivity of repression by TRD of MBD1 suggests that 
deacetylation may be involved. Collectively, these studies indicate that DNA methylation 
attracts a group of methyl-CpG binding transcriptional repressors, two of which are 
shown to associate with histone deacetylases. 
A causal link between DNA methylation and histone deacetylation is further strengthened 
by studies that show parallel effects of DNA demethylating agents and TSA in reactivating 
transcription of sequences repressed by DNA methylation. In one study, mouse fibroblast 
L cells are stably transfected with either a methylated or a non-methylated tk gene (Eden et 
al, 1998). Subsequent immunoprecipitation of chromatin with an antibody against 
acetylated histone H4 revealed that, in contrast to the non-methylated tk gene, the 
methylated tk gene was not enriched for acetylated histones. TSA treatment results in an 
increased expression of the methylated tk gene. In addition, TSA treatment can increase 
the accessibility of the methylated tk gene locus to nucleases, suggesting that acetylation 
of histones re-establishes features of transcriptionally active chromatin despite the 
presence of DNA methylation. Similar results are obtained with integrated transgenes that 
are subjected to spontaneous epigenetic silencing with the concomitant appearance of 
DNA methylation and loss of histone hyperacetylation (Pikaart et al, 1998). Again, both 
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151 
6.1 Outstanding questions: 
How do the MeCP/ HDAC complexes repress transcription? 
Work on MeCP2 and MIBD2/ MeCP1 has provided insight as to how the covalent 
marking on cytosine can trigger further modification of the chromatin, and presumably 
lead to transcriptional silencing. Several mechanistic questions need to be addressed: How 
does histone deacetylation lead to transcriptional silencing? Can MeCPs repress 
transcription through HDAC independent pathways? 
Studies of RPD3 (yeast homolog of HDAC1/2) established that recruitment of histone 
deacetylases by Ume6 transcriptional repressor to specific sequences leads to local 
deacetylation of histone tails in vivo (Rundlett et al., 1998; Kadosh and Struhi, 1998). 
This short range modification of chromatin seems sufficient to extinguish transcription. It 
remains to be demonstrated whether MeCP/ HDAC complexes exert a similar effect on a 
methylated nucleosomal template. MeCP2 has been shown to exert long distance 
repression on a promoter in a transient transfection assay; is the interaction with histone 
deacetylase sufficient to account for the repression? The repression by TRD of MeCP2 
was not completely relieved by TSA. In the case of MBD2, repression on certain 
promoters is not sensitive to TSA. Therefore, it is very likely that these MeCPs can also 
repress transcription in a deacetylation-independent manner. Isolation of novel nuclear 
proteins that interact with these MeCPs is likely to shed light on this issue. 
What are the biological roles of these methyl-CpG binding 
repressors? 
Question also arises as to whether MBD1, IVIBD2/MeCP1 and MeCP2 have redundant 
functions in the repression of methylated sequences. There are differences between these 
MeCPs. MBD1 and MeCP2 are both chromosomal proteins, whereas MBD2I MeCP1 
seems to be loosely bound in the nucleus (based on low salt extractability from the 
nucleus; Meehan et al, 1992). MeCP1 has a strong preference for high methyl-CpG 
density in vitro, therefore an untested possibility is whether MBD2 binds cooperatively to 
multiple methyl-CpGs or the MeCP1 complex contains multiple MBD2 molecules 
resulting in high affinity for densely methylated DNA. Is there tissue-specific expression 
of these MeCPs? Preliminary data suggests that this may be the case. For example, rat 
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brain nuclear extracts have high levels of MeCP2 but low levels of M1BD2 (see Figure 
4.2.3). 
It has been shown that under some circumstances, methylation per se is not sufficient for 
transcriptional silencing, and repression on methylated templates is concomitant with 
packaging of the naked DNA into nucleosomes (Buschhausen et al., 1987; Kass et at., 
1996). It is uncertain which MeCP is involved in the chromatin assembly coupled 
repression. Hence, the physiological substrates for each of the MeCPs will be crucial to 
distinguish their functional differences and biological role. 
The phenotype of the mouse knockout of MeCP2 resembles that of DNMT 1, and 
indicates that other MeCPs/ MIBDs are not sufficient to substitute for MeCP2 (Tate et al., 
1996). It is hopeful that gene targeting of the other member of the MIBD family will 
provide further insights into the biological roles of these proteins. Important questions 
that can be answered through gene targeting experiments include: 
Are these proteins essential for mammalian development? 
Is gene expression mis-regulated in the absence of MeCP? 
Which are the target genes of these MeCPs? 
Recently, it is found that the Rett syndrome, a progressive neurodevelopmental disorder, 
is caused by mutations within the MECP2 gene (Amir et al, 1999). These patients suffer 
from gradual loss of speech, and develop microcephaly, seizures, autism and ataxia. The 
finding underlines the importance of MeCP2, and deregulation is likely to bring about 
disease state. 
The gene for MBD2 has been disrupted in mouse (B. Hendrich, personal 
communication). Interestingly, cell-lines derived from the knockout mice failed to repress 
transfected methylated constructs efficiently, and did not contain MeCPI activity. These 
findings are consistent with the result showing that MBD2 is a major determinant of 
MeCP1 and is a methyl-CpG binding transcriptional repressor. Such a mouse model is 
invaluable for dissecting the biological role of MED2. 
An experimental tool that is currently available to study the in vivo substrates of these 
MeCPs is the chromatin immunoprecipitation assay (Aparicio et al, 1997; Tanaka et al, 
1997; Alberts et al, 1998; Kadosh and Struhl, 1998b; Rundlett et al, 1998; Tanaka et at, 
1998; Cosma et al, 1999). This technique involves fixation of nuclear proteins on the 
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DNA using formaldehyde, sonication of the chromatin to small fragments, and finally 
enrichment of chromatin bound to specific protein by immunoprecipitation. As MeCP2 
and MBD 1 are shown to be stably bound onto mitotic chromosomes, one can isolate and 
analyse the sequences that are bound by MeCP2 or MBD1 in vivo. 
Transiently transfected methylated constructs in mammalian cells are presumably 
repressed by endogenous MeCPs. Using the chromatin immunoprecipitataion assay, it is 
possible to address the following questions: 
which MeCP(s) is associated with the methylated DNA? 
are HDACs recruited to the methylated DNA? 
are deacetylated histories associated with the methylated DNA? 
is the promoter occupied by basal transcriptional machinery under the repressed 
state? 
if MBD2 is bound to the transfected methylated DNA, is the NuRD complex 
associated with MBD2 on the DNA? 
in MIBD2 null cell-lines, can the NuRD complex be targeted to the transfected 
methylated DNA? 
3) How can the inactive state of methylated nucleosomal DNA be 
reversed? 
It is of interest to understand how the transcriptional machinery gains access to specific 
loci (e.g. tissue-specific genes) amidst of the bulk of the methylated genome. A recent 
report suggests how a densely methylated CpG island can be activated (Ferguson et al, 
1998). The progesterone receptor (PR) gene is an estrogen-responsive gene and in certain 
human breast cancers, DNA methylation at the CpG island of this gene can lead to 
transcriptional inactivity. Treatment with 5-aza-dC can reactivate the PR gene through 
DNA demethylation and activation of the ER gene. Intriguingly, it is shown that the 
ectopic expression of ligand-bound estrogen receptor (ER) can reactivate the PR gene 
even in the presence of DNA methylation. Most importantly, induction of the silenced 
methylated PR gene by ER was blocked by co-expression of a dominant negative form of 
SRC-1A. SRC-1 is a coactivator with an intrinsic histone acetyltransferase activity, and 
can potentiate the activity of ligand-bound ER (McInerney et al, 1996; Spencer et al, 
1997). This result demonstrates that the association between ER and coactivator is crucial 
in mediating the induction of the methylated PR gene. Therefore, a possible mechanism to 
154 
overcome the effect of DNA methylation is to recruit proteins with histone 
acetyltransferase activity that can reverse the state of histone acetylation (Figure 6.1). 
6.2 MeCPs: proteins with no footprint 
It has been reported that the CpG island of human PGK- 1 gene on the inactive X-
chromosome is heavily methylated but no footprint was detected over the methylated 
region (Pfeifer et al, 1990). This suggests that MeCPs are not bound to methylated 
sequences in vivo. A possible explanation for this observation is that the occupancy of 
MeCP at a particular methylated site is not saturated, i.e. 100 %. Indeed, there are more 
methyl-CpGs in the genome (2 x 10) compared to the number of molecules of MeCPs (5 
X  106  MeCP2 in a rat brain cell, and 2 x io MBD1 in a HeLa cell). Alternatively, the 
binding of MeCPs on chromatin is transient, as suggested by the loose interaction of 
MeCP1 with chromatin based on the ability to extract MeCP1 from the nucleus using low 
salt (Meehan et al, 1992). This is unlikely to be the case for MeCP2 and MIBD1 which are 
stably bound to chromosomes. Both MeCP2 and tvIBDl have potent transcriptional 
repression domains that can mediate long range repression, therefore such mechanism 
may suffice to effectively repress methylated sequences in the genome. 
6.3 The mojo of MBD2 
An interesting twist to the MBD2 story comes from a report claiming that MIBD2 contains 
5-methyl cytosine demethylase activity (Bhattacharya et al., 1999). MIBD2b was shown to 
catalyse the conversion of methyl-CpG to CpU by the direct removal of methyl-group. 
The same group also studied the end products of the demethylation process using a 
purified DNA demethylase from human cells (Ramchandani et al, 1999). Although the 
authors did not show that the purified DNA demethylase is MBD2, they presented 
evidence that the demethylase hydrolyses 5-methyl cytosine to cytosine and methanol. As 
pointed out by Wolfe et al. (1999), the newly discovered MBD2 demethylase and a yet 
unknown demethylase from human cells have remarkable biochemical and unprecedented 
catalytic properties. However it is unfortunate that the MBD2b demethylase activity 
cannot be reproduced by two laboratories, namely this laboratory and Dr. Wolfe's 
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Figure 6.1. How can the inactive state of methylated 
nucleosomal DNA be reversed? 
HAT, histone acetyltransferase. TF, transcription factor. 
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6.4 Is MBD3 a methyl-CpG binding protein? 
MBD2 and MBD3 are related proteins with highly similar C-terminus regions. Despite the 
similarity between these two proteins, only MBD2 can bind specifically to methylated 
DNA both in vitro and in vivo (Hendrich and Bird, 1998). It is likely that differences 
within the MBD-like region contribute to the disparity in their DNA binding property. The 
finding that xMBD3 which is a component of the Xenopus NuRD complex, binds 
specifically to methylated DNA instigates the reinvestigation of whether the mammalian 
MBD3 is a methyl-CpG binding protein. Both MIBD3 expressed in E.coli and insect cells 
showed a clear preference for methylated DNA using bandshift assays. This binding 
activity was also dependent on the MBD-like region, as a truncated version of MBD3 with 
half the M1BD-like region did not bind methylated DNA. However, competition 
experiments using non-methylated and methylated competitor DNA failed to reveal a clear 
answer regarding the specificity of the DNA/ protein complex. In the light of equivocal 
data, additional assays need to be developed to address this question critically. 
6.5 Repression by DNA methylation: more to chromatin than meet the eye 
In the cell, the likely situation is that different genes are regulated differently, i.e. not all 
genes will be repressed by methylation. It is also likely that methylation-sensitive genes 
are controlled through both direct and indirect repression by DNA methylation. 
A good example is the mouse M-lysozyme gene. The myeloid-specific mouse M-
lysozyme gene is methylated and silenced in non-myeloid cells (Figure 6.2). The 
myeloid-specific expression is primarily regulated by a downstream enhancer (MLDE, 
Klages et al, 1992). The MLDE contains the binding site for ubiquitous GABP 
heterotetrameric transcription factor. The binding of GABP to the recognition site is 
inhibited by methylation at a single Hpall site, thus in non-myeloid cells, DNA 
methylation inhibits the tissue-specific enhancer activity (Nickel et al, 1995). During 
myeloid differentiation, the MLDE becomes demethylated and M-lysozyme expression is 
activated (Schmitz et a!, 1997). Treatment of non-expressing cells such as the mouse 
fibroblasts, lymphocytic T-cells and myeloid precursor cells with demethylating agent 5-
aza-dC induces demethylation and restores the in vivo footprint at GABP site. 
Interestingly, when these cells are treated with TSA, the e*pression of M-lysozyme gene 
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Figure 6.2. Regulation of macrophage-specific (M-lysozyme) gene 
expression by DNA methylation: direct and indirect repression. 
MLDE, M-lysozyme downstream enhancer. Only a single methylated site 
within the MLDE is shown. 
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(Ammerpohi et a!, 1998). The level of induction of M-Iysozyme gene expression was 
comparable with that achieved by 5-aza-dC. The results strongly suggest that both direct 
and indirect mechanisms are involved in repressing expression of M-lysozyme gene. 
In two other reports, TSA failed to reactivate hypermethylated, transcriptionally silenced 
tumour suppressor genes in tumour cells, and expanded CGG repeat of FMRJ in fragile 
X patients (Cameron et al, 1999; Coffee et a!, 1999). When the tumour cells were treated 
with 5-aza-dC in conjunction with TSA, a synergistic and robust reactivation of the 
hypermethylated genes was observed. In the case of methylated FMRJ, TSA was shown 
to reverse the acetylation status of histone H4, but transcription was not restored. 
However, when the fragile X cells were treated with 5-aza-dC, histones H3 and H4 
associated with FMR1 became acetylated and transcription was restored. The result 
strongly suggest that both direct (methylation induced steric occlusion of regulatory factor 
binding) and indirect (MeCPs or chromatin mediated repression) effects were operating to 
repression transcription of methylated sequences. 
6.6 Functions of DNA methylation? 
In vitro methylated genes transfected into mammalian cells become transcriptionally 
silenced. The correlation between methylation of genes and silencing are well documented 
in the mammalian system. 5-aza-dC or 5-aza-C treatment can reactivate previously 
methylated and silenced genes or proviruses. Several of the known mammalian methyl-
CpG binding proteins (MeCP2, MBD2 and MIBD1) are active transcriptional repressors 
(Nan et al, 1997; Nan et a!, 1998; Ng et al, 1998; Ng et al). It leaves little room for doubt 
that DNA methylation in vertebrates is involved in repression of methylated sequences. 
Curiously, it is found that the genome of an invertebrate (Ciona intestinalis) is composed 
of methylated genes and non-methylated transposable elements (Simmen et al, 1999). Are 
the methylated genes repressed by DNA methylation? What is the function of DNA 
methylation in this organism? 
Organisms with 5-meC have to bear with the mutagenic burden of using DNA 
methylation system. 5-meC can spontaneously deaminate to form thymine. As thymine is 
a naturally occurring base, a T/G mismatch is obviously a difficult lesion to be corrected 
by DNA repair system(s). An attractive candidate repair protein to deal with such 
mutagenic event is the DNA thymine glycosylase (Wiebauer and Jiricny, 1989; 1990). 
TDG preferentially excises the thymine base from a TIG mismatch in vitro. Intriguingly, 
IJ9J 
mammals also have a methyl-CpG binding protein with a TIG glycosylase activity 
(MIBD4; Hendrich et a!, 1999). So, the question is: what is the role of methyl-CpG 
binding in MBD4? 
The studies of methyl-CpG binding proteins are pivotal in understanding the DNA 
methylation system in vertebrates and complementary molecular, biochemical and genetics 
tools will inevitably provide new exciting insights into the functions of DNA methylation. 
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Cytosine residues in the sequence 5'CpG (cytosine—guanine) arc 
often postsynthetically methylated in animal genomes. CpG 
methylation is involved in long-term silencing of certain genes 
during mammalian development'-' and in repression of viral 
genomes34. The methyl-CpG-binding proteins MeCPI (ref. 5) 
and MeCP2 (ref. 6) interact specifically with methylated DNA 
and mediate transcriptional repression' - '. Here we study the 
mechanism of repression by MeCP2, an abundant nuclear protein 
that is essential for mouse embryogenesis'°. MeCP2 binds tightly 
to chromosomes in a methylation-dependent manner 2. It 
contains a transcriptional-repression domain (TRD) that can 
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Figure 1 Interaction of MeCP2 with mSin3A and histone deacetylases. a, Western 
blot analysis of HeLa nuclear proteins pulled down by immobilized GSTor by GST-
fusion proteins that included different regions of MeCP2 (see b). Numbers 
correspond to amino-acid positions in the protein. Blots were probed with 
antibodies against mSin3A (antibody K-20), or against HDAC1 and HDAC2. The 
lower HDACI band probably corresponds to a degradation product of HDAC1. 
The HDAC2 band in lane 108-392 is displaced upwards because a large amount 
of fusion protein migrates with the HDAC2. b. Map of regions of MeCP2 that do (+) 
or do not (-( pull down mSin3A and HDACs. The thick black line corresponds to 
the corepressor-interacting region defined by these experiments. MBD, methyl-
CpG-binding aomain'. 
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function at a distance in vitro and in vivo'. We show that a region 
of MeCP2 that localizes with the TRD associates with a corepres-
sor complex containing the transcriptional repressor mSin3A and 
histone deacetylases' 3 ' 9. Transcriptional repression in vivo is 
relieved by the deacetylase inhibitor trichostatin A 20, indicating 
that deacetylation of histories (and/or of other proteins) is an 
essential component of this repression mechanism. The data 
suggest that two global mechanisms of gene regulation, DNA 
methylation and histone deacet-ylation, can be linked by MeCP2. 
DNA methylation is associated with altered chromatin struc-
tures2t23 . As MeCP2 binds tightly to chromatin in a methylation-
dependent manner, it seemed possible that transcriptional repres-
sion may be due to recruitment by MeCP2 of a chrornatin-modify-
ing corepressor. A corepressor complex containing mSin3 and 
histone deacetylases (HDACs) is thought to exert its effects by 
modulating chromatin structure" - ". We therefore asked whether 
regions of MeCP2 could 'pull down' the mSin3-containing core-
pressor complex from nuclear extracts. We used proteins containing 
glutathione S-transferase (GST) fused to different regions of MeCP2 
in 'puildown' reactions, and probed proteins bound to these 
complexes with antibodies against mSin3A, HDAC1 and HDAC2. 
A region in the centre of MeCP2 could bind all three proteins 
(Fig. la). GST alone and regions outside the interacting region of 
MeCP2 did not pull down any of the corepressor proteins (Fig. la). 
Control nuclear proteins (proliferating cell nuclear antigen and 
TATA-binding protein) were not bound by MeCP2 (data not 
shown). The region of MeCP2 that interacted with the corepressor 
substantially overlaps the TRD, as defined in vivo (Fig. lb)'. 
To test for a possible in vivo interaction between native MeCP2 
and the mSin3 corepressor complex, we used antibodies against 
MeCP2 and mSin3 to immunoprecipitate proteins from rat brain 
nuclear extracts (Fig. 2a). Both anti-MeCP2 antibodies precipitated 
mSin3A as well as MeCP2. Four different anti-mSin3 antibodies 
immunoprecipitated MeCP2 as well as mSin3 (the anti-Sin3 anti-
body AK  1 precipitated less MeCP2 than the other antibodies). 
Immunoprecipitates of transiently expressed HDAC2 also con-
tained MeCP2 (data not shown). These results led us to expect 
that MeCP2 would be associated with a catalytically active de-
acetylase complex. This was confirmed by the finding that both anti-
MeCP2 antibodies precipitated deacetylation activity, which was 
abolished by the highly specific deacetylase inhibitor trichostatin A 
(TSA) 2° ( Fig. 2b). Antibodies against components of the corepressor 
complex, mSin3A and HDAC1, also immunoprecipitated deacety-
lase activity, as expected, whereas control antibodies (anti-CDK7 
antibody and preimmue serum) gave background activity 
(Fig. 2b). 
Does MeCP2 interact with mSin3 itself or with another compo-
nent of the complex? To answer this question, we assayed the ability 
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Figure 2 Co-immunoprecipitation of rnSin3. MeCP2 and histone deacetylase 
activity from rat brain nuclear extracts, a, Western blot of immunoprecipitates 
3repared using antibodies against MeCP2 (antibodies 670 and 674) or mSin3 
antibodies AK11, AK 12, K-20 and RE) or using preimmune serum. Probes were 
3nti-mSin3A (RE) and anti-MeCP2 (670 and 674) antibodies, b, lmmunoprecipita. 
ion of hastone deacetylase activity from rat brain nuclear extracts with antibodies 
igainst MeCP2 (670 and 674), HDAC1, mSin3A or cyclin-dependent kinase 7 
CDK7) or with preimmune serum, in the presence or absence of 5 ng mr' 
USA. Precipitated activities from duplicate parallel experiments are shown as 
sercentage total activity added to each tube (19,200d.p,m. per 2h in the 
xpenment shown). 
Figure 3 MeCP2 interacts with mSin3A, but not with HDACs. a, In vitro-translated 
35S labelled mSin3A and HDAC5 1 and 2 were incubated with an immobilized 
fusion protein containing GSTond amino acids 108-392 of MeCP2 (Fig. Ib). Input 
protein (I) (20% of total), protein bound by the 108-392 fusion protein (B) and 
protein bound by GSI alone (G) were analysed by SDS-PAGE. b, Deletion 
constructs of mSin3A were transcribed and translated in vitro to give 20S-labelled 
products and processed as in a. Input (I) corresponds to 10% of total. c. Maps of 
the mSin3A deletion constructs 13,  indicating truncated proteins that did () or did 
not)-) bind to MeCP2. Regions of strong binding to MeCP2 are indicated by the 
thick black lines (top). 
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of the co repressor- interacting region of MeCP2 (residues 108-392) 
to bind in vitro-translated mSin3A, HDACI and HDAC2. mSin3A is 
the preferred binding partner, as the HDACs have a much weaker 
affinity for MeCP2 (Fig. 3a). There is probably a direct interaction 
between MeCP2 and rnSin3A, although we cannot exclude the 
possibility that an unknown component of the translation lysate 
mediates indirect binding. We mapped the sites of interaction 
between MeCP2 and mSin3A by translating in vitro a series of 
mSin3A proteins with deleted portions (ref. 13) and testing their 
ability to bind to amino acids 108-392 of MeCP2 (Fig. 3b, c). The 
amino-terminal half of the HDAC-interactjon domain (HID)" of 
mSin3A was common to most fragments that were able to binding 
MeCP2, but a deletion lacking all but the carboxy-terminal 48 
amino acids of HID (zHID) also bound efficiently, indicating a 
strong binding site within the C-terminal 200 amino acids of 
mSin3A (Fig. 3). We infer that the interaction between MeCP2 
and mSin3A involves both the N-terminal half of the HID of 
mSin3A and the C-terminus of mSin3A. MeCP2 and deacetylases 
seem to bind to distinct sites within the 375-residue HID region, as 
both can bind simultaneously (Figs la and 2a, b). 
To determine whether deacetylation is important for the effects of 

















transcriptional repression with TSA 20. We transiently transfecti 
mouse L929 fibroblasts with a reporter gene, which either did (G 
or did not (G 0 ) have GAL4-binding sites near its promoter, in tI 
presence or absence of a GAL4—TRD fusion construct". In tI 
absence of repressor, the ratio of G 5 expression to control 
expression was unaffected by TSA, remaining close to unity (Fi 
4). In the presence of the GAL4—TRD repressor, the G 5:G0 expre 
sion ratio was about 0.2, but was increased 2.8-fold by TS, 
Incubations with TSA for 24h (Fig. 4) or 9 (data not showt 
gave essentially the same result, eliminating the possibility that TS 
exerted its effects by arresting the cells at a stage of the cell cyc 
where repression was minimal. Repression by GAL4—TRD was m 
completely alleviated by TSA in any of the experiments (Fig. 4, dat 
not shown). The results indicate that a component of repression 1: 
the TRD may be deacetylase-independent, consistent with tl 
observation that mSin3A retains some ability to repress transcri 
tion even in the absence of associated HDACs' 3 . 
Our results indicate that repression by the TRD of MeCP2 relie 
to a significant extent, on histone deacetylation. Evidence for 
functional relationship between DNA methylation and chromati 
has come from studtes showing that methylated DNA packaged 
chromatin is incapable of transcription, whereas methylated DN, 
alone or chromatin alone remains transcriptionally active 2223 . Give 
the strong correlation between deacetylation of histone protein tail 
and transcriptional repression 24, the idea that methylated DN 
provokes deacetylation is attractive 25 , and is supported by evidenc 
that TSA can substitute for the demethylating drug 5-azacytidine t 
derepress methylated ribosomal RNA genes in plants 25. Our result 
indicate that MeCP2 may provide a mechanistic bridge betwee: 
DNA methylation and histone deacetylation. Recruitment c 
the corepressor complex by chromatin-bound MeCP2 may leai 
to local deacetylation of core histones (and perhaps of othe 
proteins involved in transcription 27), with consequent eliminatiot 
of transcription. 
Methods 
GST pulidown assay. GST and GST fusion proteins (6 R.g) were firs 
immobilized on glutathione-Sepharose beads. The coated beads were the 
incubated with 60 p.g HeLa cell nuclear extract in buffer A (20mM 1-IEPES pF 
7.9, 150 m NaCl, 0.5mM EDTA, 1 m dithjothrejtol, 10% glycerol, 0.1°, 
Triton X-100) for 2h at 4 °C. After five washes with buffer A, the protein 
bound to the beads were eluted in Laemmli buffer and analysed by westerl 
blotting nearly as described". The primary antibodies used were K20 (anti 
mSin3A, Santa Cruz Biotech. Inc.), anti-HDACI, and anti.HDAC2 (ref. 13) 
Nuclear extract (6 p.g protein) was loaded as a positive control. Polyclona 
antiserum against mammalian HDAC1 was raised against a synthetic peptidi 
corresponding to the C-terminal domain ofHDAC I (EEKPEAKGVKEEvK1J 
as described19 . 
Immunoprecipitatlon. Antibodies (4p.l serum, or 2 g purified lgG) wer, 
immobilized on protein A-Sepharose beads and washed with 20 m HEPE 
p1-1 7.9, 0.1 M NaCl, 10% glycerol, 0.2mM EDTA and 0.01% Triton X- 100. Thi 
antisera were: ants-MeCP2 (670) raised against the amino acids 207-492 o 
MeCP2; anti-MeCP2 (674) raised against amino acids 1-392 of MeCP2 
anti-mSin3A (RE)' 1 ; and anti-mSin3AJB antibodies AK- 11, K-20 and AKI 
(Santa Cruz Biotech, Inc.) Preimmune serum was from the rabbit that wat 
subsequently immunized with MeCP2 amino acids 207-492. Bound anti-
bodies were incubated with 20 iLg brain nuclear extract" in 240 p.1 wash buffei 
plus I mg mt_i  BSA for 1.5 h. Beads were washed three times and protein was 
eluted in Laemmli buffer. lmmunoprecipitated proteins were detected b 
western blotting. 
Immunoprecipitatlon of histone deacetylase activity. Aliquots (100 p. 
protein) of rat brain nuclear extract were incubated for 16 h at 4 °C, with 5 p. 
affinity-purified antibodies against UDACI or mSin3A (Santa Cruz Biotech. 
Inc.) or with whole antiserum against MeCP2 (670 or 674) or CDK7 (a gift 
from J. Shuttjeworth) or with preimmune serum. The final volume was 500 pJ 
in 20 m 1-IEPES pH 7.9, 150 m NaCl, 0.1% Nonidet P40, 0.25% gelatin, 
1 mM EDTA, 0.5mM EGTA, 0.2% NaN 9 , 0.1 mM PMSF, and 1 p.gmr' each of 
TSA treatment 	- + 	- + 	- + 
GAL4-TRD (ng) 0 	 100 	 200 
100 bp 
5xGAL 
Reporter: 	 Human 3-actin promoter  
Reporter: G0 	
Human -actin promoter 	I I l5gai 	'] 
Effector: 	CMV promoter PT 
GAL4-TRD 
MeCP21_______ 	 1 
MBD 	TRO 
Figure 4 Relief of TRD-mediated repression of transcription by the deacetylase 
inhibitor ISA. Mouse fibroblasts (L cells) were transfected with reporter genes 
that did or did not contain GAL4 DNA-binding sites (G5 or C O3 respectively), in the 
presence or absence of a fusion between the GAL4 DNA-binding domain and 
amino acids 207-492 of MeCP2. After 24h, transfected cells were treated with 
TSA (shaded bars) or left untreated (white bars) and were incubated for a further 
24 h. Columns represent the mean ratio between 13-galactosidase activities of C 5 
and G0 in three independent experiments (t standard deviation). Relative p. 
galactosidase activity in the absence of ISA and GAL4-TRD was normalized to 
1.0 CMV. cytomegalovirus: bp. base pairs 
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Iprotinin, leupeptin and pepstatin A. Antibody-bound material was pelleted 
with protein A-Sepharose (Pharmada), washed and assayed for histone 
feacetylase activity as described. The substrate was a synthetic peptide 
:orresponding to the 18 N-terminal residues of histone H4, chemically 
tcetylated using 3H-labelled acetic anhydride (Amersham) and added at 
X 10d.p.m.perassay. 
n vitro binding assay. Intact mSin3A, HDAC1 (a gift from T. Kouzarides), 
-IDAC2 and fragments of mSin3A (ref. 13) were labelled with [35S]  methionine 
ising a coupled transcription-translation TNT system (Promega). GST-
(4eCP2 fusion proteins or GST (3g) were first bound to glutathione-
epharose beads. The slurry was then incubated with the labelled products 
1 l) in 100l buffer B (50mM HEPES pH 7.9, 250 m NaCl, 1mM EDTA, 
1 mM dithiothreitol, 10% glycerol, 0.1% Triton X- 100,0.5mg ml' BSA) at 4°C 
'or 2 h. After washing the beads for three times with buffer B, the bound 
iroteins were eluted in Laemmli loading buffer, fractionated by SDS-PAGE, 
md detected by autoradiography. 
Iransfection and 3-gaiactosidase assay. Mouse fibroblasts (L cells) were 
ransfected with reporters G 0 or G5 in the presence or absence of GAL4-
rRD(207-492). Transfection and .gaiactosidase assays were performed 
early as described'. Fresh medium with or without 100 ng ml' TSA was added 
o the mouse L929 fibroblast cells 24h after transfection and the cells were 
:ollected after a further 24 h. In some experiments, treatment with TSA was 
•educed to 9 h. 
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MBD2 is a transcriptional repressor belonging to the 
MeCP1 histone deacetylase complex 
Huck-Hui Ng', Yi Zhang 2, Brian Hendrich', Cohn A. Johnson 3 , Bryan M. Turner 3 , 
Hediye Erdjument-Bromage 4 , Paul Tempst4 , Danny Reinberg2 & Adrian Bird' 
Mammalian DNA is methylated at many CpG dinucleotides. The 
biological consequences of methylation are mediated by a family 
of methyl-CpG binding proteins. The best characterized family 
member is MeCP2, a transcriptional repressor that recruits his-
tone deacetyIases 7 . Our report concerns MBD2, which can bind 
methylated DNA in vivo and in vitro4 and has been reported to 
actively clemethylate DNA (ref. 8). As DNA methylation causes 
gene silencing, the MBD2 demethylase is a candidate transcrip-
tional activator. Using specific antibodies, however, we find here 
that MBD2 in HeLa cells is associated with histone deacetylase 
(HDAC) in the MeCP1 repressor complex'- 9 . An affinity-purified 
HDAC1 corepressor complex 10" 1 also contains MBD2, suggesting 
that MeCP1 corresponds to a fraction of this complex. Exogenous 
MBD2 represses transcription in a transient assay, and repression 
can be relieved by the deacetylase inhibitor trichostatin A (TSA 
ref. 12). In our hands, M5D2 does not demethylate DNA. Our 
data suggest that HeLa cells, which lack the known methylation-
dependent repressor MeCP2, use an alternative pathway invol-
ving MBD2 to silence methylated genes. 
Previous work showed that Mhd2h, a truncated form of mouse 
Mbd2 (Fig. in), binds DNA in vitro in a methylation-dependent 
manner4. Full-length recombinant mouse MBD2a (Fig. la) also 
formed a complex with a densely methylated probe in a bandshift 
assay, but did not bind to non-methylated counterpart (Fig. ib). To 
search for MBD2-associated proteins, we first raised polydonal 
antisera against recombinant MBD2. Antibodies were tested on 
western blots of HeLa nuclear extract and assessed for their ability 
to discriminate between MBD2 (in particular the MBD3-like 
MBD2h form) and its relative, MBD3 (ref. 4). Antiserum S923 
bound to recombinant MBD2h, but not to MBD3 (Fig. Ic). Anti-
serum R593 recognized MBD2b and cross-reacted with MBD3 
(Fig. ic). In HeLa extract, S923 antibodies detected an approxi- 
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Fig. 1 MBD2a binds methylated DNA specifically and is part of the methyl-CpG binding complex. MeCP1. a, Maps of full-length M8D2a and a hypothetical trun-
cated form, MBD2b, that initiates at a downstream methionine 4 . b. Recombinant MBD2a forms a complex with probe MeCG1 1(26 methyl-CpGs), but not with 
the non-methylated form CG1 1. c, Anti-MBD2 antisera 5923 and R593 probed against western blots of HeLa nuclear extract (26 pg protein; NeLa NE), recombi-
nant MBD2b (30 ng; ref. 4) and recombinant MBD3 (30 ng; ref. 4). d, lmmunoprecuprtates with anti-MBD2 antiserum 5923 (aMBD2) contained only the 48-kO 
M8D2a protein. MBD2a always resolves as a doublet band for unknown reasons; the doublet resolves less well at higher concentrations of antibody due to the 
increased presence of closely migrating 196. The control was pre-immune serum (P1). e, 5923 anti-MBD2 antibodies supershift the bandshift complex between 
MeCP1 and the methylated DNA probe MeCO Ii. No supershift was seen with pre-immune serum or of the non-specific CG 11 complex (P1). t. Depletion of MBD2 
from HeLa cell nuclear extracts with 5923 antiserum (2.5, Sand 10 p1) causes loss of MeCP1 complex in a bandshift assay. Pre-immune serum (P1) has no effect. 
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Fig. 2 MBD2 is associated with histone deacetylases in the MeCP1 
complex. a. Anti-MBD2 antibodies co-immunoprecipitate HOAC 
activity from HeLa cell extracts, but pre-immune serum (P1) and 
control antibodies against MBD1 and CDK7 do not. bc. Anti-
HDAC1 antibodies (10, 20 and 30 ii) deplete MeCP1 bandshift 
activity (b) and MBO2 (C) from a HeLa nuclear extract. Control non-
immune serum does not deplete MeCP1 or MBD2. MBD2 was 
detected by western blot using 5923 antiserum. d, Anti-MBO2 anti-
bodies co-immunoprecipitate HDACI. HOAC2 and RbAp48 from 
Heta nuclear extracts. Co-migration with immunoglobulin heavy 
chain leads to aberrant migration of RbAp48 in the immunopre-
cipitated lane. e, Polypeptides retained on HOAC1 (eHOACI) and 
GST (czGST) antibody columns after separation by SOS-PAGE fol-
lowed by silver staining. Known components of the complex" are 
Labelled (right). Mass spectrometric and sequence analysis of the 
43-kO band from the fraction isolated using anti-HDAC1 antibod-
ies identified a peptide (VLYIDIDIHHGDGVEEAFYTIOR) contained 
in HOAC1, as well as a peptide (GLQGVGPGSNDE1USAVASALHTSS-
APITGQVSAAVEK) that matches the M802 sequence. It is not 
known whether HDAC1 • represents an alternative form or degra-
dation product of HDAC1. The data suggest roughly equimolar 
amounts of HDACI*  and MBD2 in this band (data not shown). f, 
M8D2a, RbAp46. RbAp.48 and HDACI were detected by western 
blot in nuclear extract (input) and in complexes that were affinity 
purified with anti-HDAC1 antibodies. 
am am 
control Ab 	CiHOAC1 
d 
- 
VAC2 — —. 
mately 49-kD band corresponding to hill-length 
MBD2a (in vitro-translated MBD2a has an identical 
mobility-, data not shown), plus an approximately 30-kD 
band that may be MBD2b or a degradation product. 
S923 does not cross-react with MeCP2, MBD1 or MBD4 	e 
(data not shown). We further tested the specificity of the 
S923 antiserum against soluble nuclear proteins by 
probing western blots of S923 immunoprecipitates with 
the less-specific R593 antiserum. R593 recognizes 
MBD3 (Fig. ic), but only MBD2a was detected in the 
precipitated material (Fig. id). 
We used the highly specific S923 antiserum to deter-
mine whether MBD2 is a component of the methyl-
CpG binding activity (MeCP1; ref. 1) previously 
implicated as a transcriptional repressor 9" 3 . S923 anti-
bodies were able to quantitatively supershift the 
MeCPI complex with a probe methylated at multiple 
sites, whereas pre-immune serum was inert (Fig. le, MeCG11 
lanes). A non-specific complex with the non-methylated probe 9 
was unaffected by either immune or pre-immune sera (Fig. le, 
CG1 I lanes). When we used anti-MBD2 antibodies to deplete 
MBD2 from the HeLa extract, the MeCP1 complex was corre-
spondingly depleted (Fig. if). Pre-immune serum did not deplete 
the MeCP1 complex, and neither antiserum affected the non-
specific complex with non-methylated DNA- We conclude that 
MBL)2 is a component of the MeCPI complex. 
Several studies have indicated that methylation-dependent 
transcriptional repression involves deacetylation 6'7''7. As 
MeCP 1 is a likely repressor of methylated genes 9, we asked 
whether its constituent MBD2 is associated with deacetylases. We 
found that S923 immunoprecipitates contained up to 27% of the 
total histone deacetylase activity of HeLa extracts (Fig. 2a). 
Moreover, anti-HDACI antibodies efficiently immunodepleted 
both MeCP1 (Fig. 2b) and MBD2 (Fig. 2c) from the extract, 
whereas control non-immune serum had no effect. In addition, 
several known protein components of corepressor complexes 
were co-immunoprecipitated by MBD2 antibodies from a HeLa 
extract (Fig. 2d), indicating that MeCPI activity is due to a com-
plex between MBD2, deacetylases HDACI and HDAC2, and 
RbAp48. As a negative control, we found that retinoblastoma 
protein, which associates with HDACs (refs 18-20), was not 
immunoprecipitated by anti-MBD2 (data not shown). Mass fin-
gerprinting analysis of proteins affinity-purified using an anti- 
f 
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Tr --DAa 0 
RtApM 
HDAC1 antibody" (Fig. 2e) indicated that MBD2 is a compo-
nent of a corepressor complex. Western-blot analysis confirmed 
that MBD2 is present in complexes affinity purified with HDAC1 
antibodies, together with HDAC 1/2-associated proteins RbAp46 
and RhAp48 (Fig. 2J). 
A previous report claimed that a related methyl-CpG binding 
protein, MBD1, is a component of MeCPI (ref. 3). Subsequent 
experiments with antibodies highly specific for MBD1 failed to 
supershift or immunodeplete MeCP1 (H.-H.N. and A.B., unpub-
lished data) or to immunoprecipitate deacetylase activity (Fig. 2a). 
These and other results lead us to suspect that the anti-MBD1 anti-
body used in the previous study may have cross-reacted with MBD 
proteins that were unknown at the time. Recent work confirms the 
proposal3 that MBD1 is a methylation-dependent transcriptional 
repressor, but argues against its involvement in MeCP 1 of HeLa 
cells (H.-H.N. and A.B., unpublished data). 
HeLa cells lack detectable amounts of the known methylation-
dependent repressor MeCP2 (Fig. 3a), but are nevertheless able to 
repress transfected methylated genes 9 . We initially determined 
whether repression in the effective absence of MeCP2 was HDAC 
dependent by transiently transfecting a luciferase reporter gene 
that contained a duster of 20 methylatahle H/Ui! sites (CG 1 1) 
immediately upstream of the SV40 promoter (Fig. 3b,c). The 
M.l-lhal-methylated reporter construct was transcribed at approx-
imately 30% of the level seen in non-methylated controls (Fig. 3b). 
The same construct lacking the CGI I cluster (originally used to 
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Fig. 3 M8D2 can account for deacetylase-dependent repres-
sion of methylated genes in HeLa cells, a, Western blots show 
that MeCP2 is not detectable in HeLa extracts (26 rig), but is 
abundant in rat brain extracts (20 119). Controls show that 
m5in3A is present in both extracts. b, Transcription of the 
transiently transfected Col 1-pGL2 construct (C) is repressed by 
methylation of HI-jal sites (Hhal M+), but not by mock methy-
lation (mock M-). Repression is relieved by 100 ng/ml TSA. Per 
cent relative activity of the promoters is expressed as the ratio 
of luciferase to 3-galactosidase activities. c, Map of reporter 
gene constructs. CG1 1-pGL2 contains 45 methylatable Hhal 
OW including the promoter-proximal CG1 1 cluster. Compari-
son of DNA polymerase-t and 3-actin promoter constructs, 
each with five Gal4 binding sites. The 5V40 enhancer is 
marked (Enh). dc, Co-transfectiori of a construct encoding 
MBD2a fused to the Gal4 DNA-binding domain together with 
the DNA pol 3 (d) or 3-actin (e) reporters into mouse L cells 
causes transcriptional repression. Relative activities are the 
ratios of luciferase to 3-galactosidase (d) or 3-galactosidase to 
luciferase (e) activities. ISA (100 naJml) relieves repression of 
the DNA pol 13 reporter. 
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identify MeCP1 activity') was minimally repressed 
by I-thaI site methylation (X. Nan and A.B., unpub- 
lished data). TSA treatment reduced methylation- 	 o,is i, pminoier 	 ______ 
dependent repression (Fig. 3b), indicating that ''AL 	 Lic 
deacetylation is involved. We next asked whether 
MBD2 was itself a repressor by transiently express-
ing MBD2a fused to the Ga14 DNA-binding 
domain. Transcription of a co-transfected reporter d - 
gene encoding the human DNA polymerase-3 pro-
moter (plus Ga14 DNA-binding sites) was inhibited 
by Ga14-MBD2a, but repression was abolished by . 
TSA (Fig. 3d). A reporter under control of the 
human ACTB (encoding 0-actin) promoter was 	 rie 
also repressed by the fusion protein, but repression 
was weakly reduced by TSA (Fig. 3e). Promoter-
specific responses to derepression by TSA have been 
observed 20 previously. Repression of both promot- 
ers depended on the presence of Gal4-binding sites 	 - + 	+ 
in the reporter construct (data not shown). The 
results indicate that repression of at least some pro- 
moters by MBD2 depends on deacetylation. 
Given the unexpected association of a putative demethylase with 
transcriptional repression complexes, we tested the demethylation 
activity of in vitro-translated mouse 4 or human8 MBD2b expres-
sion constructs. Translation products complexed with methylated 
ISA 	- 
] .i-t., p.ont.' 
5,.A.. 
:1 Ii - + - + 
TSA 
DNA (Fig. 4a), indicating correct protein folding, but methylated 
CCGG and GCGC sites in the same probe (Fig. 4c) were not sus-
ceptible to HpaII or H/Ial after prolonged incubation under pub-
lished conditions8 (Fig. 4b). Moreover, we did not observe 
dissociation of the MBD2 bandshth complexes due to demethyla- 
Fig. 4 Absence of demethylation by in vitro-trans-
lated MBD2b. a, DNA probe MeCG1 1 was 32P end 
labelled and incubated with no protein (lane 1), 
in vitro translation products of MBD2b expression 
constructs pETMbd2b (lane 2; ref. 4) or pHis-
dMlase8 (lane 3), or with a mock in vitro-transla-
tion reaction (lane 4). Differing mobilities of 
complexes on 8% polyacrylamide gels (compare 
lanes 2,3) is probably due to the greater size of 
the pHis-dMlase protein (37 tO) compared with 
ptTMbd2b protein (30 tO). b, MeCG1 1 is suscepti-
ble to Mxpl (M), but remains resistant to Hpall (H) 
and Hhal (Hh) after a 3-h incubation with either 
human (ms) or mouse (bit) MBD2b. The asterisked 
band is a probe contaminant. c. The 160-bp 
duplex probe MeCG11 contains 19 lIhal sites 
(short barbed arrows) and 7 Hpall sites (long 
arrows) that were methylated to completion with 
M.Hhal and M.Hpall. 
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tion of binding sites during the prolonged assay (Figs lb and 4a). 
Attempts to demethylate other oligonudeotide and plasmid sub-
strates with bacterially expressed MBD2, in vitro-translated 
MBD2b or anti-MBD2 imniunoprecipitates from HeLa extracts 
were similarly unsuccessful (data not shown). It may be that 
MBD2 has a dual role as both a DNA methylation-dependent 
repressor and an activator of genes that are silenced by methyla-
lion. Diametrically opposed activities might theoretically be com-
bined in a protein that serves as a switch between active and 
inactive chromatin states. This speculative hypothesis depends, 
however, on verification of the demethylase activity of MBD2. 
Our data uncover a novel mediator of methylated gene silencing. 
Although MeCP2 and MBD2 both repress transcription of methy-
lated DNA via a deacetylase-containing corepressor complex, there 
are differences between them. Tightly bound MeCP2 (refs 2,21) 
has the character of a structural component of the chromosome 
that ensures long-term silencing of methylated sequences. 
MBD2/MeCP1, on the other hand, is released from nuclei by low 
salt t , suggesting that it is not stably complexed with DNA. The 
MeCP1 subset of the HDAC corepressor complex may be a cat-
alytic complex that alters methylated DNA-containing chromatin 
during a transient visit. There is also a difference in binding speci-
ficity between MeCPI and MeCP2. MCCP2 binds to single methy-
lated sites22, whereas MeCPI requires regions of dense CpG 
methylatio&. Conceivably, each MeCPI complex contains multi-
ple molecules of MBD2, thereby enhancing binding to local dus-
ters of methyl-CpG. Assessment of this possibility awaits future 
purification and compositional analysis of MeCPI. Already, the 
differences between M13132 and MeCP2 suggest that they may have 
somewhat different roles in transcriptional silencing. 
Methods 
Plasmids. We constructed plasmid pCMV-Gal4-MBD2a by inserting a 
NaeIISspI fragment of MB132a cDNA (ref. 4) into Baml-11-blunted pCMV-
Ga14 vectors and pGEX5-MBD2a by inserting the same NaeI/Sspl fragment 
of MBD2a cDNA into BamHl-blunted pGEX5xI vector (gift from S. Mac-
Neill). We sequenced all constructs to confirm identity. CGI l-pGL2 
luciferase reporter was a gift from X. Nan (unpublished data). Plasmid 
pHis-dMTase was a gift from M. Szyf8 . The Gal4-DNA polymerase-
luciferase reporter5 3 was a gift from J.  Millbrandi. 
Transfection and reporter assays. We transfected mouse fibroblast L cells 
and 13-galactosidase assays essentially as described 56 and detected 
luciferase activity using a luciferase assay kit (Promega). Transfection mix-
es included reporter (2 pg;  with Ga14-binding sites), effector (2 1kg; Ga14-
MBD2a) and internal control reporter (2 ig either human ACTB promot- 
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er driving -galactosidase or pGL2 SV40 promoter/enhancer driving 
luciferase). We transfected HeLa cells with CGI 1-pGL2 luciferase reporter 
(1 l.1g either mock methylated or methylated with Hhal methyltransferase) 
and human -actinfll-galactosidase reporter (I sg) using Lipofectamicse 
(Gibco IIRL) according to the manufacturer's instructions. We treated cells 
with TSA (100 ng/ml) for 24 h before collection. 
Bandslsifts, insmunodepletion and immunoprecipitation assays. We per -
formed bandshift assays as described'. For immuriodepletion of MBD2 or 
MeCPI activity, we immobilized the antibodies (5-30 pi serum) on pro-
tein-G sepharose (Pharmacia). After washing the beads with P135 (plus I M 
NaCl and 0.1% Triton X-100) and binding buffer (50 mM l-(epes, pH 7.9, 
150 m NaCl, 0.5mM EDTA. 10% glycerol, 0.1% Triton X- 100), we incu-
bated the beads with HeLa nuclear extract (40 1g) in binding buffer for 2 h 
at 4°C. Aliquots of the supernatant were then used for bandshift and west-
ern-blot analysis. We performed immunoprecipitations as described'. For 
immunoprecipitation of histone deacetylase activity', we used HeLa whole 
cell extract, lysed in Tris (50 mM, pH 8.0), NaCl (ISO mM), EDTA (0.5 
mM), EGTA (0.5 mM), 1% NP40, -mercaptoethanol (5 mM) and pro-
tease inhibitors, as input. 
Antibodies, western blots and affinity purification. Antibody S923 was 
raised in sheep against GST-MBD2a fusion protein. In this preparation of 
affinity-purified recombinant protein, only 20% was full length, so the 
sample was biased toward the tagged amino-terminal portion of MBD2a. 
Antibody R593 was raised in rabbit against GST-MBD2b fusion protein. 
Anti-mSin3A (AKI I), anti-HDAC2 (H-52) and anti-Rb (C-15) were pur-
chased (Santa Cruz). Anti-RbAp48 was raised against the synthetic peptide 
CENIYNDEDPEGSVDPEGQGS as described 24. Antibodies against 
MeCP2 (ref. 5) have been described. We performed western blots as 
described 3, except the buffer used was Tris HCI (50 mM, pH 8.0), NaCl 
(150 mM), 0.05% '1 1ween-20 and 1% dried milk powder. Complexes were 
affinity purified using anti-HDAC I antibodies as described".  
Demethylase assays. We carried out in vitro transcription/translation of 
MBD2 expression plasmids and demethylase assays as described'. We 
analysed restriction digests of MeCG II probe by electrophoresis on 8% 
polyacrylamide gels. 
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DNA methylation and chromatin modification 
Huck-Hui Ng*  and Adrian Bird 
DNA methylation and chromatin modification are two global 
mechanisms that regulate gene expression. Recent studies 
provide insight into the mechanism of transcriptional silencing 
by a methyl-CpG binding protein, MeCP2. MeCP2 is shown to 
interact with the Sin3/histone deacetylase co-repressor 
complex. Thus, this interaction can provide a mechanistic 
explanation for the long-known relationship between DNA 
methylation and chromatin structure. Moreover, several studies 
have shown that inhibition of histone deacetylases by specific 
inhibitors can reactivate endogenous genes or reporter 
constructs previously silenced by DNA methylation. Taken 
together, the data strongly suggest that DNA methylation can 
pattern chromatin modification. 
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ER estrogen receptor 
HAT histone acetyltransferase 
HDAC histone deacetylase 
MeCP methyl-CpG binding protein 
NF nuclear factor 
PR progesterone receptor 
SRC-1 steroid receptor coactivator-1 
TF transcription factor 
TK thymidine kinase 
TRD transcriptional repression domain 
TSA Trichostatin A 
Introduction 
Methylation of cytosines at the carbon 5 position of CpG 
dinucleotides is a characteristic feature of many eukaryot-
ic genomes. In vertebrates, 60-90% of all CpGs are 
methylated, leaving a minor part of the genome methyla-
tion free. Many of the remaining non-methylated CpGs 
(-15% of all CpGs in human DNA) are found in CpG 
islands [1], which usually include functional promoters. 
A large body of evidence accumulated over the years sug-
gests that DNA methylation is incompatible with 
transcriptional activity. Initially, many studies document-
ed a strong correlation between DNA methylation and 
gene inactivity [2].  The loss of expression from artificially 
methylated gene constructs upon transfection into tissue 
culture cells strongly supported this hypothesis [3]. 
Furthermore, the application of a DNA-demethylating 
agent, 5-azacytidine (5-aza-C), was shown to bring about 
the reactivation of previously methylated, silenced 
endogenous genes [4] and retroviruses [5]. 
DNA methylation and chromatin 
Earls' experiments demonstrated that artificially methylat-
ed DNA can adopt a distinctive chromatin structure upon 
integration into the genome [6]. This conformation ren-
ders the DNA refractory to nuclease or restriction 
endonuclease digestion and also leads to the loss of 
DNase-1-hypersensitive sites. On the other hand, 
unmethylated CpG islands, which are associated with pro-
moters of many genes, possess a nuclease-sensitive 
chromatin structure that differs from the bulk of the 
methylated genome [7]. CpG island chromatin was found 
to contain highly acetylated historic H3 and H4. 
Is the inactive chromatin structure associated with DNA 
methylation important for the loss of transcriptional activi-
ty? This question was critically addressed by experiments 
analyzing the kinetics of transcriptional arrest from methy -
lated templates [8]. Both methylated and non-methylated 
versions of the herpes simplex virus thymidine kinase 
(HSV TK) gene were equally active during the first 
8 hours after microinjection into rodent cells. It was only 
after longer periods (>8 hours) that the inhibitory effect of 
DNA methylation was felt on the methylated reporter Con-
struct, as measured by the accumulation of HSV TK RNA. 
It was hypothesized that the injected DNA was not fully 
assembled into chromatin at early times, and that the DNA 
methylation status had no effect on transcriptional activity 
in the absence of chromatin. Indeed, when an in vitro 
reconstituted chromatinized methylated reporter was 
introduced into the cells, it became transcriptionally inert. 
Subsequently Kass et al. [9] showed clear evidence for a 
time-dependent repression of methylated template follow-
ing injection into Xenopus oocytes. Loss of transcriptional 
activity from the methylated template coincided with the 
appearance of a nucleosomal array in the vicinity of the 
promoter and the disappearance of engaged RNA poly-
merases. The above studies demonstrate that DNA 
methylation can lead to alteration of chromatin structure. 
Until recently, the molecular mechanism by which DNA 
methylation represses transcription remained largely 
unknown but a few reports hinted at a connection with his-
tone deacetylation. In one instance, an inhibitor of histone 
deacetylase (HDAC), sodium butyrate, was shown to ele-
vate the expression of a methylated episomal reporter gene 
[10]. It was also reported that both sodium butyrate and 
Trichostatin A (TSA a specific inhibitor of HDACs [II]) 
can substitute for the DNA-demethylating agent, 
5-aza-2'-deoxycytidine (5-aza-dC) in restoring transcrip-
tion from previously methylated and silenced plant 
ribosomal RNA genes 1121. The interchangeable effect of 
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TSA and a DNA-demethylating agent prompted the 	promoter. These results show that deacetylation causes 
notion that DNA methylation and histone deacetylation silencing of the methylated reporters and they suggest that 
may operate along a common mechanistic pathway to 	MeCP2 may be the mediator responsible. 
silence transcription. 
Histone hypoacetylation and 
transcriptional repression 
It is evident from numerous studies (for review, see [131) 
that transcriptional repressors often function in the context 
of chromatin by recruiting a common chromatin-modifying 
complex. For example, Mad-Max heterodimers and unli-
ganded nuclear hormone receptors were found to associate 
with the mSin3 co-repressor complex [14-191. This multi-
protein complex contains catalytically active HDACs 
(HDAC1 and HDAC2). An underlying theme that emerged 
is the targeting of HDACs to the chromatin by sequence-
specific DNA-binding proteins [20]. Deacetylation of 
histone H3 and H4 by the HDACs presumably leads to the 
formation of a chromatin environment that inhibits tran-
scription. Indeed, HDAC inhibitors TSA or trapoxin were 
shown to relieve the repressive activity associated with the 
mSin3 co-repressor complex. 
DNA methylation and histone deacetylation 
MeCP2 is a chromosomal protein that binds specifically to 
methylated DNA both in vitro and in vivo, via its methyl-
CpG binding domain [21-23]. In addition, MeCP2 can 
'invade' chromatin in a methylation-dependent manner 
and, in vitro at least, can displace historic HI [24]. A high-
ly basic central region of MeCP2 was shown to repress 
transcription in vivo. In a recent study [25"], a region of 
MeCP2 encompassing the transcriptional repression 
domain (TRD) has been shown to bind components of the 
mSin3A/HDAC complex. The interaction between 
MeCP2 and the co-repressor complex was further substan-
tiated by reciprocal co-immunoprecipitation experiments 
using native rat brain nuclear extracts. As mSin3A is the 
preferred binding partner of MeCP2 in vitro, it is proposed 
that MeCP2 recruits the co-repressor complex via interac-
tion with mSin3A in vivo. TSA was able to relieve the 
TRD-mediated transcriptional repression, indicating that 
histone deacetylation is indeed a critical component of the 
repression mechanism. 
Using biochemical fractionation methodology, Jones et 31. 
[26"] have found that Xenopus MeCPZ co-purifies with 
both the Sin3A protein and the HDAC activity through 
several chromatography steps [26"], strongly suggesting 
that MeCP2 can also form a stable complex with the 
Sin3A/HDAC proteins in the Xenopus system. The associ-
ation between MeCP2 and the Sin3A co-repressor 
complex was also confirmed by co-immunoprecipitation 
experiments [26"]. As in mammals, repression by the 
TRD of Xenopus MeCP2 can be alleviated by TSA. More 
importantly, the authors also reported that TSA can relieve 
the inhibition imposed on methylated reporters injected 
into the oocytes, as the drug was able to restore transcrip-
tion and hypersensitive sites of the methylated hsp70 
A causal link between DNA methylation and histone 
deacetylation is further strengthened by studies that show 
parallel effects of DNA-demethylating agents and TSA in 
reactivating transcription of sequences repressed by DNA 
methylation. In one study, mouse fibroblast L cells were 
stably transfected with either a methylated or a non-methy-
lated rk gene [27"]. Subsequent immunoprecipitation of 
chromatin with an antibody against acetylated histone H4 
revealed that, in contrast to the non-methylated ik gene, 
the methylated ik gene was not enriched for acetylated his-
tones. TSA treatment resulted in an increased expression of 
the methylated 1k gene. In addition, TSA treatment 
increased the accessibility of the methylated tk gene locus 
to nucleases, suggesting that acerylation of histories can re-
establish features of transcriptionally active chromatin 
despite the presence of DNA methylation. Similar results 
were obtained with integrated transgenes that were sub-
jected to spontaneous epigenetic silencing with the 
concomitant appearance of DNA methylation and loss of 
histone hyperacetylation [281. Again, both butyrate/TSA 
and 5-aza-C were able to restore transgene expression. 
Are endogenous genes that are repressed by DNA methyla-
tion also affected by treatment with a histone deacetylase 
inhibitor? This question is addressed by two recent reports. 
The myeloid-specific mouse M-lysozyme gene is methylat-
ed and silenced in non-myeloid cells. When non-expressing 
cells - such as mouse fibroblasts, lymphocytic T-cells and 
myeloid precursor cells - are treated with TSA, the expres-
sion of M-lysozyme is induced even though the gene 
remains methylated [291. The level of induction of M-
lysozyme gene expression is comparable with that achieved 
by the demethylating agent 5-aza-dC. The effect of TSA on 
methylated endogenous genes has also been tested in the 
fungus Neurospora crassa [30"]. Inhibition of histone 
deacetylation results in the re-expression of a methylated 
copy of the hygromycin resistance gene. The degree of 
derepression by TSA was found to be comparable to that 
caused by DNA demethylation using 5-aza-C. A similar 
result was also observed at the Tad/am locus. 
Although the above-mentioned studies provide strong evi-
dence that DNA methylation may influence the 
underlying histone modification pattern, it is important to 
note that not all data support this idea. For example, 
although TSA treatment can reactivate some methylated 
genes in Neurospora crassa, the expression of other methy-
lated regions remains unaffected [30"]. Similarly, 5-aza-C 
can reactivate dormant, methylated proviral genomes in 
chicken cells [5] but TSA in this system fails to restore 
transcription (RN Eisenman, personal communication). In 
general, caution needs to be exercised when interpreting 
the results with HDAC inhibitors such as TSA. It is impor -
tant to be certain that the effect seen can be attributed 
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How might the inactive state of methylated nucleosomal DNA 
hypothetically be reversed? (a) Restoration of histone acetylation. (I) 
Binding of transcription factors (TFs) to methylated DNA can (ii) recruit 
protein(s) with HAT activity. Next (iii), the assembly of this protein 
complex can lead to the acetylation of core histories and (iv) 
subsequent transcription. (b) DNA demethylation. Methylated DNA 
may undergo demethylation either (i) through passive or (ii) active 
demethylation processes. The loss of DNA methylation through either 
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demethylation process may lead to the acetylation of histones 
associated with demethylated DNA. (i) Passive DNA demethylation 
involves the binding of nuclear factors (NFs) to the DNA. Persistent 
binding of nuclear factors in the vicinity of methylated DNA can lead to 
the failure of the maintenance methyltransferase to restore fully 
methylated CpG sites during DNA replication. (ii) Active DNA 
demethylation requires a demethylase that catalyzes a reaction leading 
to the removal of methyl groups from methylated cytosine residues. 
directly to deacetylation of chromatin at the methylated 
genes under study. 
Important unanswered questions 
Is transcriptional repression by MeCP2 entirely caused 
by histone deacetylation? 
In both the mammalian and Xenopas systems, TSA treat-
ment did not completely restore transcription from the 
reporter repressed by the TRD of MeCP2 [25,26"]. It 
has been shown recently that transcriptional repression by 
the amino terminus of mSin3A is independent of the his-
tone deacerylases [31]. In addition, a region in mSin3A was 
found to interact in vitro with a component of the 
basal transcription complex, TFIIB. As this TFIIB- 
interacting region does not correspond to either of the two 
transcriptional repression domains in mSin3A, its func-
tional significance remains to be tested in vivo. It is 
possible that there is a HDAC-independent mode of 
repression by the MeCP2/Sin3 complex, which needs to 
be understood. 
It has been shown recently that MeCP2 can repress 
Spi-activated transcription in Drosophila cells in a 
methylation-dependent manner [32]. It is unclear, how-
ever, whether MeCP2 is recruiting a co-repressor 
complex to repress the methylated reporter or if the 
repression is a consequence of steric exclusion of the Spi 
transcription factor from binding to the promoter by 
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MeCP2. It would be interesting to know if MeCPZ inter-
acts with the Drosophila homologue of Sin3. 
Is all Indirect repression of methylated genes caused 
by MeCP2? 
It has been shown previously that HeLa cells can effi-
ciently repress methylated reporter constructs in vivo 1331 
but MeCPZ is below the limit of detection in HeLa cells 
and is therefore unlikely to repress methylated genes in 
this cell line (H-H Ng, A Bird, unpublished observation). 
Recently, a family of mammalian proteins that contain 
regions with homology to the methyl-CpG-binding 
domain of MeCP2 was discovered by searching the 
expressed sequence tag (EST) databases [34,35]. 
Interestingly, these other methyl-CpG-binding proteins 
can be detected in the nuclear extract of HeLa cells (H-H 
Ng, A Bird, unpublished observation). It is important to 
test if they are involved in the methylation-dependent 
repression seen in this cell line. 
How can the inactive state of methylated nucleosomal 
DNA be reversed? 
It is of great interest to understand how the transcriptional 
machinery gains access to specific loci (e.g. tissue-specific 
genes) amidst the bulk of the methylated genome. 
A recent report 1361 suggests that even a densely methy-
lated CpG island can be activated. The progesterone 
receptor (PR) gene is estrogen-responsive and, in certain 
human breast cancers, DNA methylation at its CpG island 
can lead to transcriptional inactivity. Treatment with 5-aza-
dC can reactivate PR through DNA demethylation and 
activation of the estrogen receptor (ER) gene. Intriguingly, 
it was shown that the ectopic expression of ligand-bound 
ER can reactivate PR even in the presence of DNA methy-
lation. Most importantly, induction of the silenced 
methylated PR by ER was blocked by co-expression of a 
dominant negative form of SRC-1A. SRC-1 is a coactivator 
with an intrinsic histone acetyltransferase (HAT) activity 
and can potentiate the activity of ligand-bound ER [37,38]. 
This result demonstrates that the association between ER 
and coactivator is crucial in mediating the induction of the 
methylated PR. Therefore, a possible mechanism to over-
come the effect of DNA methylation is to recruit proteins 
with HAT activity that can reverse the state of histone 
acetylation (Figure la). 
An alternative way of reversing the inactive state of methy-
lated DNA is through DNA demethylation, a process that 
leads to the removal of the methyl group on methylated 
cytosine residues (Figure Ib). Active DNA demethylation 
activities have been reported in extracts from chick embryo 
[39] and certain tissue culture cells [401. DNA demethyla-
tion can also occur via a passive route (i.e. not catalysed by 
enzymatic factors). Recent studies [41',42] lend support to 
this passive mode of DNA demethylation, which is depen-
dent on DNA replication. Binding of nuclear factors (either 
transcription factors or EBNA-l) to the DNA was shown to 
be necessary for the loss of DNA methylation after DNA 
Figure 2 
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Two self-propagating epigenetic cycles that could stabilize 
(a) transcriptionally competent or (b) transcriptionally incompetent 
chromatin states. The cycles are based upon hypothetical interactions 
between methylated/non-methylated DNA and deacetylated/acetylated 
histories. Preliminary evidence for the existence of arrow I comes from 
a recent study in the fungal system showing that the histone 
deacetylase inhibitor TSA can induce DNA demethylation at specific 
genomic loci [30"1, but this was not seen in mammalian systems 
127,36,461. It is not known whether absence of DNA methylation 
can induce histone hyperacetylation (arrow II). Arrow Ill is entirely 
hypothetical at this time but arrow IV, connecting DNA methylation with 
histone deacetylation, has firm biochemical support l26,27l. 
replication. It was hypothesized that the nuclear factors 
may block the access of maintenance DNA methyltrans-
ferase to the hemi-methylated sites that are formed during 
DNA replication, with the result that fully-methylated sites 
cannot be restored. The remaining hemi-methylated sites 
would subsequently be lost by dilution through further 
rounds of DNA replication, or these sites may he the sub-
strate for active DNA demethylation. 
DNA methylation and chromatin modification: 
a self-propagating epigenetic cycle? 
An intriguing observation has been made by Selker 
[30"] when using TSA to reactivate the expression of 
the hygromycin-resistance gene and Tad/a,,, loci. The 
genomic methylation at these two regions was found to 
be reduced, raising the possibility that histone acetyla-
tion status can either directly or indirectly influence 
DNA methylation patterns. One hypothetical scenario is 
that TSA brings about histone acetylation, so that the 
methylated nucleosomal DNA becomes transcriptionally 
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active and consequently repels DNA methylation. If so, 
the status of chromatin modification can potentially 
feedback onto DNA methylation and reinforce the two 
modes of epigenetic silencing [30"] (Figure 2a). 
Interestingly, a similar phenomenon of HDAC inhibitor-
induced demethylation was observed in zebrafish 
embryos [43]. Butyrate treatment was found to inhibit de 
novo methylation of plasmids microinjected into 
zebrafish embryos. 
Conversely, can the inactive state of chromatin attract 
DNA methylation (Figure 2b)? It is important to note that 
DNA methylation is not necessarily the primary cause of 
gene inactivity, but could he a secondary event that may 
follow transcriptional shutdown [44,45]. Perhaps the DNA 
methyltransferase - either independently or assisted by 
accessory proteins - is capable of reading the histone 
acetylation patterns on the chromatin and its de novo 
m ethyl transferase activity can respond differentially to dif-
ferent states of chromatin modification. In this case, 
deacetylated chromatin would provoke de novo methyla-
tion. This self-reinforcing mechanism, supported by both 
DNA methylation and histone deacetylation, could pro-
vide a stable state of inactive chromatin, unless overcome 
by other mechanisms (see Figure 1). 
Conclusion 
There are now several studies indicating that gene silenc-
ing by DNA methylation involves historic deacetylation. 
The association between MeCP2 and a multiprotein com-
plex capable of deacetylating histories provides a probable 
molecular mechanism of transcriptional repression by this 
protein. Now that other methyl-CpG-binding proteins are 
known, it will be important to establish their role in inter-
preting the methyl-CpG signal. It seems likely that the 
study of the MeCP protein family will greatly increase our 
understanding of the biological consequences of DNA 
methylation. 
Note added in proof 
A recent study reports that genes silenced by CpG island 
methylation cannot be reactivated by TSA without prior 
partial demethylatiori of the DNA with 5-aza-dC [461. It is 
suggested that CpG island mechylation has a dominant 
effect over historic deacetylation. 
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ATP-dependent nucleosome remodeling and core histone acetylation and deacetylation represent mechanisms 
to alter nucleosome structure. NuRD is a multisubunit complex containing nucleosome remodeling and 
histone deacetylase activities. The histone deacetylases HDACI and HDAC2 and the histone binding proteins 
RbAp48 and RbAp46 form a core complex shared between NuRD and Sin3-histone deacetylase complexes. 
The histone deacetylase activity of the core complex is severely compromised. A novel polypeptide7 highly 
related to the metastasis-associated protein 1, MTA2, and the methyl-CpG-binding domain-containing protein, 
MBD3, were found to be subunits of the NuRD complex. MTA2 modulates the enzymatic activity of the 
histone deacetylase core complex. MBD3 mediates the association of MTA2 with the core histone deacetylase 
complex. MBD3 does not directly bind methylated DNA but is highly related to MBD2, a polypeptide that 
binds to methylated DNA and has been reported to possess demethylase activity. MBD2 interacts with the 
NuRD complex and directs the complex to methylated DNA. NuRD may provide a means of gene silencing by 
DNA methylation. 
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Packaging of DNA into chromatin allows the cell to 
store its genetic information efficiently and has an im-
portant role in regulating gene expression (Workman and 
Kingston 1998). Dynamic changes in chromatin struc-
ture can facilitate or prevent the access of the transcrip-
tion machinery to nucleosomal DNA, leading to tran-
scription regulation. Recent studies have revealed two 
mechanisms by which chromatin structure can be al-
tered. One mechanism involves multisubunit protein 
complexes that use the energy derived from ATP hydro-
lysis to alter the structure of, or 'remodel', nucleosomes 
(for review, see Tsukiyama and Wu 1997 ; Kadonaga 
1998 ; Varga-Weisz and Becker 1998 ; Travers 1999). The 
other mechanism involves covalent modification of 
nucleosomes, in particular acetylation of the core his-
tone tails and methylation of DNA (for review, see Grun-
stein 1997 ; Kuo and Allis 1998 ; Struhi 1998 ; Ng and Bird 
1999). 
'Present address: Lineberger Comprehensive Cancer Center, aeptart. 
ment of Biochemistry and Biophysics, University of North Carolina at 
Chapel Hill, Chapel Hill, North Carolina 27599-7295 USA. 
'Corresponding author. 
E-MAIL reinbedl@umdnj.edu ; FAX (732) 235.5294. 
Since the discovery of histone acetylation by Allfrey et 
al. (1964), a general correlation between historic acetyla-
tion and gene activity has been established (Hebbes et al. 
1988). The enzymes that catalyze histone acetylation 
and deacetylation have been identified (Brownell et al. 
1996; Taunton et al. 1996). Several transcriptional coac-
tivators have histone acetyltransf erase (HAT) activity, 
whereas several transcriptional corepressors have his-
tone deacetylase activity (for review, see Grunstein 
1997 ; Kuo and Allis 1998 ; Struhi 19981. In addition, mu-
tagenesis studies with Gcn5 and Rpd3, the prototypical 
histone acetyltransf erase and deacetylase, respectively, 
confirmed the long-speculated role of histone acetyla-
tion and deacetylation in transcription regulation 
(Kadosh and Struhl 1998a ; Kuo et al. 1998 ; Wang et al. 
1998). Moreover, Rpd3 / Si n3-dependent repression has 
been shown to be directly associated with the deacety-
lation of lysine 5 of histone H4 in the promoters of 
UME6-regulated genes (Kadosh and Struhi 1998b ; 
Rundlett et al. 1998). However, how core histone acety-
lation/deacetylation leads to transcriptional activation/ 
repression remains to be elucidated. 
Methylation of cytosine at CpG dinucleotides is a 
common feature of many higher eukaryotic genomes. 
The NuRD complex and DNA methylation 
Many studies have established a general correlation be-
tween DNA methylation and gene inactivation (Razin 
and Riggs 1980). However, the underlying molecular 
mechanism remained unknown until recently. It was 
found that MeCP2, a protein that specifically binds to 
methylated DNA, copurifies with the Sin3A/HDAC co-
repressor complex and that the histone deacetylase in-
hibitor TSA relieves MeCP2-mediated transcriptional re-
pression (Jones et al. 1998 ; Nan et al. 1998). Recently, 
four mammalian proteins containing regions homolo-
gous to the MeCP2 methyl-CpG-binding domain, 
MBD1-4, were identified by searching the expressed se-
quence tag (EST) databases (Hendrich and Bird 1998). In-
terestingly, MBD2 was claimed to he a DNA dcmethyl-
ase, and MBD4 was shown to be an endonuclease poten-
tially involved in DNA mismatch repair (Bellacosa et al. 
1999; Bhattacharya et al. 1999). The functions of MBDI 
and MBD3 are unknown. 
To develop a mechanistic understanding of how core 
histone acetylation regulates transcription, we have 
studied the histone deacetylases HDAC1 and HDAC2 
(Taunton et al. 1996 ; Yang et al. 1996). Using a combi-
nation of conventional and affinity chromatography, we 
previously purified and characterized two HDAC 1 / 
HDAC2-containing histone deacetylase complexes, the 
Sin3A/HDAC complex, and the NuRD complex (Zhang 
et al. 1997, 1998a,h). The two protein complexes share 
four polypeptides: HDAC1, HDAC2, RbAp46, and 
RhAp48. In addition, each complex contains three 
unique polypeptides (Sin3A, SAP30, and SAP18 in the 
Sin3 complex, and Mi2, p70, and p32 in the NuRD com-
plex). Interestingly, the NuRD complex also possesses 
nucleosorne remodeling activity, most likely because of 
the presence of Mi2, a member of the SWI2/SNF2 heli-
case/ATPase family (Tong et al. 1998 ; Xue et al. 1998 ; 
Zhang et al. 1998a). 
To gain insight into the function of the NuRD com-
plex, we have identified its p70 and p32 subunits. We 
demonstrate that these polypeptides have an important 
role in modulating the histone deacetylase activity of 
NuRD. Furthermore, we provide evidence linking NuRD 
function to methylated DNA. 
Results 
MTA2 and MBD3 are components 
of the NuRD complex 
Previously, we reported the purification of NuRD, a mul-
tisubunit complex containing both histone deacetylase 
and nucleosome remodeling activities (Zhang et al. 
1998a). Through extensive purification using conven-
tional methods, combined with affinity purification us-
ing antibodies against Mi2, the largest subunit of the 
complex, we determined that this complex is composed 
of seven subunits, including the SWI2/SNF2 helicase/ 
ATPase domain-containing Mi2 protein, the two histone 
deacctylases HDAC I and HDAC2, the two histone-bind-
ing proteins RbAp46 and RhAp48, and polypeptides of 70 
and 32 kD (Zhang et al. 1998a). The conventionally pu- 
rified complex also contains minor contaminating poly -
peptides that did not copurify with NuRD activity (Fig. 
IA, lane 3 ; see also Fig. 3B of Zhang et al. 1998a). 
We expanded our previous studies by identifying each 
of the polypeptides present in the conventionally puri-
fied fraction of NuRD. Protein sequencing of the doublet 
migrating around 32 kD revealed that it corresponds to 
two in-frame spliced forms of MBD3, a member of a pro-
tein family containing the methyl-CpG binding domain 
(Hendrich and Bird 1998). We named the two spliced 
forms MBD3a and MBD3b. The major form in the NuRD 
complex is MBD3h, which only contains a portion of the 
methyl-CpG binding domain (Fig. 2A,B). Interestingly, 
MBD3 is highly related to MBD2 (80% similar, 72% 
identical ; see Fig. 2A), a protein recently claimed to have 
DNA demethylase activity (Bhattacharya et al. 1999). 
Sequencing of the 70-kD polypeptide identified it as a 
novel protein highly related 65% identical) to a candi-
date metastasis-associated protein, MTA1. Therefore, 
we refer to this polypeptide as MTA2 (Fig. 2C). Interest-
ingly, MTAI was reported to be a component of the 
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Figure 1. MTA2 and MBD3 are components of the NuRD com-
plex. (A) Silver staining of an SDS-polyacrylaniide gel contain-
ing purified NuRD (lane 3) and samples derived from different 
antibody columns, as indicated at top. The identity of each poly-
peptide was defined by microsequencing and/or Western blot 
analysis and is indicated at right. The histonc deacetylase core 
complex present in both the Sin3/SAP30 complex and the 
NuRD complex is indicated with a bracket and denoted as Core. 
Peptide sequences derived from the bands labeled as MTA2, 
MBD3a, and MBD3h are presented in Fig. 2. Sequencing of the 
hand labeled as HDAC1 + MBD2 derived from HDAC1 anti-
body column suggest the presence of both HDACI and MBD2. 
Peptides specific for HDAC1 and MBD2 are VMTVSFHK and 
GLQGVGPGSNDETLLSAVASALHTSSAPITGQVSAAVEK, re-
spectively. Mass-spectrometric analysis of the three polypep-
tides between Mi2 and MTA2 found in the conventionally pu-
rified NuRD fraction (lane 3) identified these contaminants as 
HCAP (GenBank accession no. AF020043), SA-1 (GenBarik ac-
cession no. Z75330), and SB1 /DX5423E (GenBank accession no. 
S78271). (B) Western blot analysis of the samples used in A. The 
proteins detected are indicated at right. 
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A 	MBD2a 	 411aa 
MBD2b 	 -fJ------------------ 	262aa1 72% 
MBD3a 	 - 	I 	 291 aaj Identical 
MBD3b 	 -"'-1•••J 	 259aa 
B M 	ER 	KR 	lIE 	C 	PAL 	P 	Q 	C 	WERE 	S 	V 	PER 	AOL 
TCGGCCGOCCACAOOGGTr?TACTATAGCCCGAGCGGGAAGAAGTCCGcGCAAGCCGCCFcGCGCGCTAC 
SAGE 	RD 	V 	F 	'(YR 	PACK 	K 	F 	ES 	K 	P 	Q 	L.A 	WY 
CGOCGGcTCCATACc1AGCACC'1'FcGACTTCCCCACGGCCAAC 
L 	0 	C 	S 	H 	C 	L 	S 	T 	F 	C 	F 	K 	T 	C 	K 	65 
C hifrAl 	MAaICIYRVGDYVYPniSSSNPYLIRAIEELNKTANGNVEAKwCFYRRRCISsmIALADFJiATLSVCYAlCPCADNGFF 	80 
-. Figure 2	ScucI7ceai1ilsisofIvlI3Ii)larid :1111111-1 	-111 	-1 - 
lv1lA2. 	A) Schematic representation of 
hflTA2 	MAANMYRVCDYVYFFNSSSNPYLVRRTERLNKTA3SANEAxWCLFRRRDISSSLF4SLADSNAR----------------64 
I 	liii 	III 	J ii 	I 	11 	HIIIHIIIIIIII 	11111 	I 111111 	III 	III 
the two forms of MBD2 and MBD3. The ---------------- 	64 
open box represent the methyl-CpG bind- hM'rAi 	GElS 	 160 
iii 	domain (11BlI) initially identified iii 
IleP2 (also see B). 	I''l3t 	t.ieiiBaiil 	acces- 
bJqrA2 	-EFEEESKQP --- CVSEQQR}iQLKHRELPLSRQFESLPATHIRGKCSVTLLNETDILSQYLEKECCFFYSLVFDPVQKTh 	140 
I 	I 	III 	I TIP 	 I 	
1 	
11 	I lillIllIll 	111111 	I 	I 	'liii 	II 	11111 	I 	II 
sion nos. 	for MBD2 and MBD3 	are zvaSrA2 	-EEESKQP --- GVSEQQR}IQL1OiRRLFLSRQFRSLPAThIRGKCSVTLLNETDILZ4QYLDKEDCFFYSLVFDPVQKfl 	140 
AF072242 and AF072247, 	respectively. h1fPA1 	LADKGEIRViRYQADIP0LLCmRDQSRLE7QV BA 	PLTDKQIDQFLWARSVGTFARALDCSSSVRQPSLi4M 	240 
The in-frame spliced form !\lBD3Fonly 
contains part of the MBD. (B) Sequences 
bifrA2 	LADQGEIRVGCKYQAEIPDRLVECESDWRNQQ4E 	DPPLTDRQIDQFLWAF.AVG'FFARALDCSSSIRQPSL}41I 	220 
liii 	III: 	III 	III 	I 	11111111 	111111 	III 	III 	11111111111 	II 	11111111111 	liii! 
and splicing junctions of the MBD3a and EM'FA2 	LADQGEIRVGCKFQAELFDRLAEGESiRNQQK14GCVWDPJPLTDRQ1DQFLWARAVGTPARALDCSSSIRQPSLHH 	220 
MBD3h. The orange nucleotides that en- hMTAL 	SMAASRDITLFHAirLHIG4IYDISKAISALVPQGGPVLCRDEMKn4SASEANLFEEALEKYCKDFTDIQQDFLPWKSL 	320 
code 5' portion of J'1.B1I are spliced out in II 	111111111 	liii 	I 	II 	I 	I 1111111111111 	II 	II 	II 	r 	iii 
derived 





















1P1V11 	III 	I 	II 	I 	II 	III 	II 	I 	II 	rn 	ii MBD3b. The peptide sequence 
from the hand labeled as MBD3a in Fig. IA MMTA2 	 300 
is 	underlined. 	Other 	peptides 	derived hMTA1 	TSIIE?YYNWKTrCRYVQQKRLKAAEAESKLKQV'(IPNYiS(PNPNQISVSA4VKAGVVNGTGAPCQSPCAGRACESCYTTQ 	400 
from the I'1BD3 bands of Fig. IA have II'''IIIIIIlIIl'IIIIIIIIII'IIIIIIIII1 	111111 	Il 	-Ill 	1 	1111:111 
perfect match to 11v1BD,: KEELVQQVR, 
AI4TA2 	ASIVQF'(9iWK'n'DRYIQKRLKAAEADSKLKQvYIPTYTKPNPNQIIsvnSKpc-MiiGaGFQ-----KGL'rCESCWI'TQ 	374 







TMDLPK, GKPDLNTALPVR, and NP- wifPA2 	ASIVQFHWKlFORYIQQBALKAAEADSKL.KQVYIKPNPNQIISVCSKPG-W4GPQ-----KGL'iESH'PTQ 	374 
GVWLNTTQPLCK. (C) MTA2 is related SIFA1 	SYQWYS1PPLS4QCRIcASGTYW(YGGUO4P'rRLmER2GPWRSP1SPH -CLPARSSGSP -------- KPA3GCFRQAF 	471 
to 	the 	metastasis-associated 	protein lIIIIIHIIIIIHIIIIIHIIIIIIII.II 	I 	. 	I 	I 	II? 	I 	1 	11 	1 
MTA1. Amino acid sequence alignment of 
AIITA2SAOWYADCPPNMOCRLCASCWIYWKKYGGLKTPTQLEGATRGTTEPHSRGHLSRPEAQSLSPYTTSMMMLLAKNRQTF 	454 




1111 	ii 	ii 	ii 	ii 	ii 	II 	liii 	I 	II 	III 	I 
human MTA2 (GenBank accession no. mWFA2 	SAQWYAPPNNQCRLCASQWIY 	<YGGcKYP1'QLAARrTEPHsRGHLSRPEAQsLSPY7-rSANRAKLLaIo1RQTF 	454 
A13016591), mouse MTA2 (GenBank ac- hMTPa 	YLH3'TKLTRIARRLCREILRPWHNPYLPINSAAIKAECTARLPEASQSPLVLKQAVRKPLBAVLRYLHPRPPKPO 	552 
cession no. AF159259) with human 1v11Al IIIIIIIIIIII''I.I 	IIIIIIII.IIIIII.III.I 	... 	II 11 	11 I 
. bifrA2 	LiQ'rrxLpRLARsMcRDLLQPRRRRPYApINMIKAECSxRLpKTpLKrHpLvRcpLApIvKDL----------524 
(GenBank 	accession 	no. 	U3 1 13). 	Se- 111111111111111111111111111111111111111111111111111111111111 	111111111 
quence alignment was performed using mM'rA2 	L.L.QTTKLPRLARRMCROLLQPRRAARRPYAPINANAIKAECSIPLPi(AAi(TPLKIHPLVRLPLA'rIvKDL----------524 
Gap of the GCG program lUniversity of hMTAF 	PVKSVSSVLSSLTPARVAPVI064GSPTILCKRSYEQ}64GVD4MKKRLLMPSRGLA14HGQTRJO.1GPSRNLLLNGKSYPTK 	632 
Wisconsin, Madison). Peptide sequences . 	I 	. 	I I. 	I 	' 	' I. 	I. 	I 	I 	II I 	II' 	- 
- 	 - 	 - 	- hifrA2 	----------- VAQAPLKPKTPRGTKTPINRNQLSQNRCWGIMVKR-----------AYE'I'MACAGVPFSANCRPLkSC 	582 obtained from 	microsequencing of the 
band labeled MTA2 in Fig. 1A are under- s3ftA2 	----------- VAQAPLKPKTPRGTKTPItNQLTQNRCLGGIMVKR ----------- KYE1'MAGAGVPPSANGRPLSG 	682 
lined. The putative zinc-finger is indicated 
by green triangles. The putative leucine 
lOfFAF 	VRLIRCGSLPPVIcRRRi94WIDAPGDVMPKEFRKIRRL.L.SSSEriAAP.RPYKPIALRQSQ.ALPPRPFPPA?VN___ 	707 
II 	II 	III 	III 	I' 	:11:111 	1:111111 	I.'. 	1.1 	1111. 
zipper is indicated hy purple dots. The yel- 
hIITA2 	- -- IRSSAQPAAKRQKL.NPADAPNPVFVATKD'FRALRXALTi{LFIIRRAARRPNLPLKVXPTLIAVRPPV?LPAPSHPAS 	659 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 	IIIIIIIII 	11111 
low box indicates a potential tyrosine ki- mMTA2 	---IRSSSQPAABAQKU4PADAPNPVVVATiRALRi(ALTHLRAARRPNLPLK51tP1'LMWRPPvPL.PASSuPAs 	659 
nase phosphorylation site. Human and Ai 	-DEPIVIED 	715 
mouse MTA2 are 98 9% identical and are 
i 65% and 63% dentical to hunianMTAl, hMTA2 	
TNEPIVL 	668 
IIIIIIIII 
respectively. m}fFA2 	TNEPIVLED 	668 
NURD complex based on four peptide sequences that 
happen to he common between MTA1 and MTA2 (Xue 
et al. 1998). Analysis of the amino acid sequences of 
MTA proteins identified one putative zinc-finger do-
main, one leucine zipper domain, and a potential tyro-
sine kinase phosphorylation site (Fig. 2C). The expres-
sion level of MTA1 was found to he elevated in meta-
static breast cancer cell lines and metastatic cancer 
tissues, such as colorectal, gastric, and esophageal carci- 
nomas (Toh et al. 1994, 1997, 1999). Similarly, we also 
found that the MTA2 expression level is elevated in cer-
vical cancer tissue (data not shown). However, the cause-
and-effect relationship between cancer metastasis and 
overexpression of MTA proteins is not known. 
To further establish that MTA2 and MBD3 are integral 
components of the NuRD complex, antibodies against 
these polypeptides were produced. Western blot analysis 
using MTA2 antibodies demonstrated that MTA2 copu- 
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rified with the NuRD complex and its associated nucleo-
some remodeling and histone deacetylase activities 
(Zhang et al. 1998a). Affinity purification using anti-
MTA2 antibodies resulted in the isolation of a protein 
complex composed of seven polypeptides, all present as 
major polypeptides in the conventionally purified NuRD 
complex (Fig. IA, cf. lanes 2 and 3). The identity of the 
polypeptides present in the anti-MTA2 affinity purified 
complex was verified by Western blot analyses as shown 
in Fig. I  (lane 2). The other polypeptides present in the 
conventionally purified NuRD complex (lane 3) were ab-
sent in the complex isolated through affinity chromatog-
raphy using anti-Mi2 (Zhang et al. 1998a) or anti-MTA2 
(Fig. lA, lane 2) antibodies. Moreover, these polypeptides 
did not coelute with subunits of the NuRD complex 
through conventional chromatography (see Fig. 3B of 
Zhang et al. 1998a). Thus, we conclude that these poly-
peptides are contaminants. 
Antibodies against MBD3 were capable of immunopre-
cipitating recombinant MBD3 protein, however, these 
antibodies failed to immunoprecipitate the NuRD com-
plex (data not shown), suggesting that MBD3 is not ac-
cessible in the NuRD complex (see below). 
Immunopurification experiments using antibodies 
against HDACI, which should result in the isolation of 
most of the polypeptides associated with HDAC1, re-
sulted in a complex pattern of polypeptides (Fig. 1A, lane 
4). Comparison of the polypeptides present in this frac-
tion with those present in the NuRD and Sin3 com-
plexes established that most polypeptides in the anti-
HDAC 1 purified sample were present in the NuRD or 
Sin3 complex (Fig. 1A,B). Interestingly, the reported de-
methylase MBD2 was also present in the anti-HDAC1 
purified sample (Fig. 1&B, lanes 4 ; see below). In addi-
tion, we found that four polypeptides (HDAC1, HDAC2, 
RhAp48, RbAp46) were common to the Sin3 and NuRD 
complexes (Fig. IA), whereas the other polypeptides 
(Sin3, SAP30, Mi2, MTA2, MBD3) were specific to one of 
the two complexes (Fig. 1A,B, lanes 2,5). 
The studies described above establish that both MTA2 
and MBD3 are integral components of the NuRD com-
plex and suggest the existence of a shared core historic 
deacetylase complex composed of HDAC1, HDAC2, 
RbAp48, and RbAp46. These results also suggest a pos. 
sible connection between the NuRD complex arid 
methyl-CpG binding proteins. 
MTA2 promotes the assembly of a catalytically active 
histone deacetylase complex 
Having established that HDAC1, HDAC2, RbAp48, and 
RbAp46 are shared components of the Sin3 and NuRD 
complexes, we asked whether these four polypeptides 
can form a core protein complex. We began the studies 
by investigating whether a historic deacetylase core com-
plex could be isolated from HeLa cells. These studies 
uncovered different complexes containing these foum 
polypeptides (data not shown). However, we were unable 
to isolate a complex containing only these four polypep-
tides. A possible explanation is that the putative HDACJ 
RbAp core complex is limiting with respect to polypep. 
tides that may associate with it. 
We next asked whether an HDAC/RbAp core complex  
could be reconstituted from recombinant polypeptides. 
In agreement with our previous studies, which demon 
strated that the HDAC and RbAp association requires 
cotranslation and/or the presence of a molecular chap-
erone (Zhang et al. 1998b), we failed to reconstitute the 
core complex using individually purified HDAC1 anc 
HDAC2 from baculovirus-infected SF9 cells and RbAp4( 
and RbAp48 purified from Escherichia coli (data not 
shown). Thus, we performed coinfection experiments us-
ing recombinant baculoviruses expressing each of the 
four putative core subunits with Flag-tagged HDAC1. 
HDAC1 and its associated polypeptides were purifiec 
through multiple chromatographic steps, including ion 
exchange, immunoaffinity, gel filtration, and glycerol 
gradient sedimentation (Fig. 3A). Western blot analysis 
demonstrated cofractionation of the four polypeptides 
during each of the purification steps (data not shown) , 
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Figure 3. 	Purification of a recoinbinani 
bistone deacetylase core complex. (A) Sche 
matic representation of the steps used tc 
purify the historic deacetylase core com-
plex. (B) Silver staining of an SDS-poly• 
acrylamidc gel containing the purified cort 
complex. The identities of the major poly 
peptides and protein size markers are mdi 
cated. (Cl Western blot analysis of a par-
tially purified HeLa nuclear extracts (lane I 
and the purified core complex (lane 2). Tht 
identities of the polypeptides are indicated 
D) Coomassie blue staining of an SDS 
polyacrylamide gel containing the purifiec 
NuRD complex (lane I) and individual re 
combinant NuRD components. Mi2 
HDAC1, and MBD3b are purified froir 
baculovirus-infected SF9 cells. MTA2 ant 
RhAps were produced in Escherichia coli 
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Silver staining of the sample derived from the last puri-
fication step revealed the presence of four major poly-
peptides (Fig. 3B). The identity of these polypeptides was 
:onfirmed by Western blot analysis (Fig. 3C). The con-
taminating protein of about 70 kD (Fig. 3131 does not react 
with MTA2 antibodies (Fig. 3C). These results suggest 
that a complex containing HDAC and RbAp polypep-
tides can be formed. However, the histone deacetylase 
activity of this core complex was severely compromised 
:ornpared to that of native NuRD complex when equal 
Western blot units of HDACs or RbAps were used (Table 
1 ; data not shown). 
We next analyzed whether the addition of the other 
NuRD subunits (Mi2, MTA2, and M13133) to the core 
2omplex could restore the activity to the level of the 
native NuRD complex. The addition of highly purified 
Fig. 3D) recombinant Mi2 and MBD3h (or MBD3a, data 
riot shown) purified from baculovirus infected-SF9 cells, 
ar MTA2 produced in Escherichia coil, independently or 
In combination, did not affect the histone deacetylase 
activity (Table 1, and data not shown). In light of these 
negative results and to determine the identity of the sub-
units affecting enzymatic activity, we investigated the 
polypeptides of the NuRD complex that interact with 
subunits of the core HDAC/RbAp complex. 
We began the study by asking whether subunits of the 
putative core complex, as GST-fusion or Flag-tagged pro-
teins, could interact with MTA2 that was translated in 
vitro using the rabbit reticulolysate system. We found 
that none of the core subunits interacted with MTA2 in 
this assay (Fig. 4A). However, we observed an interaction 
between GST-MBD3b and MTA2 under the same con-
dinons (Fig. 4A). We extended this finding by demon-
strating a direct interaction using GST-MBD3b and 
MTA2 produced in Escherichia coil (Fig. 4131. We next 
analyzed whether MBD3b interacts with components of 
the core complex. This analysis demonstrated that 
MBD3b is able to interact with highly purified Fig. 31)) 
UDAC1, RhAp48, and RhAp46 in a GST pull-down assay 
Table 1. Effect of NuRD subunits on histone 
deacetylase activity 
3H-labeled acetate 
Complex/protein 	 released (cpm) 
- 32±6 
NuRD 6176±213 
Core (SF9) 301 t 32 
Core (SF9) + MTA2 (F, coIl) 357± 17 
Core SF9) + MBD3 SF9) 308 ± 19 
Core (SF9) + Mi2 SF91 324 ± 7 
Core (SF9) + MTA2 (SF9) 2466 ±250 
MTA2 JSF91 1604 ± 106 
Different subunits of the NuRD complex were analyzed for his-
tone deacetylase activity and for their ability to regulate the 
histone deacetylase activity of the HDAC/RbAp core complex. 
The activity was compared to that of the NuRD complex using 
equal Western blot Units of HDACs. Assays were performed as 
described in Materials and Methods. The numbers shown rep-
resent an average of at least three independent assays. 
A B 	MTA2 C Mi2 	HUACI RbAp46 RbAp48 
- 
(D 0 (O 	<aO 
200- 200- 
- 97- -, 
43- — — 08- 
29- 43- 
18- 29- 
1234567 123 123 	456 09101112 
Figure 4. MBD3 interacts with MTA2 and components of the 
histone deacetylase core complex. (A) GST pull-down assays 
show that in vitro-translated MTA2 only interacts with M13133. 
Equal amounts (5 p1) of in vitro-translated and labeled MTA2 
was incubated with 10 .i1 of glutathione—agarose beads or anti-
Flag beads coated with 2 pg of proteins as indicated at the top. 
After extensive wash, hound proteins were eluted, resolved by 
SDS-PAGE, and visualized by autoradiography. Ten percent of 
input was loaded on lane 1. (B) MTA2 directly interacts with 
MBD3. An experimental procedure similar to A was used except 
that MTA2 was purified from Escherichia coli (Fig. 3D, lane 3). 
Bound proteins were eluted, resolved by SDS-PAGE, and visu-
alized by Western blot. (C) MBD3 interacts with components of 
the core complex in a GST pull-down assay. Assays were per-
formed as in B. Input proteins are indicated at top and are the 
same as those used in Fig. 3D. 
(Fig. 4C, lanes 6,9,121. These interactions appear to be 
specific because MBD3b failed to interact with Mi2 un-
der the same conditions (Fig. 4C, lane 3). The finding 
that MBD3 engages in multiple interactions with sub-
units of the core complex is consistent with the result 
demonstrating that antibodies against MBD3 could im-
munoprecipitate recombinant MBD3, but failed to irn-
munoprecipitate the MBD3-containing NuRD complex, 
as discussed above. Collectively, these findings suggest 
that MBD3 is embedded within the NuRD complex. 
To verify these in vitro protein-protein interaction 
studies, we coinfected SF9 cells with five baculoviruses 
each expressing one of the four core subunits and MTA2. 
The complex was purified as described above (Fig. 3A). In 
light of the protein-protein interaction results described 
above, we expected that during affinity purification and 
gel-filtration chromatography the four subunits of the 
core complex would copurify, but would he separated 
from MTA2. However, to our surprise we observed co-
purification of MTA2 with the core HDAC/RhAp com-
plex during affinity purification and gel-filtration chro-
matography (Fig. 5 ; data not shown). More importantly, 
we found that this complex is active in deacetylating 
core histones (Fig. 5A ; Table 1). The activity was similar 
(within 2.5-fold) to that of the native NuRD complex 
(Table 1). Our interpretation of these results is that ei-
ther the association of MTA2 with the core complex 
requires cotranslation or, alternatively, that mammalian 
MTA2 can associate with the endogenous insect MBD3 
that mediates the association between MTA2 and core. 
Silver staining (Fig. SB) and Western blot (Fig. 5C) analy-
ses of the fractions derived from the gel-filtration col-
umn indicate the presence of MTA2 and the HDAC/ 
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Figure 5. MTA2 is required for the formation of a functional 
histone deacetylase complex. (A) Histone deacetylase activities 
of the fractions derived from gel filtration S200 columns. His-
tone deacetylasc core complex as well as core plus MTA2 were 
purified using the procedure described in Fig. 3A (see Materials 
and Methods for details). In the histone deacetylation assays 
using core- and core + MTA2-derived fractions approximately 
equal Western blot units of HDACs were used. The elution 
profiles of different size markers are indicated. (B) Silver stain-
ing of an SDS-polyacrylamide gel containing the core + MTA2 
fractions derived from the S200 gel filtration column analyzed 
in A. The identities of the polypeptides are indicated and were 
confirmed by Western blot analysis which is shown in C. (C) 
Western blot analysis of the fractions shown in B. 
RhAp core polypeptides coeluting with HDAC activity. 
Moreover, the silver-staining analysis revealed polypep-
tides in the 30-kD range coeluting with histone deacety-
lase activity (Fig. 5B). Western blot analysis revealed that 
antibodies directed against the human MBD3 protein re-
acted, although weakly, with a polypeptide of -30 kD 
that coeluted with the histone deacetylase activity. We 
concluded that the MBD3-imrnunoreactive 30-kD poly-
peptide is likely the SF9 cell-derived MBD3 (Fig. 5C). 
The silver-staining analysis demonstrates that the com-
plex is highly pure and suggests that the coelution of 
HDACS, RhAps, MTA2, and insect-derived MBD3 is a 
functional association and not the result of protein ag-
gregation. 
To further analyze the specificity of MTA2 in direct-
ing the formation of an enzymatically active histone 
deacetylase complex, we performed coinfections as 
above, but coinfected a baculovirus-expressing MBD3 
with components of the HDAC core complex in the pres- 
ence and absence of MTA2. Following affinity purifica-
tion, the purified complexes were divided and analyzed 
for histone deacetylase activity (Fig. 6A) and protein 
composition by western blots (Fig. 6B). As above, the 
core complex was severely compromised in its enzymat-
ic activity (Fig. 6A). The presence of MBD3 was without 
effect. However, coinfection with MTA2 in the presence 
or absence of MBD3 resulted in the recovery of a com-
plex that was enzymatically active (Fig. 6A). Consistent 
with our finding that MTA2 can direct the formation of 
an enzymatically active histone deacetylase complex, 
we found that infection of SF9 cells with a recombinant 
baculovirus-expressing Flag-tagged MTA2 followed by 
purification on a column containing antibodies against 
the Flag tag resulted in the isolation of an MTA2-con-
taming complex that was enzymatically active (Table 1). 
Silver staining and Western blot analysis revealed that in 
addition to MTA2, polypeptides corresponding to the in-
sect HDAC and RhAp were present in the affinity-puri-
fied sample (data not shown). Collectively, these studies 
demonstrate that MTA2 directs the assembly of an ac-
tive histone deacetylase complex and that the associa-
tion of MTA2 with the core HDAC/RhAp complex re-
quires MBD3. 
The NuRD complex interacts with MBD2 and is 
tethered to methylated DNA 
The finding that MBD3 is a component of the NuRD 
complex suggests a possible connection between the 
NuRD complex and methylated DNA. Therefore, we in- 
B 
Core - + + + + 
MTA2 - - + - + 
MBD3 - - - --  
• 	-MTA2 
La .. HDAC2 
• •••. RbAp48 RAp46 
—- MBD3 
12345 
Figure 6. MTA2 directs the formation of an enzymatically ac-
tive histone deacetylase complex. (A) Relative histone deacety-
lase activities of different coinfections. SF9 cells were infected 
with different combinations of viruses. The complexes were 
affinity purified through Flag-tagged HDACI using antibodies 
against Flag. The purified complexes were divided for deacety-
lase assay shown in A and Western blot analysis shown in B. (+) 
Presence of the viruses in the coinfection. (B) Western blot 
analysis of the samples used in histone deacetylation assays 
shown in A. Antibodies against RhAps cross-reacted with 
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vestigated whether the NuRD complex could specifi-
cally bind to methyl-CpG-containing DNA using a gel 
mobility-shift assay. We found that NuRD and MBD3 
failed to bind to DNA. However, under the same condi-
tions, MBD2 bound specifically to methylated DNA (Fig. 
7A, cf. lanes 2-6 with 15-18). This is in agreement with 
previous studies (Hendrich and Bird 19981, Moreover, be-
cause MBD3 is likely embedded in the NuRD complex, 
and the major form of MBD3 present in the complex is 
MBD3b, which only contains part of the methyl-CpG-
binding domain (Fig. 2A), it is not surprising that NuRD 
failed to directly bind to methylated DNA. 
Because MBD3 is highly related to MBD2 and we 
found that MBD3 is able to interact with each compo-
nent of the historic deacetylase core complex (Fig. 40, 
we investigated whether MBD2 associates with histone 
deacetylase complexes. Immunoprecipitation experi-
ments using antibodies against HDAC1 resulted in the 
immunoprecipitation of MBD2 (Fig. lB, lane 4). How-
ever, as described above, MBD2 is absent from the NuRD 
complex isolated through conventional (Fig. IB, lane 3) 
or affinity (Fig. 1B, lane 2) purification procedures. None-
theless, the similarity between MBD2 and MBD3 pro-
teins prompted us to analyze whether MBD2 could 
physically interact with the NuRD complex. In this ex-
periment, full-length and a truncated form of MBD2 
(Hendrich and Bird 1998) were analyzed. The repression 
domain of MBD1 (H-H. Ng and A. Bird, unpubi.), a pro-
tein related to MBD2 and MBD3 through the methyl- 
A  
CpG DNA-binding domain (Hendrich and Bird 1998), 
was used as a control. Different GST-MBD fusion pro-
teins were independently incubated with purified NuRD 
complex and possible interactions were analyzed by GST 
pull-down assays followed by Western blot analyses us-
ing antibodies against different components of the 
NuRD complex. Whereas GST-MBD1 failed to interact 
with the NuRD complex, both forms of MBD2 inter -
acted with the NuRD complex, and the full-length form 
of MBD2 interacted more efficiently (Fig. 7B). Thus, we 
conclude that MBD2 is able to interact directly with 
components of the NuRD complex. 
The interaction between MBD2 and the NuRD com-
plex prompted us to analyze whether MBD2 could tether 
the NuRD complex to methylated DNA. We analyzed 
this possibility using the gel mobility-shift assay with 
methylated DNA as the probe. Under these conditions, 
and in agreement with the studies presented above, 
NuRD failed to hind to DNA, but MBD2 bound to the 
methylated DNA specifically (Fig. 7C ; data not shown). 
Importantly, the addition of NuRD to a DNA-binding 
assay containing MBD2 resulted in the production of a 
new DNA-protein complex that migrates slower than 
the MBD2-DNA protein complex. Additionally the 
amount of DNA in the NuRD-MBD2 ternary complex 
was greater than the amount of DNA in the binary 
MBD2-containing complex. The observed supershift is 
specific because addition of 3 j.ig of BSA (10 x the amount 
of NuRD used) or other proteins was without affect (data 
GAC probe 	 GAM6 probe 
Figure 7. The NuRD complex can be t,ir-
geted to methylated DNA by MBD2. 
Gel mobility shift assay shown that the 
NuRD complex does not bind to methyl-
ated DNA directly. The GAM6 probe con-
tains six methyl-CpG sites and was previ-
ously described (Nan et al. 1993(. Binding 
reactions were resolved on a 2% agarose 
gel as described in Materials and Methods, 
(B) GST pull-down assays demonstrates an 
interaction between MBD2 and the NuRD 
complex. The assays were performed as 
described in Fig. 4B using different GST 
fusion proteins as indicated at the top. (C) 
Gel mobility-shift assay shown that the 
NuRD complex is able to super-shift the 
DNA-MBD2 binary complex (cf. lanes 2 
and 3(. The probe used is MeCGI 1, which 
contains 27 methyl-CpG sites and was de 
scribed previously (Ng et al. 1999). Binding 
reactions were resolved on a 1% agarosc 
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The NuRD complex and DNA methylation 
not shown). Therefore, we conclude that NuRD is teth-
ered to methylated DNA via MBD2 and that the inter-
action of NuRD with MBD2 stabilizes the MBD2-DNA 
protein complex. 
Discussion 
In this study we have identified MTA2 and MBD3 as two 
subunits of the NuRD complex. MTA2 is related to the 
metastasis-associated protein MTA1, whereas MBD3 is 
related to MBD2, a methyl-CpG-binding domain-con-
taining protein recently claimed to possess demethylase 
activity. In addition, we provide evidence that MTA2, 
through an interaction with MBD3, has an important 
role in modulating the enzymatic activity of the histone 
deacetylase core complex composed of HDAC1 and 
HDAC2 and RhAp48 and RbAp46. Furthermore, we 
demonstrate that the methyl-CpG binding protein 
MBD2 is able to tether the NuRD complex to CpG-
methylated DNA. 
The connection between NuRD 
and cellular proliferation 
The nucleosome remodeling and histone deacetylase 
NuRD complex contains seven subunits. In addition to 
the histone deacetylase core HDAC1, HDAC2, RhAp46, 
and RhAp48, it contains Mi2, MTA2, and MBD3. It is 
interesting to note that MTA2 is 65% identical to the 
metastasis-associated protein MTA 1, whose expression 
level was found to be elevated in different types of cancer 
tissue as well as metastatic breast cancer cell lines (Toh 
et al. 1994, 1997, 1999). Similarly, we found that MTA2 
is highly expressed in rapidly dividing cells at both the 
RNA and protein level (data not shown) indicating a cor-
relation between MTA2 expression and cellular prolif-
eration. Another component that links the NuRD com-
plex to cellular transformation is MBD3. This protein 
was initially identified because it contains a domain re-
lated to the methyl-CpG-binding domain of MeCP2 
(Hendrich and Bird 1998). However, in agreement with a 
previous report (Hendrich and Bird 1998), MBD3 is not 
able to bind to methyl-CpG specifically (Fig. 7A). More-
over, two alternately spliced forms of MBD3 were iden-
tified. The predominant form present in the NuRD com-
plex is a spliced variant deleted of the methylated CpG-
binding domain. Interestingly, MBD3 is highly related to 
MBD2, which was also identified as a colon cancer an-
tigen (Scanlan et al. 1998). The fact that two components 
of the NuRD complex are linked to malignancy, in con-
junction with the fact that patients with dermatomyo-
sitis, who produce antibodies against Mi2 (Seelig et al. 
1996), have an increased risk to malignancy (Airio et al. 
1995), suggests a link between the NuRD complex and 
malignancy. Indeed the accumulative evidence strongly 
suggest that histone deacetylases, in particular HDAC1 
and HDAC2, are associated with polypeptides that regu-
late cellular proliferation. The first mammalian HDAC 
complex to be described was Sin3, which associates with 
the Max-Mad heterodimer required for cellular differen-
tiation (for review, see Amati and Land 1994 ; Pazin and 
Kadonaga 1997). Additionally, Sin3 associates with the 
corepressor NcoR/SMRT, which negatively regulates 
transcription of genes targeted by nuclear hormone re-
ceptors and has been linked with acute promyelocytic 
leukemia (Grignani et al. 1998 ; Lin et al. 1998). Further -
more, HDAC1 was found to he associated with the tu-
mor suppressor Rb protein (Brehm et al. 1998 ; Luo et al. 
1998 ; Magnaghi-Jaulin et al. 1998). Moreover, our recent 
studies have uncovered that SAP30, a component of the 
Sin3 complex (Laherty et al. 1998 ; Zhang et al. 1998b), 
associates with the Rh-binding protein RBP1 as well as 
with the p53-binding protein p33'' (Y. Zhang and D. 
Reinberg unpubl.). 
NuRD is targeted to methylated DNA 
Since the discovery of the first nucleosome remodeling 
factor, the SWI/SNF complex, about a dozen different 
chromatin remodeling factors, from different organisms, 
have been described (for review, see Bjorklund et al. 
1999 ; Travers 1999). However, it is not known whether 
these remodeling factors function on a genome-wide ba-
sis or whether they are targeted to specific genes. Ge-
netic studies indicate that transcription of only a frac-
tion of genes is affected by the SWI/SNF complex (Hol-
stege et al. 1998), but until recently it was not clear how 
the SWI/SNF complex is recruited to promoters of SWI/ 
SNF-regulated genes. The first evidence suggesting that 
the SWI/SNF complex can be targeted to specific genes 
came from studies on the human -globin promoter. It 
was demonstrated that a SWI/SNF-related chromatin re-
modeling factor E-RC1 is required for the erythroid 
Kruppel-like factor, ELKF, to activate transcription in 
vitro using a chromatin-assembled template (Armstrong 
et al. 1998). Recently, Nasmyth and coworkers demon-
strated that the SWI/SNF complex is recruited to the HO 
promoter by SWI5 in vivo in a cell cycle-dependent man-
ner (Cosma et al. 1999). Therefore, targeted nucleosome 
remodeling is at least one mechanism by which nucleo-
some remodeling complexes can function to activate 
transcription. Similarly, histone deacetylase complexes 
may also be targeted to specific promoters. For example, 
the histone deacetylase HDAC2 interacts with the tran-
scription factor YY1, and thus could be recruited to pro-
moters containing YY1-binding sites (Yang et al. 19961. 
Moreover, the Sin3/HDAC complex can be recruited by 
Mad-Max, Ume6, and unliganded nuclear hormone re-
ceptors to specific promoters (for review, see Pazin and 
Kadonaga 1997). Additionally, the Sin3-histone deacety-
lase complex can also be recruited via the methyl-CpG 
binding protein MeCP2 to methylated regions of the ge-
nome (Jones et al. 1998 ; Nan et al. 1998). Therefore, tar-
geted deacetylation represents at least one mechanism 
by which histone deacetylase complexes can be re-
cruited. 
Previously, we and others have shown that the NuRD 
complex has both nucleosome-remodeling and histone 
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deacetylase activities (Tong et al. 1998 ; Xue et al. 1998 ; 
Zhang et al. 1998a). It was also shown that recruitment 
of the NuRD complex to a promoter results in transcrip-
tion repression (Kehie et al. 1998 ; Xue et al. 1998). We 
proposed that the NuRD complex is targeted to specific 
genes by transcription factors (Zhang et al. 1998a). 
The NuRD-subunit MTA2 contains a zinc-finger 
(CX 2CX I7CX2C) belonging to the type found in tran-
scription factors that bind to the GATA sequence in-
volved in hematopoiesis and heart development (Orkin 
1992; Lyons 1996). These observations prompted us to 
analyze whether MTA2 or the NuRD complex could 
bind to the human 3-g1obin gene promoter using the gel 
mobility-shift assay. This assay failed to detect any DNA 
binding activity (data not shown). This negative result 
can be explained because several amino acids involved in 
GATA sequence recognition are not conserved in the 
MTA2 zinc-finger domain (Omichinski et al. 1993). 
Similar to previous studies demonstrating that Mad, a 
protein that interacts with the Sin3—histone deacetylase 
corepressor complex, but is not an integral component of 
the complex, can recruit the corepressor complex to spe-
cific promoters (for review, see Pazin and Kadonaga 
1997), we found that the methyl-CpG binding protein 
MBD2, although not an integral component of the 
NuRD complex (Fig. 1B), has the ability to directly in-
teract with the NuRD complex and recruit it to methyl-
ated DNA (Fig. 7). The implication of this result is that 
the NuRD complex may play a role in methylation-as-
sociated gene silencing. In support of this hypothesis are 
recent findings demonstrating that artificial recruitment 
of MBD2 to promoters results in repression of transcrip-
tion, which was reversed by the histone deacetylase in-
hibitor Trichostatin A (Ng et al. 1999). All of the evi-
dence discussed above suggests that MBD2 functions as 
a transcriptional repressor. However, it is worth noting 
that MBD2 was recently reported to have demethylase 
activity (Bhattacharya et al. 1999). Because DNA meth-
ylation causes gene silencing, a demethylase is likely to 
function as a transcriptional activator. It remains to be 
determined how MBD2 activity can he converted from a 
repressor to an activator. Given the similarity between 
MBD2 and MBD3 (72% identical), we tested the recom-
binant MBD3 protein (produced in Escherichia coli or 
SF9 cells) and the native NuRD complex for demethylase 
activity and failed to detect such an activity (data not 
shown). 
Can NuRD also be recruited to promoters by gene-
specific DNA-binding protein? It has been shown that 
the Drosophila gap gene hunchback can interact with 
Drosophila Mi2 and potentially recruit the NuRD com-
plex to repress hunchback-regulated HOX genes (Kehie 
et al. 1998). Recently, it was also reported that Ikaros, a 
zinc finger DNA-binding protein essential for lympho-
cyte lineage determination, through interaction with 
Mi2, recruits the NuRD complex to heterochromatin re-
gions (Kim et al. 1999). It is therefore likely that DNA-
binding proteins, which in principle have a restricted 
specificity as compared to MBD2, can also target the 
NuRD complex to specific genes. The interplay between  
sequence-specific DNA-binding proteins and MBD2 in 
recruiting the NuRD complex to specific genes may rep-
resent another pathway for regulation of the NuRD com-
plex. 
The function of the NuRD complex 
The NuRD complex was purified based on its histone 
deacetylase and nucleosome remodeling activities (Tong 
et al. 1998 ; Xue et al. 1998 ; Zhang et al. 1998a). The 
biochemical association of the historic deacetylase and 
nucleosome remodeling activities suggest that these two 
enzymatic activities are functionally related. It is con-
ceivable that nucleosome remodeling may be required 
for nucleosomal historic deacetylation in vivo. There-
fore, the presence of these two activities in one protein 
complex may represent an efficient way to facilitate dy-
namic changes in nucleosome structure. Based on the 
finding that a similar protein complex is also present in 
Xenopus eggs (Wade et al. 1998), we believe that the 
function of the NuRD complex is rather general. Several 
reports have already shed light on its potential biological 
function. Studies in Drosophila implicated NuRD in re-
pression of homeotic (HOX) genes and Polycomb-group 
genes (Kehle et al. 1998). In addition, NuRD has been 
shown to he associated with the zinc-finger DNA-bind-
ing protein Ikaros in toroidal structures presumed to be 
associated with centromeric heterochromatin in the G 1 
and S phase of the T-lymphocyte cell cycle (Brown et al. 
1997; Kim et al. 1999). This suggests that NuRD is in-
volved in centrorneric silencing, consistent with the re-
quirement of histone deacetylase activity for the main-
tenance of the underacetylated state of centromeric his-
tones (Ekwall et al. 1997). It is interesting to note that 
Ikaros is required for the differentiation of all three lym-
phoid lineage (Georgopoulos et al. 1994). Because Ikaros 
can recruit NuRD, it is possible that NuRD may play an 
important role in lymphocyte development. We provide 
evidence indicating that NuRD is potentially involved in 
transcriptional repression of methyl-CpG through an in-
teraction with the methyl-CpG-binding protein MBD2. 
Therefore, the two best-characterized histone deacety-
lase complexes, Sin3 and NuRD, are both involved in 
transcriptional repression of methylated DNA. MBD2 
was recently shown to be a component of the MeCP1 
complex (Meehan et al. 1989 ; Ng et al. 1999). Because 
MeCP2 binds methylated DNA much tighter than 
MeCP1 (Meehan et al. 1989 ; Lewis et al. 1992), it is pos-
sible that the Sin3/HDAC complex may be involved in 
long-term silencing of methylated DNA sequences, 
whereas the NuRD complex may he involved in tran-
sient silencing of some methylated genes. 
To maintain epigenetic silencing of genes through 
multiple cell divisions, newly deposited histories that 
are acetylated in the cytoplasm must be deacetylated 
(Jeppesen 19971. The identity of the histone deacetylase 
complex responsible for this function is unknown. It is 
intriguing that Ikaros forms a higher-order toroidal struc-
ture with NuRD that colocalizes with components of 
the DNA replication machinery upon T-cell activation 
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(Avitahi et al. 1999; Kim et al. 1999). Therefore, the 
nucleosome-remodeling and histone deacetylase activi-
ties of the NuRD complex are ideal candidates for 
deacetylating the deposition-related acetylated lysine 
residues during chromatin maturation. 
Materials and methods 
Purification of the NuRD complex and cloning of MTA2 
and MBD3 
The procedure for conventional purification of the NuRD com-
plex has been described (Zhang et al. 1998a). The purified NuRD 
complex derived from Mono S column was concentrated using 
a centricon concentrator and was resolved on a 10% SDS-poly-
acrylamide gel. After Coomassie blue staining, protein bands 
were excised and subjected to in-gel tryptic digestion. The pre-
viously identified polypeptides were verified by mass-spectra-
metric analysis (Erdjurnent-Bromage et al. 1998 ; Geromanos et 
al. 1998). Protein bands corresponding to p70 and p32 were se-
quenced as described (Zhang et al. 1997). The peptide sequences 
obtained were used to search the EST database. Multiple EST 
clones were identified and were used to construct the full-
length cDNA clones encoding p70 and p32. Clones encoding 
alternative spliced forms of p32 (MBD3a and MBD3b) were iden-
tified in human and mouse by sequencing EST clones (see text). 
Affinity purification using anti-MTA2, anti-HDAC1, and anti-
SAP30 was based on a previously published procedure (Zhang et 
al. 1998b) using HeLa nuclear extracts fractionated on phospho-
cellulose and DEAE-52 columns. 
Baculoviruses, recombinant core complex, and antibodies 
Baculoviruses expressing RbAp46, RbAp48, and HDAC1 have 
been described (Hassig et al. 1997 ; Verreault et al. 1998) Bacu-
lovirus-expressing HDAC2 was constructed using the pFastBac 
HTh vector (GIBCO BRL) and was a gift from Dr. Ed Seto (Mof-
fitt Cancer Center, Tampa, FL). cDNAs encoding His-tagged 
Mi2 and MBD3 and Flag-tagged MTA2 were constructed using 
the pVL1392 vector and the recombinant viruses were gener-
ated using BaculoGold DNA (Pharmigen). Historic deacetylase 
core complex and core plus MTA2 were purified using the pro-
cedure shown in Figure 3A. Extracts derived from SF9-infected 
cells 11 grams) were loaded onto a 35-ml DEAE-cellulose col-
umn and were eluted with six column volumes using a linear 
gradient of buffer C (20 mm Tris-HC1 at pH 7.9, 0.2 rnrvi EDTA, 
10 mm 13-ME, 0.2 mm PMSF, 10% glycerol) from 50 mm to 400 
mm of KC1 (BC50-BC400). The fractions containing the peak of 
the recombinant core complex (160-269 mrvi KC1) were pooled 
and incubated with 0.5 ml of anti-Flag M2 affinity gel (Eastman 
Kodak) at 4°C for 2 hr. Proteins were eluted with 0.5 ml of 
BC400 containing 0.1 mg of Flag peptide. The affinity purified 
core complex was further purified through a gel filtration Seph-
adex-200 (10130) column. The complex eluted with an apparent 
mass of -450 kD. Finally, the core complex was purified by 
sedimentation through a 15%-50% glycerol gradient. Recombi-
nant HDAC1-Flag and MBD3-His proteins were purified using 
anti-Flag M2 affinity gel (Eastman Kodak) and Ni 2 -NTA aga. 
rose (Qiagen), respectively. Recombinant RbAp48 and RhAp46 
were generated by cleaving the GST fusion proteins produced in 
Escherichia coli with thrombin. Antibodies against Mi2, Sin3, 
1-IDACI, HDAC2, RbAp48, RbAp46, SAP30, and MBD2 were 
described previously (Zhang et al. 1998a ; Ng et al. 1999). Anti-
bodies against MTA2 and MBD3 were generated by injecting 
recombinant proteins into rabbits. 
Hist one deacetylase assays 
Core historic octamers were purified from HeLa cells as de-
scribed [Zhang et al. 1998h) and acetylated with yeast Hat ip in 
buffer containing 50 misi HEPES (pH 7.8), 50 mm KCI, 0.1 mM 
EDTA, 1 mm DTT, 1 mm PMSF, 10 mm sodium butyrate, 10% 
glycerol, 5 pm [ °H]-acetyl coenzyme A, and 0.5 mg/ml core his-
tones. Acetyiated core histories were purified on a phosphocel-
lulose column. Histone deacetylase assays were performed as 
described (Zhang et al. 1998b) with 1 ug of labeled core histories. 
Gel inability shift assays 
Gel mobility-shift assays were performed with modifications 
from a published procedure (Meehan et al. 1989; Nan et al. 
1993). Data presented in Figure 7A used GAM6 probe and the 
binding reactions were carried out in 20 mm HEI'ES buffer at pH 
7.9, 1 mm EDTA, 3 rims MgCl,, 10 mm 2-mercaptoethanol, 4% 
glycerol, 0.1% Triton X- 100, and 500 ng of poly [dIG-C)] at 25°C 
for 30 mm. Each reaction contains 0.1 ng of probe and 10-80 ng 
of recombinant MBDs or 50-300 ng of the NuRD complex. The 
reactions were loaded onto a 2% agarose gel and resolved with 
0.5x TBE containing 5 mm magnesium acetate and 3% glycerol. 
The supershift assay shown in Figure 7C used the MeCGI 1 
probe in a reaction similar to the above except it also contained 
100 mM NaCl, 0.1 mg/ml BSA, and 300 ng of Eschcrichia coli 
DNA as competitor. Approximately 200 ng of GST-MBD2a and 
300 ng of NuRD were used. Reactions were incubated on ice for 
2 hr before electrophoresis on a 10/,,  agarose gel. 
GST pull-down assays 
Approximately 2-3 pg of GST fusion proteins were bound to 
glutathione-Sepharose heads and incubated with in vitro trans-
lated, or purified recombinant proteins, or purified NuRD com-
plex at 4°C for at least 4 hr. Beads were then washed three times 
with buffer containing 300 mist KC1 and 0.05% NP40 for three 
times before loading onto SDS-PAGE. The hound proteins were 
revealed by fluorography or Western blot analysis. 
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In addition to its well-documented effects on gene silencing, 
cytosine methylation is a prominent cause of mutations. In 
humans, the mutation rate from 5-methylcytosine (m 5C) to 
thymine (T) is 10-50-fold higher" than other transitions and 
the methylated sequence CpG is consequently under-represented'. 
Over one-third of germline point mutations associated with 
human genetic disease' and many somatic mutations leading 
to cancer` involve loss of CpG. The primary cause of mutability 
appears to be hydrolytic deamination. Cytosine deamination 
produces mismatched uracil (U), which can be removed by 
uracil glycosylase°" °, whereas m 3C deamination generates a GT 
mispair that cannot be processed by this enzyme. Correction of 
m5CpGTpG mismatches may instead be initiated by the thyinine 
DNA glycosylase, TDG" 2 . Here we show that MBD4, an unre-
lated mammalian protein that contains a methyl-CpG binding 
domain' 3" 4, can also efficiently remove thymine or uracil from a 
mismatches CpG site in vitro. Furthermore, the methyl-CpG 
binding domain of MBD4 binds preferentially to 
 M5  CpGTpG 
mismatches—the primary product of deamination at methyl-
CpG. The combined specificities of binding and catalysis indicate 
that this enzyme may function to minimize mutation at methyl-
CpG. 
MD134 (ref. 14) was identified in a database search for proteins 
with a methyl-CpG-binding domain (MBD) resembling that of the 
transcriptional repressor MeCP2 (refs 13, 15). Hypothetical trans-
lation of the full-length human and mouse MBD4 complementary 
DNAs revealed an amino-terminal methyl-CpG-binding domain  
and a carboxv-terminal region that was closely related to the 
glycosylase/endonuclease domains of bacterial repair proteins 
(Fig. Ia). Related proteins include the 8-oxoG'A mispair-specific 
,idenine glycosylase MutY of Escherichia coii16 , the GT mismatch-
specific thymine glycosylase Mig of Methanobacterium therrno-
tiutotrophicurn', the thymine glycol glycosylase Endoill of E. coil' 8 
and the photodimer - specific UV-endonuclease of Micrococcus 
iuteus' 9  (Fig. ib). Mouse and human MBD4 proteins are 86% and 
95% identical in the methyl-CpG-binding domain and the C-
terminal glycosylase-like domain, respectively, but are less con-
served elsewhere (Fig. la). 
On the basis of these relationships, we asked whether human 
MBD4 has DNA glycosylase or endonuclease activity. The presence 
of a methyl-CpG-binding domain led us to postulate that MBD4 
might be involved in the processing of DNA damage associated with 
methylated CpG sites. Upon incubation of recombinant human 
MBD4 with a fluorescently labelled oligonucleotide duplex contain-
ing a single GT mismatch in a CpG context, an abasic site was 
generated by the removal of the niispaired pyrimidine by glycosidic 
bond cleavage (Fig. 2a). In addition to the G•T mispair, GU 
substrates were also cleaved (Fig. 2b), but the processing of other 
base/base mismatches, including CA, CC and GG, was not 
observed (data not shown). That MBD4 is a mismatch specific T/U 
DNA glycosylase was confirmed by high-performance liquid chro-
matography (HPLC) analysis of the product mixture. Free Tor U 
could be detected in reaction mixtures which contained MBD4 and 
G'Tor GU mismatches, respectively (data not shown). The sugar-
phosphate backbone of DNA was not cleaved unless treated with hot 
alkali or the human AP-endonuclease HAP1 (ref. 20; and Fig. 2a). 
HAP1 cleaves oligonucleotide substrates at the 5' end of abasic sites. 
In the assay shown in Fig. 2a, HAPI generates two fragments: a 5' 
fluorescein-labelled 23-mer terminated at its 3' end with a hydroxy 
group; and a 37-mer that has at its 5' end the baseless sugar 
phosphate from which the mispaired T has been removed by the 
action of MBD4. Neither glycosylase nor endonuclease activity 
could be detected on perfectly matched substrates containing 
symmetrically methylated, hemimethylated or non-methylated 
CpG sites (Fig. 2b). From these experiments, we conclude that 
MBD4 is a mismatch-specific T/U glycosylase that lacks endonu-
clease activity. 
A CpG sequence context for the mismatch was preferred, but was 
not absolutely required, as G•T and GU mismatches in other 
sequences were also processed, albeit at a reduced rate (Fig. 2c; 
i:i. 	 Cj ni 
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Figure 1 MBD4 contains a conserved glycosylase-like domain and a methyl-CPG-binding 
domain, a, Diagram of MBD4 showing the N-terminal MBD and the C-terminal 
glycosylase domain. Percentage conservation between human and mouse proteins is 
shown below each shaded domain, b, Amino-acid sequence alignment of human MBD4 
(amino acids 429-539) with the E. co//thymine glycol glycosylase EndollI, the 8-oxoGA- 
specitic adenine glycosylase MutY. the Mig G  glycosylase of M. tttermoautotrophicum 
(Mthe) and the M. luteusUV endoriuclease (Miut). Asterisks mark residues found in all the 
proteins triangle indicates the residue that, when basic 	, is diagnostic of an 
endonuclease (glycosylase/lyase). 
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Figure 2 MBD4 is a mismatch-specific T/U DNA glycosylase. a, MBD4 does not cleave 
the sugar-phosphate backbone of a mismatched DNA substrate (lane—). Cleavage occurs 
only upon the addition of hot alkali (lane NaOH) or human FIAP1 endonuclease (lane 
HAP -1). b, CT and C-U mispairs are substrates for  ghycosylase processing by full-length 
MBD4. Ohigonucleotde substrate JJ, containing the appropriate mismatches or the 
corresponding perfectly matched, methylated or unmethylated controls, was incubated 
with MBD4 (see Methods). Apyrimidinic sites were then cleaved with hot alkali. Substrate 
and product bands are indicated. c, Kinetics of MBD4 glycosylase action in CC and non-
CC sequence contexts. CU (diamonds) or CT (squares) in a CG context is Compared with 
CT in a GG context (triangles). d, A C-terminal fragment of MBD4 that includes the 
glycosylase domain (amino acids 379-580; see Fig. 4a) can process C-U or CT 
mismatches, a, b and d are fluorescence scans of denaturing 15% polyacrylamide gels. 
M denotes m 5C. 
and data not shown). The methylation status of cytosine in 
CpG-TpG or CpG-UpG mismatches did not affect the glycosylase 
reaction in this assay (Fig. 2b). Substrate specificity in vitro is 
therefore similar to that of the other known mammalian G-T 
mismatch-specific DNA glycosylase, TDGIM2. As anticipated from 
the amino-acid sequence alignment (Fig. lb), the glycosylase 
activity resides in the C-terminal region of MBD4, as a polypeptide 
corresponding to amino acids 379-580 could process G-T and G-U 
mispairs (Fig. 2d), whereas polypeptides in which the C terminus 
was deleted were inactive (data from Figs 2 and 3 are summarized in 
Fig. 4a; and data not shown). The substrate specificity and flanking 
sequence preference of full-length MBD4 and its C-terminal frag-
ments were similar (compare Fig. 2b, d), indicating that the methyl-
CpG-binding domain (see below) did not influence site preference 
in this assay. 
Next, we investigated the DNA-binding specificity of MBD4. 
Mouse MBD4 binds to densely methylated DNA molecules in vitro 
and localizes to heavily methylated foci in mouse cell nuclei when 
overexpressed°. Bandshift assays with probes that contained non-
base-paired regions, however, revealed additional specificity. 
Human MBD4 gave a strong complex with a probe that had three 
m'CpG-TpG mismatches but bound relatively weakly when 
rifCpG-mCpG pairs were substituted at these sites (Fig. 3a, left 
panel). The probe with non-methylated, mismatched CpG-TpG 
sites also gave a weak complex. We conclude that both GT 
mismatch and nf C moieties are important for recognition by 
MBD4. Dependence of mismatch binding on the methyl-CpG-
binding domain was shown by bandshift assays with truncated 
versions of MBD4. The N-terminal 165 residues, which include the 
DNA-binding domain, retained specificity for the methylated mis-
match (Fig. 3a, right panel), whereas fragments that excluded all or 
part of the domain could not bind any of the probes (Fig. 4a; 
polypeptides 1-580 and 379-580). The results show that MBD4 
preferentially binds to the mismatch that results from hydrolytic 
deamination of m 5C in mammalian genomic DNA. 
The complexes in Fig. 3a were formed under conditions in which 
processing of the mismatched site is undetectable (data not shown). 
After incubation for 20min at 37°C, MBD4—DNA complexes 
reproduced the specificity of the glycosylase reaction, which prefers 
mismatches in a CpG context, but is indifferent to methylation 
(Fig. 2b). The full-length protein and a C-terminal fragment lacking  
the methyl-CpG binding domain (379-580; Fig. 3c) formed a 
complex with each of the mismatched probes (Fig. 3b), but a 
truncation lacking the C-terminal glycosylase-like domain did not 
form the complex (data not shown). As other DNA glycosylases 
bind tightly to the abasic site resulting from their catalytic action", 
we suspected that the observed complexes also represented product 
binding by MBD4. Accordingly, we found that the glycosylase 
domain (379-580) and the intact form of MBD4 bound efficiently 
to abasic sites under the same conditions (Fig. 3c; and data not 
shown). Thus the N terminus of MBD4 binds to the MG-TG 
mismatch that is the substrate for base removal, whereas the C 
terminus, following processing, binds to the abasic product of the 
reaction. 
MBD4 shows no apparent amino-acid sequence similarity to 
TDG, a protein that also excises mispaired T and U from G-T and 
G-U mismatches' 12. The two proteins probably evolved from 
different ancestors, as TDG is related to a bacterial G-U-processing 
enzyme, Mug", whereas MBD4 seems to have arisen through the 
fusion of a glycosylase domain, such as that of bacterial MutY, to an 
N terminus that may target the enzyme to methylated mismatches. 
TDG does not contain a met hyl-CpG-binding domain. Despite 
these sequence differences, MBD4 and TDG show very similar 
catalytic specificities in vitro, both enzymes preferring G-T and 
G-U mismatches within a CpG context'. In addition, both proteins 
bind to the apyrirnidinic site that arises following mismatch 
processing (ref. 21; and Fig. 3b, c). 
MEDI (identical to M13134) is reportedly a binding partner of 
MLHI, a protein implicated in mismatch repair 24 . It was proposed 
that MBD4/MEDI is an endonuclease that binds to hemi-methy-
lated CpG sites and directs mismatch repair via a single strand nick 
towards the newly replicated strand, in a manner analogous to 
bacterial MutH -26 . Against this hypothesis, we find that MBD4 
lacks endonuclease activity. The weak binding of MBD4 to hemi-
methylated CpG sites compared with symmetrically methylated 
CpG24  or mCpGTpG mismatches also argues against the MutH 
homologue model. 
We propose instead that the function of MBD4 is to counteract 
the mutability of m 5C by initiating conversion of n'i 5CpG-TpG 
mismatches back to m 5CpGCpG. Among the sequences that we 
have tested, only m 5CpG-TpG shows both preferential binding by 
the N terminus of MBD4 and processing by its catalytic domain 
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Figure 4 The properties of MBO4 suggest a role in initiating repair of m tCpG.TpG 
mismatches. a, Summary of DNA-binding and T glycosylase activity of truncated MBD4 
polypeptides against m °CpG.TpG (data is from Figs 2 and 3; and data not shown). The 
failure of the 160-580 protein to process mismatches is unexplained (aberrant protein 
folding?). b, Of the DNA sequences tested, only the methylated mismatch m tCpG.TpG is 
both bound by the N terminus of MBD4 and processed by its glycosylase domain, c, A 
scheme for the role of TG glycosylases in initiation of repair of deaminated methyl-CpG 
pairs. Solid circles in b and c indicate interstiand base mismatches. 
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Figure 3 DNA-binding specificities of MBD4 arw its truncated derivatives to DNA 
containing methylated and non-methylated duplexes with or without GU or GT 
mismatches. a, Binding of full-length MBD4 (left) and the N-terminal 165 amino acids of 
MB04 (right) to probe 'BH' (see Methods), which contains three potential CpG mismatch 
sites. Within each probe, all three sites were CpGCpG duplex (CG-CG), m 5CpGm5CpG 
duplex (MG-MG), mtCpGTpG mismatch (MGTG) or CpGTpG mismatch (CG-TG). Major 
complexes (C) are indicated. The slower migrating complexes in the MG.MG  and MG-TG 
lanes of the 1-165 panel may be due to binding of more than one protein molecule to the 
probe. b, Full-length MBD4 incubated under conditions that favour the glycosylase 
reaction with fluorescently labelled probe JJ, in which a single CpG site was methylated or 
mismatched as shown (see Methods). Complexes were formed with GU or TG 
mismatches regardless of methylation status. For comparison, the complex between 
CG.TG  mismatch and the T glycosylase TOG is shown (lane TOG). c, Under the same 
conditions, a C-terminal fragment (amino acids 379-580; see Fig. 4a) that can carry out 
the glycosylase reaction complexed with all mismatches in probe JJ, which was 
mismatched or methylated as shown. Asterisk denotes an abasic site. 
(Fig. 4b). Although processing of mismatches in vitro was not 
accelerated by methylation, it is possible that in vivo the N-terminal 
domain targets MBD4 to these sites as they arise by hydrolytic 
deamination of m °C (Fig. 4c). Repair of the resulting abasic site may 
involve interaction with MLHI (ref. 24). Given the known impor -
tance of CpG to TpG transitions in genetic disease and cancer, it will 
be of interest to test the effect of MBD4 loss on mutation frequency 
and cancer predisposition. El 
Methods 
Protein expression. 
MEtD4 deletion constructs were made by PCR amplification from an MBD4 eDNA and 
cloning the resulting products into the pET6H vector. Recombinant proteins were 
expressed and purified as described". N-terminal constructs were made by amplifying 
with the 5' primer °C.(CTGcTCCATGGGCACGACTGC,GCT(,-3' and one of the 
following 3' primers: (580) 5'-GCGGGATCCTGAGCTTGAAAGCTGCAG-3'; (539) 
5'.GCGGGTACCAATCCCATGAAGCTC-3' (165) 5'-GCGGATCCGATGTC-
AGC;GcTGccATG-3'; (112) 5'-GCGCAGCTGATAAAGTACACACTC-3'. The 1457 
construct was made by cloning the N-terminal Ncol fragment of the 1-580 construct into 
pET6H. (,-terminal constructs were made by amplifying with the 580 primer (above) and 
one of the followings' primers: 11601 5'-CGCCATGGCAGCCCTGACATC-3'; (379) 
5' -GCGCCAT(;GGCTCrGAAATGGACAACAAC-3'. 
Enzymatic activity assay. 
The enzymatic activity of the wild-type and mutant recombinant proteins was monitored 
using a 'nicking asssy. A 60-mer double-stranded oligonucleotide substrate containing 
different mismatches was prepared by annealing oligonucleotides to give the 'JI' duplex: 
5'TAGACA1-!-GccCTcGAGThcCATGGATCCGATGTZR.AC(:rCAAACCrA(ACGAATrCCG-3' 
3'ATCrGTAACC,GGAGCTCCATC,GTACCTACxtCTACAGYrC;GA(TVFGGATCrt,.CVrAAGGC.F-5' 
where F is fluorescein and R = G or A, Y = C, ns 5C, Tor U, and Z = (f-or m'C (see 
underlined dinudeotide). A 0.5 jiM solution of the labelled lower strand and I jiM 
solution of the unlabelled upper strand were heated for 5 min at 95°C in 10 m Tris-l-ICI 
p118.0,50mM NaCl, and the solution was allowed to cool slowly to room temperature. In 
standard 'nicking reactions 50 nM substrate and 50 nM protein were incubated for I hat 
37°C in a total volume of 20 pi in lx nicking buffer (50mM Tris-HCI pH 8.0. I mM DT!', 
0.1 mg ml - ' BSA, 1 niM EDTA(. The reaction was stopped by adding NaOH to a final 
concentration of 90 mM and heating for 10 min at 99°C. The NaOH treatment cleaves the 
Al' sites resulting from the removal of the mispaired bases by the glycosylase. After adding 
0.5 p.1 10 mg rn! 1  transfer RNA, I/In vol. 3M NaOAc pH 5.2 and 3 vol. cold ethanol 
(-20'Q to the reaction mixture, the DNA was precipitated at -20°C for I h. pelleted by 
centrifugation and washed with 80% ethanol (-20'C). The dried DNA was resuspended in 
lOpI formamide buffer (90% formamide, lx ThE) and heated for 5 min at 99°C before 
loading on a 15% denaturing polyacrylamide gel. The fluorescein-labelled DNA fragments 
were detected using the blue fluorescence mode of the Phosphorlmager (Storm 860, 
Applied Itiosystems). The HAP! endonuclease was expressed and purified from a done 
donated by!. Hickson. 
In some experiments, glycosylase activity was also assayed by incubating 1-10 ng 
recombinant protein with a radiolabelled 27-mer ohgonucleottde. 
5' .TCAGATrCGCCc(JrGATAAGCT 
3' -AGTCFAAGCGCGGTCGACGCTATICGA 
(where M signifies m'Cl. in 25mM sodium phosphate pH 7.2, 10mM EDTA, 50mM 
NaCI and 1 mg ml - ' BSA for 30 min at 37°C. Piperidine was added to I M and the reaction 
was incubated at 90°C for 30 mm, after which the reactions were completely dried under 
vacuum. Samples were resuspended in 90% formamtde gel loading buffer?,  denatured at 
95 ?(; for .5 min. and separated on a 5% denaturing polvacrvlanside gel. 
Bandstiift assays. 
Standard bandshift reactions (Fig. 3a) utilized P-labelled 'ISH' probes that contained 
three CpG sites (underlined below) whose methylation/mismatch status was varied. The 
Eli probes used in Fig. 3c were 
5'TCAGATrCGCGCZGGCTGCGATAAGCTGZGCGGATCCZGG I-cQ3' 
3'AGTCTAAGCGCGGYCGACGCTAT7CGACGYGCCTAGGGYCC'GTCG' 
where Y = C, na tC, Tot U, and Z = Cot mtC (See underlined dinucleotides). The three 
CpG sites were identically modified/mismatched within each probe. Binding reactions 
were carried out at room temperature for 30 min in 20 m HEPES pH 7.9.25mM NaCl, 
10 m -mercaptoethanol, 1 mM EDTA, 4% glycerol. 1% digitonin and 50 ng sonicated 
E. colt DNA. The glycosylase reaction does not occur under these conditions (data not 
shown). Complexes were electrciphoresed through 6 1ya polyacrylamide gels in 0.5 X TEE 
at 4'C. 
Complexes formed under conditions favourable to the glycosylase reaction (Fig. 3b, c) 
utilized the fluorescent or 32 P-labelled JJ oligonucleotide (see above) as a probe. In 
standard gel-retardation reactions, 200 riM protein was incubated with 66 nM labelled 
oligonucleotide substrate and 333 nM unlabelled homoduplex oligonucleotide in 50 m 
Tris-HCI pH 8.0, I mM DTT. 5% glycerol, I mM EDTA at 37'C for 20 mm. The samples 
were electrophoresed immediately through a 6% native 0.5 X TBE polyacrylatnide gel for 
45 min at 100 V.A probe with an abasic site was generated by treatment of oligonucleotide 
JJ containing a MGUG mismatch with the enzyme uracil DNA glycosylase. 
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